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β Buffer capacity 
BTA-Cl Benzyltrimethylammonium Chloride 
CL Drug concentration in the continuous lipid phase 
CW Drug concentration in the dispersed water phase 
Ctot Overall drug concentration of the vehicle 
D Diffusion Coefficient 
DLVO Theory named after Derjagin, Landau, Verwey and Overbeek to describe forces 
between charged surfaces in liquid medium 
DSC Differential scanning calorimetry 
E30 w/o-emulsion comprising 30% of water phase dispersed in oil 
E50 w/o-emulsion comprising 50% of water phase dispersed in oil 
E70 w/o-emulsion comprising 70% of water phase dispersed in oil 
Ibu Ibuprofen 
IPM Isopropyl myristate 
Iso Emulsifier Isolan PDI 
KL/W Drug partition coefficient between oil and water phase 
KW/L Drug partition coefficient between water and oil phase 
KSC/L Drug partition coefficient between stratum corneum and oil phase 
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P Permeability coefficient 
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1 Abstract 
In this work the dependence of transdermal drug permeation kinetics on continuous phase 
drug concentration, partitioning between formulation phases, partitioning between stratum 
corneum and continuous oil phase and evaporation of volatile formulation components for a 
hydrophilic (caffeine) and a lipophilic (ibuprofen) model drug incorporated into w/o-emulsions 
of varying composition was investigated.  
The studied w/o-emulsions consisted of an oil phase into which water phase was dispersed 
in mass fractions of 70%, 50% and 30% (E70, E50 and E30, respectively). The oil phase 
consisted of a single oil component (isopropyl myristate, miglyol 812N or paraffinum 
liquidum) and the polymeric emulsifier Isolan PDI. Water phase contained sodium chloride 
and was buffered to pH 4.5 in all emulsions containing ibuprofen. Pure oil with and without 
emulsifier were selected as reference formulations. Transport experiments were carried out 
in Franz-type diffusion cells across pig ear skin at 32°C under occlusive and non-occlusive 
conditions with an infinite dosing of 0.3 g/cm2 and 0.7 g/cm2. Continuous phase drug 
concentration was determined experimentally by ultracentrifugation and theoretically by 
calculation taking into account drug partitioning between distinct phases. 
A concept for the interpretation of drug permeation was proposed that considered continuous 
phase drug concentration as the driving force for transdermal permeation. Drug distribution 
within the formulation and partitioning between stratum corneum and continuous oil phase 
were determined in order to gain a full understanding of the examined absorption processes.  
Dependence of apparent permeability coefficient Papp on fraction of drug concentration in the 
continuous phase was analyzed with a model taking into account the permeability coefficient 
of the skin Pm and the permeability coefficient of the diffusion boundary layer Pdbl. Pdbl reflects 
the diffusivity of the drug in the vehicle. By fitting this model to the experimental data using 
non-linear regression, parameter values for Pm and Pdbl were deduced. Pm values were 
consistent with the drug partitioning between stratum corneum and continuous oil phase. For 
isopropyl myristate a permeation enhancement was found in agreement with literature. Pdbl 
values were compared with calculated values using a literature model for diffusion in 
heterogeneous matrix systems. These were found in most cases to be in fairly good 
agreement with the Pdbl values.  
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Free emulsifier present in the continuous oil phase affected neither saturation concentration 
nor continuous phase drug concentration nor transdermal absorption of the model drugs. 
Thickener Aerosil 200 tremendously decreased transdermal permeation of caffeine, but did 
not show any interaction with ibuprofen. A reduction of applied dose (0.3 g/cm2 instead of 0.7 
g/cm2) did not significantly affect apparent permeability coefficient Papp. Evaporation pattern 
of all examined formulations revealed that relative water loss was independent of the 
dispersed mass fractions and the employed experimental setup, but increased as the applied 
formulation dose was reduced. 
For implementing continuous phase drug concentration concept to non-occlusive conditions, 
a formula was derived that considered observed water loss and permeated drug amount in 
order to calculate the resulting drug concentration in the continuous formulation phase over 
time. An increase of the drug concentration in the continuous oil phase was estimated which, 
however, did not lead to a measurable increase of the apparent permeability coefficient. 
To conclude, the proposed concept considering continuous phase drug concentration can be 
used to explain experimentally measured apparent permeability coefficient Papp for lipophilic 
vehicles. Applying this concept to w/o-emulsions comprising varying mass fractions provides 
a predictive tool in order to delineate the effect of physicochemical formulations parameters 
and transdermal drug delivery rate, if occlusive conditions are assumed. In case of non-
occlusive transport conditions, however, evaporation will lead to compositional changes and 
consequently changes in continuous phase drug concentration. How these alterations will 
affect apparent permeability coefficient using a finite dose requires further investigations. 
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2 Introduction and Objectives 
2.1 Introduction 
In clinical practice, a drug is rarely applied to the skin in form of a pure chemical, but instead, 
is incorporated into a carrier system, the vehicle, to guarantee efficient topical or systemic 
therapy. Suitable applicability, compatibility, adequate stability and above all, efficacy with 
respect to duration and strength of the desired pharmacological action are requirements 
directly related to the employed vehicle. Thus, the development and optimization of these 
dermatological vehicles is a challenging task [1].  
Common vehicles usually comprise several components that are often not mutually miscible, 
thus, separate phases are formed that, on the microscopic lever, are intermixed with each 
other. From the macroscopic point of view a homogeneous system is apparent that disguises 
different microstructures arising inside the formulation [2, 3]. 
It is widely acknowledged that transdermal permeation is regulated by the formulation of the 
drug product. This regulation may take place not only based on physicochemical principles 
such as diffusion and partitioning of the active ingredient, but also by an interaction with the 
absorptive epithelium, i.e. the epidermis, affecting the permeability of the drug. Hence, a 
solid knowledge of the composition, including its physico-chemical properties and present 
microstructures, is crucial in terms of achieving optimal topical delivery [4].  
However, if a finite dose of a dermatological formulation is applied onto the skin, the physico-
chemical and thermodynamic conditions of the freshly applied emulsion change radically. 
Initial structural matrix and quantitative composition will most likely change during and after 
mechanical agitation associated with the application of the product (e.g. rubbing) and/or 
evaporation of ingredients. Possible evaporation of the volatile components of some 
vehicles, for instance o/w-emulsions, can result in an appreciable increase in solute drug 
concentration, first leading to saturation conditions and then to supersaturation or drug 
precipitation. Yet, research is still in the beginning of elucidating the complicating effects of 
vehicle metamorphosis on the entire clinical picture. On the contrary, if an infinite dose is 
applied, these effects should be less pronounced [1, 3, 5]. 
To date, there is no uniform and comprehensive recommendation or guideline available that 
takes into consideration the multifaceted complexity present in dermatological formulations in 
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order to quantitatively understand the mechanisms being decisive for transdermal absorption 
processes [1, 6]. 
In all likelihood, drug concentration in the vehicle is the most crucial physicochemical 
parameter governing permeation kinetics [7]. Increasing concentration of a drug within a 
vehicle, for instance, due to evaporation processes can strongly affect overall drug 
permeation [2, 3, 8]. 
Little is known about the relationship between diffusivity in a formulation and skin permeation 
in practical studies. Drug permeation through the skin out of vehicles has to be divided into 
diffusivity and partitioning in the formulation and diffusivity and partitioning in the skin and it 
has to be clarified which parameter has larger effect on skin permeation. Yamaguchi et al., 
for example, studied the in vitro skin permeation of 22-oxacalcitriol from ointments having 
differing compositions and considered the diffusion coefficients of the drug inside the 
vehicles. Drug diffusion coefficients within the ointment differed significantly depending on 
the amount of medium chain triglycerides present [9]. 
Permeation parameters such as drug diffusivity in a formulation and drug partitioning from 
the formulation to the skin are easily altered by the composition of the formulation [10]. For 
example, the microstructure of modified water containing hydrophilic ointment DAB 1997 with 
suspended hydrocortisone-21-acetate on in vitro drug release showed distinct vehicle 
effects. Both, the colloidal structure of the cream and the presence of specific vehicle 
compounds, i.e. penetration enhancers, are likely to influence the drug permeation through 
the skin more than the total drug concentration in the cream dose [11]. 
Previous work of our group proposed the continuous phase drug concentration concept to 
delineate regulation of drug skin permeation considering drug distribution among distinct 
phases of multi-phase hydrophilic formulations. Validity of the concept was confirmed for 
occlusive and non-occlusive conditions even though vehicles underwent considerable 
changes in their composition and microstructure due to evaporation of volatile ingredients [2, 
3]. 
The idea of this work was to implement the proposed concept to lipophilic vehicle systems 
applied onto skin under occlusive and non-occlusive conditions. Concerning these systems, 
apparent permeability coefficient is dependent on drug diffusion in the vehicle and drug 
permeability through the skin. To date, drug diffusivity inside the vehicle and its overall 
contribution to total transdermal permeation has received little attention. Diffusion inside the 
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vehicles is mainly dependent on the properties of the drug and the excipients, but also on 
phase fractions intermixed with each other and on arising microstructures. Additionally, drug 
concentration in the external oil phase can be influenced by the presence of free emulsifier, 
interactions with additives like thickeners or changes vehicles undergo in the course of their 
application like evaporation of volatile components. The extent of water loss and 
consequently the degree of occurring compositional changes is furthermore dependent on 
the applied dose. 
2.2 Objectives 
The goal of this PhD thesis was to implement continuous phase drug concentration concept 
to lipophilic vehicle systems under occlusive and non-occlusive conditions, i.e. w/o-emulsions 
of varying phase fractions and oil phases, in order to confirm its validity and, importantly, use 
it as a tool to delineate the contribution of diffusivity within the vehicle and permeability 
through the skin to overall apparent permeability. The combined efficiency of different 
parameters influencing the transdermal absorption process was to be clarified in order to 
establish a methodology to quantitatively understand the dependence of transdermal drug 
permeation on composition, dispersed phase fractions and microstructure of w/o-emulsions. 
Drug permeation was studied in vitro across full-thickness pig ear skin in order to control the 
experimental environment and so to elucidate individual factors that may modify permeation. 
Representative w/o-formulations consisted of emulsifier, oil, buffer or water, sodium chloride 
and were designed in order to receive diversity of their composition and variety of their phase 
ratio of dispersed to continuous phase. Drug distribution within the vehicles was determined 
by ultracentrifugation and calculated taking into account the drug partitioning between 
hydrophilic and lipophilic phase. Continuous phase drug concentration was postulated to 
describe quantitatively drug permeation rate. The use of a hydrophilic model drug that is 
mainly present in the dispersed phase and a lipophilic model drug which is mainly present in 
the continuous oil phase were the basis to test this concept and to detect possible 
interactions of formulation ingredients with the skin. To delineate the effect of formulation 
ingredients on skin barrier function more detailed, drug distribution experiments between 
isolated stratum corneum and continuous oil phase were performed. With respect to clinical 
practice, permeation was further studied non-occlusively considering changes formulations 
undergo due to evaporation of volatile components. Emphasis was laid on the investigation 
of changes in the phase ratio between dispersed to continuous phases and accordingly 
changes in continuous phase drug concentration in order to expand the proposed concept to 
the situation of non-occlusive application. 
Introduction and Objectives 
 
 
 
Miriam Reiser   University of Basel, 2008 
 
 
 - 24 - 
Drug skin permeation was further investigated in dependence of formulation parameters like 
emulsifier content, thickener content and dose. 
Caffeine (hydrophilic) and ibuprofen (lipophilic) were applied as model drugs with different 
solubility properties The studied w/o-emulsions consisted of an oil phase into which water 
phase was dispersed in mass fractions of 70%, 50% and 30% (E70, E50 and E30, 
respectively). Oil phase consisted of a single oil component (isopropyl myristate, miglyol 
812N or paraffinum liquidum) and polymeric emulsifier Isolan PDI. Water phase contained 
sodium chloride and was buffered to pH 4.5 in all emulsions containing ibuprofen. Pure oil 
with and without emulsifier was selected as reference formulation. The formulations were 
designed specifically for elucidating the effect of different continuous phase drug 
concentrations, microstructures and oil bases on transdermal delivery. 
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3 Theoretical Section 
3.1 THE SKIN 
3.1.1 Structure and Function of the Skin 
Human skin (cutis, integumentum commune) is one of the most extensive and readily 
accessible organs of the human body covering a surface area of approximately 2m2 with a 
thickness of 1.5 to 4 mm and a weight of 3 kg. Generally, it can be distinguished between an 
outer stratified, avascular epithelial (epidermis) and an inner vascularized connective tissue 
(dermis). Epidermis comprises of viable cellular epidermis and the outermost layer, called 
stratum corneum. The vascularized layer is formed by the dermis and the subcutis with the 
function to physiologically support the epidermis [12-15]. 
 
Figure 1. Cross-section of the skin [16] 
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Due to its complex structure and composition the skin is able to ensure various vital 
functions. The predominant task is to prevent the loss of water, electrolytes and body 
constituents while barring the ingress of harmful or unwanted molecules form the external 
environment. This protection is primarily provided by the stratum corneum. Additionally, the 
skin provides mechanical protection due to a strong fibre network and a pillow function of 
fatty tissues in the dermis. Melanin pigments in epithelial cells are protecting against 
damaging UV radiation and skin is strongly involved in the thermoregulation of the body. 
Besides, the skin offers a good protection against infections because parts of the immune 
system are located within the epidermis and dermis. Sensory functions are mainly due to the 
location of receptors for heat, pain, pressure and touch within the epidermis, dermis and 
subcutis. The skin is active in the synthesis, processing and metabolism of proteins, lipids, 
glycans and signalling molecules, it performs endocrine functions like vitamin D synthesis 
and peripheral conversion of prohormones. On the surface of the epidermis lies a thin film 
made up of skin lipids that are secreted from the sebaceous glands. These lipids are mixed 
with ingredients of sweat and act as water-repellents [17-21]. 
Two kinds of cells form the epidermis: First, the keratinocytes (90%) which are responsible 
for keratin production and are kept together by desmosomes and second, the dendritic cells 
(10%): melanocytes (pigment cells), Langerhans cells (immuno competent cells) and Merkel 
cells (responsible for perception) [16]. 
 
3.1.2 Epidermal Differentiation and Viable Epidermis 
The generation of the extracellular lipid compartment and the transformation of the 
keratinocytes into corneocytes are the main features of epidermal differentiation. However, 
equally important is the continuous renewal of the stratum corneum, which is insured by a 
careful balance between the replenishment of new keratinocytes form the proliferating basal 
layer and the well-orchestrated loss of the most superficial cells after the so-called 
“epidermal programmed cell death” [22]. Thus, the epidermis owns a multi-lamellar structure 
that represents the different stages of cell differentiation. Generally, viable epidermis can be 
sectioned into three distinct layers: stratum basale, stratum spinosum (together forming the 
stratum germinativum) and stratum granulosum [13]. Viable epidermis undergoes continuous 
differentiation in order to form the outermost layer of the skin, the straum corneum [15]. 
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Figure 2. Viable epidermis [14] 
 
The stratum basale forms a single layer of columnar amplifying cells derived from epidermal 
stem cells and is anchored to a basement membrane that separates epidermal tissue from 
underlying dermis. The constant renewal and proliferation balance the loss of dead horny 
cells from the skin surface and it is assumed that total turnover from basal layer to shedding 
is about an average of 28 days. Basal cell layer also includes melanocytes which produce 
and distribute melanin granules to keratinocytes in a complex interaction. Cells produced in 
the basal layer alter morphologically and histochemically in the course of cornification [13, 
17, 23]. 
Cylindric cells of stratum basale undergo a horizontal reorientation in the stratum spinosum, 
followed by a continuing flattening and shrinking of their nuclei as they move outwards. 
Stratum spinosum has a spiny appearance and reveals lipid-enriched lamellar bodies 
(Odland bodies) and an increase in keratin filaments, indicating the dual character of 
differentiation, protein and lipid synthesis. These Odland bodies own several tasks in 
epidermal differentiation like intercellular adhesion and dyshesion, membrane thickening, 
keratinocyte starvation and deposition of lipid-rich material necessary to form the epidermal 
permeability barrier [13, 17, 23]. 
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On their way to skin surface, the cells begin to flatten and elongate, forming the stratum 
granulosum. Keratinocytes start to manufacture keratohyalin granules, representing the early 
form of keratin. The increased keratin synthesis is accompanied by an increasing number of 
lamellar bodies [24]. The granular layer is often referred to as “transitional zone” due to its 
high biochemical activity and morphological change from living cells to dead keratin filled 
corneocytes, later forming the stratum corneum [13]. The formation of the cornified envelope 
also starts within this layer by the synthesis of an immature type of envelope underneath the 
plasma membrane which then undergoes maturation by the covalent attachment of 
preformed dedicated molecules to produce a rigid structure [25]. 
In the stratum corneum, cellular organelles and cytoplasm have disappeared and remaining 
proteins constituents are remodelled to form the dead keratin-filled corneocytes that are 
surrounded by a cornified lipid cell envelope which is stabilized by cross-linked proteins and 
covalently bound lipids.  The intercellular regions of stratum corneum are filled with lipids 
primarily generated from the exocytosis of the lamellar bodies during the terminal 
differentiation process of keratinocytes. These intercellular lipids are required for a 
competent skin barrier and form the only continuous domain in the stratum corneum [14]. 
The bottom part of the stratum corneum (stratum compactum) is very firmly bound together 
by corneo(desmo)somes and intercellular lipids and owns an important protective function. 
The top part is looser in its structure (stratum disjunctum) and undergoes desquamation by 
enzymatic digestion of the corneo(desmo)somes [26]. Figure 3 points out the differences in 
lipid composition for the stratum basale, the stratum granulosum and the stratum corneum.  
 
 
Figure 3. Lipid composition of different skin layers [14] 
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3.1.3 Stratum Corneum 
 The stratum corneum (SC) is the major source of resistance to penetration and permeation 
of the skin and consists of dead, flattened, keratin-filled cells that are embedded in an 
extracellular interlocking structure of multiple lipid bilayers, consisting of ceramides, fatty 
acids, cholesterol and cholesterols esters, all of that somewhat akin to bricks and mortar [15, 
27].This classic model, first established by Peter Elias in 1975, is still the most simplistic 
organization description for the outermost layer of the skin reducing it to a two-compartment 
system of strongly heterogeneous composition [23, 28, 29]. 
A better insight into the SC lipid matrix is a prerequisite for understanding the skin barrier 
properties. Knowing the internal structure and hydration behaviour on the molecular level is 
essential for studying drug penetration through the SC and for a more rational design of 
transdermal drug delivery systems. During the last decades, various molecular skin barrier 
models have been developed, such as the stacked monolayer model, the domain mosaic 
model of Forslind, the sandwich model of Bouwstra and the single gel phase model of Norlen 
[29-32]. 
Nevertheless, to date, a detailed picture of the molecular organization of lipids in the SC, in 
particular of the function of each ceramide subclass, has not been fully elucidated. It is clear 
that a profound knowledge of the physical properties of the SC lipids and of their interaction 
is essential for a deeper understanding of the impact of each ceramide species on the barrier 
function of the SC [33].  
For scientific purpose, stratum corneum often has to be separated from underlying epidermal 
structures. For more than 50 years, proteolytic enzymes such as trypsin have been 
extensively used for epidermal separation and keratinocyte isolation. The unique ability of 
proteases to cause selective epidermal separation has been in part explained by the 
proteolytic degradation of desmosomal proteins in the stratum corneum, which leads to cell 
dissociation. Recently, several endogenous proteases occurring in the epidermis have been 
found to play important roles in regulating epidermal cell desquamation [34, 35]. 
3.1.4 The Dermis and Subcutis 
The dermis is folded into ridges that project into the upper unvascularized epidermis and 
comprises of stratum papillare and stratum reticulare. Main components of the dermis are 
collagen and elastin fibres that form a vast network of filamentous and amorphous 
connective tissue that ensure flexibility and strength of the skin.  The skin is nourished by a 
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strong network of blood and lymph vessels that are situated in the utmost level of the dermis 
directly adjacent to the epidermis. Hair follicles, sebaceous glands and sweat glands 
originate in the dermis and perforate the stratum corneum. At the bottom of the dermis lies 
the subcutis that consists mainly of loose connective tissue and adipocytes [12, 14, 15]. 
3.2 DERMATOLOGICAL VEHICLES 
3.2.1 Overview and Classification 
In dermatology, the drug is rarely applied to the skin in the form of a pure chemical but 
instead is incorporated into a carrier system, a so-called vehicle. A formulation may be 
classified by its pharmaceutical nomenclature used in pharmacopoeias (e.g. cream, 
ointment, gel, paste), by the principal of structural matrix (e.g. emulsion, liposome, gel, 
suspension, transdermal patch) or by associated appearance (e.g. paint, milk, foam, 
shakes). However, until today no uniform and comprehensive classification is currently 
available [1]. In the European pharmacopoeia (Ph.Eur.) dermatological vehicles are 
subdivided following galenical points of view like rheology (liquid or semisolid), polarity 
(hydrophilic or lipophilic) and physico-chemical points of view (one-phase or multiple-phase). 
Generally, vehicles consist of a hydrophilic and/or lipophilic base, emulsifier, thickener, 
antioxidants and conserving agents [36].  
Buhse et al. tried to obtain a scientifically based systematic classification of dosage forms for 
topical drugs. Several methods were applied in their studies to distinguish topical dosage 
forms, among which rheology, loss on drying, thermogravimetric analysis, appearance and 
composition were the most auspicious ones. Rheology is the most discriminating property 
separating creams and lotions. Lotions can be classified as liquid emulsions and creams as 
emulsions with a semisolid appearance. Liquids possess Newtonian or pseudoplastic flow 
behaviour, whereas semisolids show plastic flow behaviour. Ointments and creams differ in 
their composition, mainly in the presence/absence of water and/or other volatile ingredients. 
Gels are distinguished from other dosage forms by their composition and especially by their 
thermal behaviour.  
Furthermore, dosage forms can be classified into liquids (solutions, suspensions, lotions) and 
semisolids (creams, gels, pastes, ointments). Ointments can be emulsions or suspensions 
and are separated from creams and gels on the basis of their composition, followed by the 
loss on drying. Generally, water plus volatiles content of less than 20% characterizes 
ointments. The low level of water and volatiles is due to a high hydrocarbon and/or 
polyethylene glycol content (>50%). Gels are semisolids and contain a gelling agent [37].  
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Table 1. Simplified characteristics and properties of dermatological formulations [adapted from [1, 36-
38]] 
Dermatological 
Formulation 
Properties and Characteristics 
Paste • Ointment with a high percentage of insoluble particulate solids (>50%) 
• Semisolid 
Ointment • Hydrocarbon based semisolids containing dissolved or suspended drug 
• High molecular weight hydrocarbons form a fine crystalline matrix in which short 
chain hydrocarbons are entrapped 
• Non-aqueous hydrophobic (single-phase) 
• Water-emulsifying: can absorb larger amounts of water, leading to w/o or o/w - 
systems 
• Hydrophilic: contain bases that are miscible with water, may contain water 
Cream • Semisolid emulsions (w/o or o/w) 
• Multiphasic 
Gel • Liquid phase is immobilized in a three-dimensional polymeric matrix of a gelling 
agent (0.5 – 2%) 
• Semisolid 
Rigid Foam • Air or other gases are emulsified in a liquid phase to the point of stiffening 
 
Modern pharmaceutical (and cosmetic) formulation development is based upon stability and 
compatibility of excipients and active agents (pharmaceutical-technological criteria), cosmetic 
acceptability, usage criteria and bioavailability of the agents at the target site 
(biopharmaceutical and therapeutic criteria). 
Table 2. Pharmaceutical-technological, biopharmaceutical and cosmetic criteria for dermatological 
formulations [adapted from [1]] 
Pharmaceutical-technological criteria Biopharmaceutical criteria 
• Stability of active drugs and ingredients • Enhanced drug delivery and retention in the skin 
• Rheological properties: consistency, 
extrudability • Controlled drug delivery and retention in the skin 
• Loss of water and other volatile 
components • Targeted drug delivery and retention in the skin 
• Phase changes, “bleeding” Cosmetic and usage criteria 
• Particle size and particle size distribution of 
dispersed phase • Visual appearance 
• Apparent pH • Odour and colour 
• Microbial contamination / sterility • Sampling and dispensing characteristics 
• Application properties • Enhanced or controlled drug release from 
the vehicle • Residual impression after application 
 
 
To increase the flux of a given drug, the selection of the vehicle is extremely important. An 
increase of the drug escaping tendency, achieved by selecting an ointment base with low 
ability to dissolve the drug, leads to enhanced penetration rates. The maximal possible flux 
can be achieved by incorporation of the drug at its maximal thermodynamic activity. 
However, the resistance of the stratum corneum is not a constant parameter and may be 
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reduced by specific vehicle effects, thus, penetration enhancers and hydration must be taken 
into consideration [39]. 
 
 
 
Figure 4. Use of vehicles on diseased skin [36] 
 
 
 
 
 
 
3.2.2 Emulsions 
3.2.2.1 Definition 
Emulsions are heterogeneous mixtures of at least one immiscible liquid dispersed in form of 
droplets in another liquid. In general, the droplet diameters are greater than 0.2 µm and 
broadly distributed. It can be distinguished between oil-in-water (o/w) or water-in-oil (w/o) 
systems, where the first phase mentioned refers to the dispersed fraction and the second 
phase mentioned refers to the continuous fraction. The volume fraction of dispersed material 
in emulsions is seldom less than 10% and sometimes as high as 90%. The majority of 
emulsions have a white, milky appearance due to the fact that the dispersed and continuous 
phases have different refractive indexes [36]. Besides o/w and w/o-emulsions, more 
complicated systems may arise, generally referred to as multiple emulsions. They are 
composed of droplets of one liquid dispersed in larger droplets of a second liquid, which is 
then dispersed in a final continuous phase. Such systems may be w/o/w-emulsions where 
the internal and external phase is hydrophilic or o/w/o which have the reverse composition 
[40, 41]. 
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Figure 5. Schematic drawing of various types of emulsions [36] 
 
 
The preparation of emulsions requires the formation of a very large amount of interfacial area 
between two immiscible liquids. The work required is given by  
AW i ∆⋅= σ  
where σi denotes the interfacial tension between the two liquid phases and ∆A the change in 
interfacial area. Since the amount of work that is required to increase the interfacial area 
remains in the system as potential energy and minimum energy levels (equivalent to 
minimum interfacial area) are generally favoured, the system rapidly undergoes whatever 
transformations possible to reduce that energy, in this case, e.g. by reducing the interfacial 
area and separation. In order to prevent this coalescence or at least reduce its rate to 
negligible proportions and, hence, guarantee stability, in almost all practical emulsions, the 
inclusion of additives, such as surfactants, finely divided solids and polymers, is obligatory. 
The additive may perform two primary functions: (I) lower the energy requirements of drop 
formation (i.e. lower the interfacial tension) and (II) retard the process of drop reversion to 
separate bulk phases. Additionally, stability is affected by the dispersing process 
(manufacture method), the characteristics and quantities of additives employed, mixing 
temperature and order of mixing [40, 41]. 
In principal, flocculation, sedimentation/creaming, coalescence and breaking are the forms of 
instability that can occur. Flocculation is the mutual attachment of individual emulsion drops 
to form flakes or loose assemblies of particles in which the identity of each is maintained. It is 
a reversible process that can be compensated by simply shaking the emulsions. 
Coalescence refers to the joining of two (or more) drops to form a single drop of greater 
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volume, but smaller interfacial area. Creaming is related to flocculation in that it occurs 
without the loss of individual drop identities. Creaming occurs over time with almost all 
emulsion systems in which there is a difference in the density of the two phases. If the 
dispersed phase happens to be denser than the continuous phase, the separation process is 
termed sedimentation. Finally, the breaking of an emulsion refers to a process in which a 
gross separation of two phases occurs [40, 41]. 
The maximum volume fraction of dispersed phase which can be obtained is 74.02 wt%, if it is 
assumed that the emulsion is composed of rigid, spherical droplets of equal size. However, it 
is possible to prepare emulsions of dispersed volume fractions far exceeding this 
“theoretical” limit because droplets generally are not monodispers. Smaller droplets will 
locate themselves in-between close packed, larger droplets. Besides, emulsion droplets are 
not rigid spheres, but highly deformable so that their shape can be changed from spherical to 
elongated or polyhedral shapes [41]. The particle size distribution of emulsions is changed 
easily by adjustment of the phase volume ratio, method of manufacture, temperature and 
viscosity. In 1933, Langevin was the first to notice that variation of the proportion of emulsion 
ingredients influences the size of oil globules [42]. 
3.2.2.2 W/O-Emulsion 
The lipid portion in w/o-emulsions is usually constituted of a mixture of lipids of different chain 
lengths. Fluid short-chain lipids are intercalated between longer-chain lipids responsible for 
the structural framework. Generally, hydrophobic skin emulsion bases are emulsions with a 
high proportion of the water phase (up to about 70%). Besides, these emulsions tend to 
break on the skin. Thus, water is released and a lipid layer remains on the skin in which there 
are many gaps which arise during the demulsification [36, 43]. 
w/o-emulsions offer a series of significant benefits compared to traditional o/w-emulsions. By 
forming an occlusive layer on the skin, they are efficiently reducing the evaporative water 
loss from the skin. They are excellent water repellents which makes them a very attractive 
formulation basis for sun care and colour cosmetic formulations. Despite of these attractive 
benefits, the use of w/o-emulsions has been limited due to an association with stability issues 
and a heavy skin fell resulting from high oil content. Typical w/o-emulsions have oil phase 
contents (emollients, waxes, emulsifiers) of 25-30 wt% and a water phase content of 70-75 
wt%. Formulating stable w/o-emulsions with oil phase content below 25 wt% is still a big 
challenge due to low oil content, currently available emulsifiers and the resulting high 
emulsion viscosity. A reduction of the oil phase content of w/o-emulsions means reducing 
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continuous phase and, by doing so, increasing the interaction between water droplets in the 
emulsion. An increase in viscosity is the direct consequence of that. Additionally, the risk of 
coalescence of water droplets increases as the average distance between the water droplets 
further decreases. However, it is possible to formulate so-called concentrated emulsions 
owning a dispersed phase content bigger than 74 wt-%. Here, the droplets cannot be 
spherical any more and assume some transitional form between spheres and polyhedra [44, 
45]. As indicated by the phase ratio, a w/o-emulsifier has to provide excellent stability to 
succeed in formulating stable emulsions with such a high internal phase content [46]. 
It is widely accepted that electrolytes dissolved in the aqueous phase of w/o-emulsions 
dramatically increase emulsion stability [45]. 
Opawale and Burgess examined the influence of sodium chloride on the stability of w/o-
emulsions using different span surfactants. Surface-active substances lower interfacial 
tension and form an interfacial film, but for long-term stability to coalescence and phase 
separation, it has been reported that strength of the interfacial film is more important than its 
effect on interfacial tension. Possibly, the addition of salt promotes interfacial elasticity, and 
decreases adsorption and/or molecular interactions of surfactants, as Na and Cl ion are 
preferentially hydrated over the surfactant molecules. This apparently results in a reduced 
interaction of water with the surfactant polar head groups and/or salting out of the surfactant 
molecules present at the interface. The use of high salt concentration (>1M) in emulsion 
formulations, however, is not recommended as this decreases the elastic behaviour of the 
interfacial film and therefore emulsion stability [47].  
Kent and Saunders studied the influence of added magnesium sulphate on the properties of 
water-in-oil (inverse) emulsions with respect to coalescence. The average droplet size of the 
emulsions increased with increasing salt concentration. These apparently contradictory 
results were attributed to differences in their relative importance. It was proposed that 
magnesium sulphate decreased/retarded the rate of surfactant adsorption at the oil-water 
interface which resulted in an increased non-equilibrium interfacial tension during 
emulsification and increased droplet size. While stability of o/w-emulsions in the presence of 
electrolyte can be described by the conventional DLVO-theory, stability of inverse emulsions 
cannot be simply described by these conventional theories of colloid stability (e.g. DLVO) as 
continuous phase possesses a very low dielectric constant. Nevertheless, electrostatic 
effects should not be ignored as they may contribute to emulsion stability. To conclude, there 
have been a number of conflicting reports in the literature concerning the role of electrolytes 
on the interfacial properties of the oil-water interface. The study revealed that datas obtained 
Theoretical Section 
 
 
 
Miriam Reiser   University of Basel, 2008 
 
 
 - 38 - 
within one study can be contradictory and that kinetic effects involving surfactant adsorption 
are very important for inverse emulsions [48].  
3.2.2.3 Methods of Preparation 
Ointments, pastes and creams tend to be produced by one or the other of the two general 
methods. Either they are made at high temperature by blending the liquid and heat-
liquefiable components together and then dispersing other solids (often including the drug) 
within the oily melt, or, in the instance of emulsions, within the aqueous phase of the 
emulsion or the freshly formed emulsion itself (fusion methods); or the drug is incorporated in 
the already solidified base (cold incorporation).  
In the fusion method for ointments, the ingredients are heated together somewhere between 
60°C and 80°C, depending on the components, and mix ed to a uniform composition while in 
the fluidized state. Cooling is then effected using some sort of a heat exchanger. Systems in 
preparation are always cooled with mild stirring until they are close to solidification.  
The fusion methods for preparing creams are a bit more complex. In this instance the 
aqueous and oil phases are heated separately to somewhere between 60°C and 80°C. As a 
general rule, the water phase is heated to 5°C abov e the temperature of the oil phase, the 
latter to prevent premature solidification during the emulsification process. Water-soluble 
ingredients are dissolved in the heated aqueous phase, and oil-soluble ingredients are 
dissolved in the oily melt, but only as long as they are heat-stable and not too volatile. If an 
o/w-system is to be made, the emulsifiers are added to the aqueous phase and the emulsion 
is formed by slow addition of the oil phase. If a w/o-emulsion is to be made, the addition 
steps are usually reversed. Therefore and generally, the discontinuous phase is added to the 
continuous, external phase containing the emulsifier [38]. 
Each method of preparation requires that energy is put into the system in some form. The 
energy may be supplied in a variety of ways, such as trituration, heat, agitation or 
homogenization. The rotor stator technology, for example is a well-established method for 
time-saving and easy emulsion preparation. A typical dispersing aggregate consists of two 
teeth rings, one of them is fixed and does not move - the stator; the other is driven by a 
motor through the shaft and turns around inside the stator - the rotor. The shear forces and 
bounce effects which are created between the running rotor and the stator treat the product 
mechanically, so for example 2 phases can be homogenized in short time [3]. 
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Figure 6. Functional principle of rotor-stator system 
 
3.2.2.4 Emulsifier  and Isolan PDI® 
There are four general classes of materials that can act as emulsifiers and/or stabilizers for 
emulsions. It includes common ionic materials, colloidal solids, polymers and surfactants. 
Each class varies greatly in its effectiveness and its mode of action.  Adsorbed non-
surfactant ions impose a slight electrostatic barrier between approaching drops. They may 
also affect the stability of the system by orienting solvent molecules in the neighbourhood of 
the interface, altering some local physical properties such as dielectric constant, viscosity 
and density, thereby producing a small stabilizing effect. Small colloidal materials (sols) 
stabilize an emulsion by forming a physical barrier between drops, thereby retarding or 
preventing drop coalescence. Particles should partially be wetted by both liquid phases, but 
with a slight preference for the external phase. Polymeric additives may change surface 
properties, but mostly are used as stabilizers. Their action may result from steric or 
electrostatic interactions, from changes in the interfacial viscosity or elasticity or from 
changes in the bulk viscosity of the system. Of the possible emulsifiers, most are true 
surfactants in that they are effective at lowering significantly the interfacial tension between 
the two liquid phases. The rule of Bancroft states that the liquid in which the surfactant is 
most soluble, will form the continuous phase in the final emulsion [41].  Often a mixture of 
surfactants with widely differing solubility properties leads to emulsions with enhanced 
stability. Synergistic effects will lead to a tremendous reduction of interfacial tensions and the 
formation of cooperative surfactant “complexes” impart greater strength, possibly leading to 
higher rigidity of the interfacial layers [41]. Emulsifiers can be classified according to the 
hydrophilic-lipophilic balance (HLB) system of Griffin. This system calculates a HLB number 
for every surfactant based on its chemical structure in a range from 0 to 20. It is proposed to 
mix emulsifiers with an oil phase of corresponding HLB value. At the high end of the scale (8 
- 18) lie hydrophilic surfactants, whereas at the low end (3 - 6) are surfactants with low water 
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solubility acting as w/o-emulsion stabilizers. Nevertheless, the HLB system does not always 
provide a clear-cut answer for a given system [41].  
The IUPAC Commission for nomenclature defines an emulsifier as “a surfactant which is 
positively adsorbed at interfaces and lowers the interfacial tension. It facilitates, when 
present in small amounts, the formation of an emulsion, or enhances its colloidal stability by 
decreasing either or both of the rates of aggregation  and coalescences” [49, 50]. Surfactants 
are classified based on their structure and physico-chemical behaviour. They are amphiphilic 
and can form aggregates such as micelles or lamellar liquid crystals. An important 
distinguishing factor is the charge of the hydrophilic head-group of the molecule. Accordingly, 
surfactants are categorized as anionic, cationic, amphoteric and non-ionic [36]. 
Other additives such as polymers and sols function primarily as stabilizers, rather than 
emulsifiers. In addition, because of their molecular size, the adsorption process for polymers 
is generally very slow relative to the timescale of the emulsification process. The primary 
function of polymers and sols in emulsions is the retardation of droplet flocculation and 
coalescence [41]. 
 
Figure 7. Isolan PDI®: Structure and Mode of Action 
 
The selected emulsifier of this work for manufacturing stable w/o-emulsions of varying phase 
ratios and oil bases is Isolan PDI®. It is a polymeric and polyfunctional emulsifier for cosmetic 
applications which mode of action is illustrated in figure 7. Isolan PDI® accumulates at the 
interface between water droplets and continuous oil phase, thus, interfacial tension is 
lowered, and a barrier (electrostatic and/or steric) between drops is established. 
Furthermore, viscosity of the oil phase and consequently the whole system is increased due 
to interactions of the hydrocarbon chains. So to say, the effective adsorbed layer thickness is 
increased and concomitantly also interfacial viscosity. Stable lipophilic lotions and creams 
can be manufactured requiring only low amounts of emulsifier (up to 3%) and no further co-
surfactants [41, 51].  
Theoretical Section 
 
 
 
Miriam Reiser   University of Basel, 2008 
 
 
 - 41 - 
Isolan PDI® belongs to the class of polymer surfactants that, quantitatively and qualitatively 
seen, often achieve considerably more if compared to low-molar-mass surfactants.  This is 
due to the plentiful possibilities of tailoring polymer architectures, taking advantage of the 
large pool of monomeric building blocks as well as of modern synthesis strategies. 
Compared to low molecular mass surfactants, polymer surfactants offer the possibility to 
combine different properties (ionic, non ionic, hydrophilic, hydrophobic) within the same 
molecule in such a way that almost every polar – non-polar gradient can be realized. The 
critical micelle concentration (CMC) is extremely low or even not existent, 
micelles/aggregates are stable at even high dilutions and aggregation numbers are 
adjustable by the macromolecular design. Properties such as foaming or viscosifying can be 
varied broadly, the polarity of the hydrophobic polymer block is adjustable and, thus, its 
compatibility and solubilization capacity can be tuned for a given solute. The required amount 
of surfactant needed can be decreased and surfactant behaviour can be controlled by 
external stimuli, e.g. changing of pH, temperature [52]. 
3.2.2.5 Characterization 
3.2.2.5.1 Lipophilic and Hydrophilic Character 
In order to distinguish between the types o/w and w/o of dermatological vehicles, there are 
several physical methods available like optical observation after blending the sample with a 
hydrophilic or lipophilic dye or simple dilution experiments with oil or water bulk phase [53, 
54]. Electric conductivity is based on the measurement of movable particles with electric 
charge that can carry electricity when a difference of electric potential is placed across a 
conductor. The conductance C in Siemens (S) is the reciprocal of the resistance R in ohms 
(Ω) of the conductor: 
R
C 1=  
The resistance R is given by: 
A
lR ⋅= ρ  
where ρ is the specific resistance of the conductor, l denotes its length and A its cross-
section area in cm2. The specific conductance or electric conductivity κ in S/cm is the 
reciprocal of the specific resistance and described by the term: 
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A
lC ⋅=κ  
A pair of electrodes connected to an external electric source is immersed into the 
dermatological formulation in order to measure its electric conductivity. The electrodes 
possess the distance l and a specific area A each. The ratio l/A is referred to as cell-constant 
of a specific measuring cell. If the water phase is continuous, a current will pass through the 
emulsion, while a continuous oil phase will fail to carry the current. The electric conductivity 
of o/w formulations was found to be in the same order of magnitude to the bulk continuous 
phase [55]. 
3.2.2.5.2 Optical Methods 
Structures within dispersed systems may range in their size from about 10 nm 
(microemulsions) over several hundred nm (liposomes) up to more than several microns 
(emulsions). The overall appearance of such systems inherently involves some obvious 
information about comprising structures. Potential physical stability of a colloidal system can 
often be understood on the basis of particle size. In particular, smaller colloids, especially 
those made up to like-charged particles, are appreciably more resistant to flocculation, 
sedimentation etc. than systems containing larger or uncharged entities. For formulations 
made up of immiscible fluids, such as emulsions or microemulsions, reduced particle size is 
an indicator of improved kinetic stability or the attainment of a thermodynamic equilibrium, 
respectively. Second, the mechanisms at work during processing can be better understood 
by quantitatively characterizing the products generated under various operational 
parameters. Third, performance of the formulation in vivo sometimes can be controlled if not 
completely understood on the basis of size consideration. Finally, the safety of multiphase 
parenteral formulations containing submicron particles can be better assessed if the absence 
of larger particles can be assured. It should be noted that Haskell provided a good 
minireview on characterization of submicron systems via optical methods [56].  
For visualization of dispersed structures that are smaller in size than several hundred 
nanometers and are optically isotropic, transmission electron microscopy (TEM) or scanning 
electron microscopy (SEM) is generally applied. Scanning electron microscopes have many 
advantages over traditional microscopes. The large depth of field allows more of a specimen 
to be in focus at one time. SEM possesses a much higher resolution, so closely spaced 
specimens can be magnified at much higher levels. The degree of magnification can be 
controlled as lenses are replaced by electron beams. Actual strikingly clear images are 
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achieved and, thus, SEM has become one of the most useful instruments in research today 
[57-60]. 
 
Figure 8. Scanning electron microscopy [61]  
 
In case of freeze fracture scanning electron microscopy, original formulation is fractured in a 
frozen-hydrated state and then observed. Specimen preparation for this method involves the 
following steps: First, a small droplet of the formulation is placed on a specimen table and 
rapidly frozen in a mixture of liquid propane and nitrogen. The samples must be rapidly cryo-
transferred into a freeze-fracturing device where the fracture is performed at low temperature 
under high vacuum. Due to this treatment, the sample will cleave along a fracture plain with 
the least cohesion. In case of an emulsion, for example, these are the hydrophobic areas of 
lipids stabilized by van-der-Waals forces, which are much weaker that the hydrogen bonds of 
the water domains. By further sublimation of ice to a depth of several nanometers, referred to 
as etching, structural details otherwise hidden in deeper ice layer can be additional exposed. 
This fracture plane is finally coated with a metal-carbon film before scanning electron 
microscope detects electrons, emitted from an electron source, that are back-scattered from 
the specimen surface. To achieve this, the specimen surface must be coated with a layer of 
metal, for example platinum with a thickness of a few nm, to render the surface conductive. If 
the metal is evaporated unidirectional at a fixed angle, usually 45° onto the specimen, a 
Theoretical Section 
 
 
 
Miriam Reiser   University of Basel, 2008 
 
 
 - 44 - 
shadow effect is generated that gives the image of a three dimensional appearance. A 
carbon film finally reinforces this metal layer.  
The SEM is an instrument that produces a largely magnified image by using electrons 
instead of light to form an image. A beam of electron is produced at the top of the 
microscope by an electron gun. The electron beam follows a vertical path through the 
microscopes which is held within a vacuum. The beam travels through electromagnetic fields 
and lenses which focus the beam down toward the sample. Once the beam hits the sample, 
electrons and x-rays are ejected from the sample. Detectors collect these x-rays, 
backscattered electrons and secondary electrons and convert them into a signal that is sent 
to a screen similar to a television screen. This produces the final image (see figure 8 and 9). 
 
Figure 9. Freeze fracture scanning electron microscopy of a w/o-emulsion comprising 70% of water phase 
dispersed in 30% oil phase (Miglyol 812N) 
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3.2.2.5.3 Ultracentrifugation 
Ultracentrifugation of dermatological vehicles like emulsions is a precious tool to gain 
information about the nature, the composition and, if the density is known, about the size of 
dispersed structures. It is a conventional method to purify and concentrate liposomal 
formulations and also used for stability testing of emulsions [62-64]. Besides, 
ultracentrifugation is applied for structural analysis of semisolid multi-phase formulations, 
typically in combination with further physicochemical methods [2, 3, 65]. 
The sedimentation and creaming processes are dependent on the specific density of each 
single vehicle component and are accelerated by the application of centrifugal forces. 
Stoke’s law describes the velocity of a creaming or sedimenting particle. An (ultra)centrifuge 
is an instrument designed to apply a rotational force to a mass (particle) and if the mass is 
unrestricted, it will move away from the centre of rotation. Hence, acceleration of gravidity g 
is replaced by acceleration of centrifugation β=ω2x, where ω is the angular velocity and x is 
the distance of the particle form the centre of rotation.  
Stoke’s law is accordingly modified to: 
0
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where v is the velocity of sedimentation, ρ and ρ0 are the density of the sedimenting 
spherical particle and the medium, respectively and η0 is the viscosity of the medium. The 
instantaneous velocity v = dx/dt of a particle in a unit centrifugal field is expressed in terms of 
Svedberg sedimentation coefficient s 
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The force at which a centrifuge is operated is often expressed in terms of the number of 
times that the force of gravity is exceeded. For example, the ultracentrifuge Centricon T-1075 
with the rotor TFT 7013 (Kontron Instruments, Mailand, Italy) used in the present work to 
fractionate the formulations produces a force in between 221290 and 448610g, depending 
on the distance from the center of rotation. 
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Lalor, Hummel and Nalenz, for instance, applied (ultra)centrifugation for separation of 
emulsions into their respective phases and subsequently determined the concentration of 
active ingredients present in each phase [2, 3, 6]. 
3.2.3 Oil and Organogel 
3.2.3.1 Definition 
Organogels are semi-solid systems in which an organic liquid phase is immobilized by a 
three-dimensional network composed of self-assembled, intertwined gelator fibres in low 
concentrations (<15%). Based on physical and chemical interactions, gelator fibres form an 
extensive mesh network that prevents solvent flow as a result of surface tension. Phase 
separations into crystalline and liquid layers are avoided owing to the balance between 
gelator aggregating forces and solubilizing solvent-aggregate interactions.  
Organogels can be distinguished from hydrogels by their predominantly organic continuous 
phase and can then be further subdivided based on the nature of the gelling molecule: 
polymeric or low molecular weight organogelators.  
Despite the large abundance and variety of organogel systems, relatively few current 
applications in drug delivery exist, owing mostly to the lack of information on the 
biocompatibility and toxicity of organogelator molecules and their degradation products. A 
number of organogel vehicles have been developed for transdermal delivery. Important 
advantages are the permeation enhancement if a suitable liquid base is selected and their 
general ease of preparation, consisting in simple dissolution of drug and gelator in the liquid 
medium.  Often fatty acids, alcohols, essential oils, fluid wax or liquid paraffin are used as 
components. Also, organogels can be applied as a drug reservoir/matrix in transdermal 
patches. Advantages of this gel vehicle include the capacity to accommodate polar and non-
polar drugs, thermo-reversibility, high degree of stability to moisture and temperature, and 
the ability to control drug release. Besides (trans)dermal delivery organogels are used for 
parenteral depot formulations as well as for oral and trans-mucosal formulations. Interest in 
the field of organogels has increased due to the strikingly rise of the discovery of substances 
that are able to gel organic solvents, but still medicinal lipophilic solutions for use on the skin 
are very uncommon [66-69]. 
One of the very famous examples is the pluronic lecithin organogel developed by Jones and 
Kloesel in the 1990s that provides a base for nonsteroidal anti-inflammatory drugs, 
hormones, selective serotonin reuptake inhibitors and opiates among others [70, 71]. 
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3.2.3.2 Physicochemical Properties 
Lipids can be roughly divided into four chemical classes: The least polar substances are 
hydrocarbons such as petrolatum or soft and liquid paraffin. Moderately polar lipids include 
many types of wax such as yellow wax and fluid wax esters (isopropyl myristate and 
ethylhexyl palmitate), which typically spread over the skin very well. Among the more polar 
lipids are most of the glycerides such as medium-chain triglycerides (neutral fat) and olive oil. 
Silicone oils are hydrophobic substances that spread extremely well. These oils include 
various compounds that contain a polyorganosiloxane as the characteristic functional group. 
Important substances include dimethylpolysiloxane (dimethicone), phenyl ethyl polysiloxane 
and cyclic methyl siloxane (cyclomethicone) [36]. 
Isopropyl myristate (IPM) is an important solvent in studies of permeation of solutes through 
skin. First, it has been suggested as a model for the stratum corneum and partitioning from 
water to IPM, PIPM, have been compared to partitioning from water to the stratum corneum or 
to permeation rates through skin. Second, IPM has been used as a vehicle for permeation 
through skin, usually hairless mouse skin [72]. Saket et al. found a good correlation between 
partitioning into the stratum corneum and partitioning into IPM, but this was limited to 
cortisone, hydrocortisone and their esters [73]. Abraham et al. showed that the water-IPM 
system is a poor chemical model for partitioning from water to the stratum corneum and for 
permeation from water through human skin. The solute factors that influence partitioning into 
IPM are quantitatively not the same as those that control partitioning into the stratum 
corneum [72]. 
3.2.3.3 Thickener and Stabilizer 
Gelling agents are usually organic, rarely inorganic macromolecules that enable formation of 
a three-dimensional frame-work by intermolecular interactions and, thus, form viscous 
solutions in aqueous or oily systems or, in higher concentrations, gels [36]. 
There are several types or organogelators which include steroid derivatives, anthryl 
derivatives, amino acid-type organogelators and organometallic compounds. Aggregation in 
organogels results from a different set of interactions. In non-aqueous liquids, the binding 
forces are primarily dipolar interactions, intermolecular hydrogen bonds or metal-coordination 
bonds [66]. 
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Table 3. Organogel formulations used in drug delivery [68] 
Organogelator used formulations Route of 
administration 
Lecithin Transdermal 
Glyceryl fatty acid esters Transdermal 
N-lauroy-l-glutamic acid di-n-butylamide Transdermal 
Poly(ethylene) Transdermal 
Sorbitan monostearate or monolaureate 
Nasal 
Oral 
Subcutaneous 
intramuscular 
N-stearoyl l-alalnine methyl or ethyl ester Subcutaneous 
Poly(methacrylic acid-co-methylmethacrylate) [and crosslinked poly(acrylic 
acid)] 
Rectal, buccal 
 
 
3.3 TRANSDERMAL ABSORPTION 
3.3.1 Drug Delivery across the Skin  
The application of dermatological formulations may be targeting the drug to three different 
anatomical locations, namely the skin itself (topical delivery), deeper tissue layers (endoderm 
or diaderm delivery) and the systemic circulation (transdermal delivery) [1]. 
Transdermal delivery has several advantages with regard to e.g. oral delivery. It circumvents 
variables that rest on the anatomical and physiological properties along the gastrointestinal 
tract, like pH gradient and nutrition, it bypasses first pass metabolism and due to the fact that 
only small drug amounts reach systemic circulation, it possesses less adverse effects. 
Special drug delivery systems like transdermal therapeutic systems (TTS) provide controlled 
administration and duration of drug action [15]. 
Figure 10 gives an overview about the drug flux that may arise following application of a 
suspension vehicle. Generally, the process of percutaneous absorption is an action of 
several consecutive steps. The drug may undergo any or all of the depicted events: First, the 
drug molecules must dissolve in the vehicle to enable its diffusion inside the formulation to 
the vehicle-stratum corneum interface. The drug diffuses passively out of its carrier and 
partitions into either the almost impermeable stratum corneum or the sebum-filled ducts of 
the pilosebaceous glands. For most hydrophilic and amphiphilic penetrants, diffusion through 
the stratum corneum will be the rate-limiting step, whereas lipophilic substances are favoured 
to penetrate this layer. Inward diffusive movement continues from these locations to deeper 
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tissues of the viable epidermal and dermal points of entry. For very lipohphilic drugs, the 
viable epidermis will act as the rate-limiting factor and clearance rate will govern its 
percutaneous absorption. For systemic delivery, drugs encounter the capillary of the 
cutaneous microvasculature and accordingly gain access to the systemic circulation. Taken 
together all of these steps, a concentration gradient is established across the skin up to the 
outer reaches of the skin’s microcirculation, where the drug is swept away by the capillary 
flow and rapidly distributed throughout the body. Systemic drug levels are usually low and 
inconsequential. If the stratum corneum is not intact, many chemicals can gain systemic 
entrance at alarming rates [38, 74, 75]. 
 
 
 
Figure 10. Different stages of percutaneous absorption [13] 
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Percutaneous absorption is a process controlled by simple passive diffusion and Fick’s law 
can be used to analyse permeation data: 
dx
dcD
Adt
dmJ ⋅−=
⋅
=  
where J is the amount of drug permeated through the skin per unit time and per unit area, A 
is the effective diffusion area and D is the diffusion coefficient (cm2/sec). dc/dx denotes the 
concentration gradient over a distance x. Assuming the conditions of a perfect sink (receiver 
concentration negligible, therefore zero) an infinite donor concentration CD, rate limiting 
membrane (skin) diffusion and partitioning between donor vehicle and rate limiting 
membrane, Fick’s first law of diffusion can be expressed as: 
h
CKD
Adt
dmJ D⋅⋅−=
⋅
=  
K represents the distribution coefficient of the diffusant between the vehicle and the 
membrane (skin) and h is the thickness of this membrane. As an exact determination of h 
and D is difficult, these parameters may be summarized in term of the permeability 
coefficient P (cm/sec): 
h
KDP ⋅=  
This permeability coefficient can be regarded as a characteristic for a specific substance-
membrane system and is, beside the drug flux and the totally permeated drug amount after a 
specific time, a common measure for steady state drug permeation. Fick’s law of diffusion 
shows that the flux J should increase linearly with concentration until the solubility limit is 
reached. The important physicochemical determinants that control diffusion of xenobiotics 
through the skin are therefore partitioning, diffusion and solubility [3, 76]. 
In clinical practice, a finite dose of 1-3 mg/cm2 is applied [77]. However, extent and rate of 
absorption of an agent is determined by vehicle properties, the agent itself and their 
interactions and resulting influences. In order to cross the epidermal barrier, drug molecules 
must possess certain characteristics including: low molecular weight (< 500 Dalton), 
moderate lipophilia (octanol-water partition coefficient between 10 and 1000) and a moderate 
melting point (< 200°C) indicating good solubility [36]. Generally, substances with greater 
hydrophobicity are absorbed more readily by the skin than less hydrophobic. Dermal 
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absorption increases as log P does from -1 to 3.5. Highly lipophilic substances (log P > 5) 
can pass easily through the stratum corneum but are generally too water insoluble to pass 
through the remaining sub-layers and to enter the bloodstream. On the other hand, the rate 
of absorption of substances through the skin is inversely proportional to molecular mass and 
size. Thus, small molecules (>150 Dalton) that are both lipid- and water-soluble are the most 
readily absorbed [78, 79]. Even when active substances exhibit such properties, it is usually 
necessary to find additional means to increase its transport across the skin and until today 
there are only few drugs on the market that fulfil the requirements of a potent topical active. 
During permeation changes in the physical environment of the skin layers occur as depth 
increases from the stratum corneum through viable epidermis into dermis. These changes 
may affect the residence time and distribution of solutes during the penetration process. 
Partitioning into the stratum corneum intercellular lipids and protein binding, i.e. binding to 
keratin, may occur and are the factors responsible for the residence time of drugs in the skin 
[80]. To summarize, for the prediction of the maximum flux of a drug, its solubility in the rate-
limiting barrier is decisive [81]. 
3.3.2 Permeation Routes 
Due to the heterogeneous structure in the stratum corneum, several pathways can be 
considered for drug permeation and it is difficult to specify the extent to which drug utilizes 
each pathway [21, 82]. 
 
 
Figure 11. Permeation routes [27]  
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A molecule may use two diffusional routes to penetrate normal intact human skin: the 
appendageal route and the transepidermal route. The appendageal route comprises 
transport via the sweat glands and the hair follicles with their associated sebaceous glands. 
These routes circumvent penetration through the stratum corneum and are therefore known 
as shunt routes. Although these routes offer high permeability, they are considered to be of 
minor importance because of their relatively small area, approximately 0.1% of total skin 
area. Transepidermal transport means that molecules cross the intact horny layer. Two 
potential micro-routes of entry exist, the transcellular (or intracellular) and the intercellular 
pathway. The principal pathway taken by a penetrant is decided mainly by the partition 
coefficient (log K). Hydrophilic drugs partition preferentially into the intracellular domains, 
whereas lipophilic permeants (log P > 2) traverse the stratum corneum via the intercellular 
route. Most molecules pass the stratum corneum by both routes. However, the tortuous 
intercellular pathway is widely considered to provide the principal route and major barrier to 
the permeation of most drugs.  
In general, the transcellular route is not very likely because substances have to pass through 
areas of high lipophilicity as well as through areas of high hydrophilicity. Recently, it has 
been discussed that drugs either diffuse laterally along the lipophilic carbon chains of stratum 
corneum lipids or that they diffuse along the corneodesmosomes (hydrophilic route). The 
intercellular spaces contain structured lipids and a diffusing molecule encounters significant 
resistance to permeation because it has to cross both lipophilic and hydrophilic structures 
before it reaches the junction between the stratum corneum and the viable epidermis [83, 
84]. Substances like estradiol with an extreme high lipophilicity further build up a depot in the 
lipophilic bilayers [85-87]. 
3.3.3 Factors Affecting Drug Permeation through the Skin 
3.3.3.1 Skin Hydration and Occlusion 
Occlusion refers to skin covered directly or indirectly by impermeable films or substances. 
Healthy stratum corneum typically has a water content of 10-20%, but if diffusional water loss 
from the skin surface is blocked by occlusion, stratum corneum hydration can be raised up to 
50%. Hydration can have several impacts on percutaneous absorption: The partitioning 
between the surface chemical and the skin is altered due to the increasing presence of 
water, corneocytes swell and possibly the intercellular lipid phase organization changes, 
accompanied by an increase of skin surface temperature and an increase of blood flow. 
Thus, skin barrier function is compromised. If hydrophilic character of the stratum corneum is 
increased, it follows, in turn, that stratum corneum – viable epidermis distribution coefficient 
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is reduced. An increase in skin volume can induce internal stresses, especially in keratin 
fibres, which need to enlarge to accommodate absorbed water. Furthermore, occlusive 
covering prevents evaporation of volatile vehicle components, maintaining its solvency for 
the drugs. All is all, occlusion is a complex event producing profound alterations, but its 
impact is also dependent on the anatomic site, the vehicle (e.g. volatility) and the properties 
of the penetrant (polarity, partition coefficient, aqueous solubility) [38, 75, 88-92]. 
Wagner et al. claimed that the hydration state of the stratum corneum obviously is more 
decisive for the drug penetration than examined lipophilic liquid compounds of the ointment 
bases and their tendency to diffuse into the stratum corneum, where they could interact with 
the stratum corneum lipids so as to change barrier properties [93]. 
Nevertheless, permeation enhancement by occlusion is not similar to all kinds of drugs. 
Penetration of lipid-soluble, non-polar molecules seems to be more likely than for polar 
molecules. So to say, a trend of occlusion-induced absorption enhancement with increasing 
penetrant lipophilicity is apparent [89]. Several studies proved the enhancing, non-enhancing 
or even retarding effect. Treffel et al. compared permeation profiles of two molecules with 
different physicochemical properties under occluded versus non-occluded conditions in vitro: 
Occlusion increased the permeation of citropten  1.6 times (lipophilic compound; partition 
coefficient 2.17), but permeation of caffeine (amphiphilic compound; partition coefficient 0.02) 
remained unchanged and, thus, confirmed that not necessarily occlusion leads to an 
increased absorption of all drugs [94]. In contrast, Walters reported on a permeation 
enhancement of caffeine when human skin was occluded. Makki et al. underlined that 
occlusion impact is a function of drug polarity, suggesting that absorption is increased only 
up to moderately lipophilic molecules, whereas it is almost ineffective in molecules of high 
lipophilicity and not or only slightly affecting permeation of amphiphilic molecules like 
caffeine. Thus, hydration induced alteration on permeation rates appear to be a function of 
the physicochemical nature of the permeant [15, 95]. 
3.3.3.2 Evaporation of Volatile Components Following Application 
In clinical and experimental situations, most dermatological vehicles undergo considerable 
changes following application to the skin, most likely due to evaporation of volatile 
components, supported by mechanical agitation associated with application of the product 
[1]. These alterations in the vehicle composition may change the activity of a drug in the 
residual vehicle phase and are possibly necessary for adequate, although generally low, 
percutaneous absorption and efficiency. Most studies on this topic report on the changes in 
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solvent concentration after application, often investigated with volatile solvent mixtures. Here, 
the flux of a given drug will change as the vehicle evaporates and is expected to be 
proportional to both the concentration of the drug in the vehicle and its activity until saturation 
is achieved. The drug may supersaturate and flux levels above those set by a saturated 
solution may be obtained. Nevertheless, when drug concentration is pushed up to a level 
where prompt crystallization is unavoidable, the drug delivery can be markedly depressed 
relative to a supersaturated system even tough the concentration is high [96]. 
Coldman et al. studied the enhancement of percutaneous absorption by the use of suitable 
volatile:non-volatile systems as vehicles and observed an increase in permeation rate due to 
the evaporation of the volatile component that lead to an increase in the solute concentration 
and, thus, a higher thermodynamic activity. A marked depression of drug delivery relative to 
the supersaturated state, attributed to occurring precipitation, has been observed by Chiang 
et al. who examined permeation of minoxidil form water/ethanol/propylene glycol mixtures as 
volatile vehicle systems [8, 96]. An interesting publication reports on a drug delivery device 
where the evaporation of ethanol from an ethanol-water mixture increased the vehicle-skin 
partition coefficient of the active substance, compensating for the loss of drug due to skin 
permeation. The consequence is a near zero order flux over the entire application time and 
an absence of a large excess of drug in the donor reservoir [97].  
To summarize, the evaporative concentration effect may even force the drug out of the 
solution and superimpose a dissolution dependency in the delivery rate. Other investigations 
focus more detailed on possible changes dermatological formulations may undergo following 
application, but without correlating the observation with drug delivery [98-100]. The general, 
but valuable conclusion of these studies is that respective phase diagrams may reflect the 
arising structure during evaporation. The dependence of drug delivery on alterations 
dermatological formulations and colloidal structures undergo due to evaporation of volatile 
components, however, does not appear to have been considered to any great extent in the 
literature.  
Müller-Goymann and Alberg related evaporative changes of water containing hydrophilic 
ointment that was modified by the incorporation of ethanol with permeation of 
hydrocortisone-21-acetate in vitro [11]. They reported on a reduced loss of volatile 
components after the incorporation of ethanol, likely due to fixation of the alcohol in the 
microstructure of the ointment. The liberation kinetics across an artificial membrane could be 
related to the arising drug concentration, but permeation kinetics, however, was equal from 
both formulations. This was accredited to penetration enhancing effects of the ethanol. The 
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effect of percutaneous absorption of hydrophilic model drugs on the emulsion type after non-
occlusive infinite dose application is presented by Ferreira et al. [101]. Hummel and Imanidis 
demonstrated that obviously varying in-vitro skin permeation of ibuprofen from several non-
occlusively applied multi-phasic dermatological formulations was only governed by the 
continuous phase drug concentration of the vehicles, independently of existing dispersed 
structures. The back diffusion of the lipophilic model drug into the dispersed phases 
compensated for the influence of the rising overall drug concentration due to evaporation of 
volatile components, so that linear drug flux with time was observed [102]. Nalenz and 
Imanidis studied sodium nicotinate permeation out of multi-phasic o/w-formulations that were 
applied non-occlusively taking especially into consideration alterations these formulations 
may undergo due to evaporation of volatile components.  During evaporation of volatile 
vehicle compounds, several phase transitions were detected, such as vesicle to 
microemulsions, phase inversion from o/w to w/o and drug precipitation. Independently of 
structural changes, continuous phase drug concentration could quantitatively describe 
permeation kinetics without the need to consider formulation effect on skin barrier function 
[3]. 
3.3.3.3 Drug-Skin Interactions 
In order to achieve a satisfying therapeutic effect, drugs have to reach their destination in 
sufficient amounts. The permeation and, consequently, the pharmacological action may be 
affected by skin metabolism, vascular and hydration effects. Especially highly lipophilic 
compounds are often adsorbed within the skin with the result of a decreased and delayed 
drug flux. The keratin-drug-binding owns a crucial importance in this point. The formation of 
reservoirs within the skin is mainly based on van-der-Waals forces and H-bonds.  
The stratum corneum reservoir is defined by three independent variables: (a) the diffusivity of 
the drug in the stratum corneum, (b) the amount of drug in the stratum corneum and (c) 
clearance of the drug from the epidermis. The diffusivity of solutes in the stratum corneum 
determines the time to reach steady state or to desorb from the stratum corneum. The 
amount of drug in the stratum corneum is defined by the affinity of the drug for the stratum 
corneum. Partitioning occurs into both the lipid and protein domains of the stratum corneum. 
Removal of solutes from the stratum corneum depends on clearance into the viable 
epidermis and hence into the dermis. Whilst clearance is normally assumed not to be rate 
limiting, a sufficiently low clearance may lead to a reduced flux through the stratum corneum 
and an increased amount retained in the stratum corneum. Steroids are famous for their so-
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called reservoir effect, but it also occurs with other substances like nicotine, caffeine or 
cationic β-blocking agents [103].  
Al-Saidan revealed a self-permeation enhancement of ibuprofen, possibly acting as an ionic 
surfactant that disrupts stratum corneum barrier. Furthermore, it is possible that some drugs 
which quickly penetrate into the skin to yield tissue concentrations high enough to exert an 
osmotic effect may increase hydration [13, 103, 104]. 
 
3.3.3.4 Drug-Vehicle Interactions 
In topical and transdermal formulations, selection of a suitable vehicle is crucial as it can 
affect both drug release and percutaneous absorption. Factors that contribute to the 
selection are: (i) solubility of the drug in the vehicle, (ii) release of the drug from the vehicle 
into the skin and (iii) enhancement of drug penetration through the stratum corneum [105]. 
Regarding the vehicle, it is the interaction between the vehicle components and the drug that 
finally determine in as much topical delivery of the formulation is efficient or not. Vehicles can 
comprise different structures like micelles or liquid crystalline stages like hexagonal phase or 
lamellar phase. Depending on where the drug is located and how strong binding forces are, 
vehicle structure will have a strong influence on its liberation [106]. Furthermore, liberation 
extent and velocity are dependent on partition coefficient, solubility of the drug in the vehicle 
and concentration of the active ingredient (see 3.3.1). In general, it can be assumed that 
polar substances are more easily liberated from non-polar vehicles and vice versa [107]. 
Vehicle-drug interactions also include thermodynamic activity of the drug in the vehicle which 
is related to its concentration in the vehicle and its activity (see 3.3.3.6.2) [1]. The maximum 
drug transfer into the skin takes place when the vehicle is saturated with the drug at the 
vehicle-skin interface. In this situation, the thermodynamic activity is 1. In some cases, 
however, thermodynamic activity may be greater than unity, for example in a supersaturated 
state due to vehicle evaporation (see 3.3.3.2). Hence, when the system deviates from 
ideality, the drug concentration must be replaced by activity αD: 
DDD C⋅= γα  
where CD denotes the donor concentration and γD is the activity coefficient [1]. Schwarb et al. 
reported on a supra-proportionally increased flux of fluocinonide through a silicon membrane 
with increasing drug concentration, likely due to increasing thermodynamic activity, while in 
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vivo skin penetration of the drug was only increased by the factor of which the magnitude of 
concentration in the respective formulation was increased [7]. 
A further drug-vehicle interaction that may affect drug permeation is the formation of ion pairs 
of charged drugs with counter ions present in the vehicle. For instance, Valenta et al. found 
that fluxes of charged lignocaine salts were significantly increased in the presence of organic 
counter ions, while inorganic salts did not influence the permeation kinetic [108, 109]. 
Several publications that deal with cationic substances and fatty acids as counter ions 
support this ion pair approach as a possible enhancing effect of fatty acids [110, 111]. In 
some cases drug permeation through the skin is not governed by the poor permeability 
through the stratum corneum. For example, when the horny layer is damaged or drug 
diffusion within the vehicle is exceptionally slow, the release rate of the drug from the vehicle 
provides the rate-limiting step in overall diffusion and the skin functions as a perfect sink [13]. 
3.3.3.5 Vehicle-Skin Interactions 
In general, skin surface is equilibrated with the surrounding environment and application of a 
dermatological formulation can perturb this balance and consequently affect skin barrier 
function. For example, lanolin, isopropyl myristate, carbon hydrates with long chain lengths 
and w/o-formulations are famous for their hydrating effects, but also dehydration and 
temperature changes may occur, dependent on the formulation selected. Concerning the 
lipids of stratum corneum, they may be extracted, fluidized or stabilized and solubility 
properties of the skin may be changed. It may be hypothesized that if the solubility parameter 
of the vehicle alters that of the skin so that it is closer to the solubility parameter of the drug, 
permeation may be enhanced [106, 112].  Gaps in the desquamating layers of the horny 
layer allow the vehicle components to enter until a depth of 2/3 to 3/4. Besides, the vehicle 
may undergo profound changes after application due to evaporation and admixing with the 
lipid surface layer of the skin [77].  
Dias et al. studied the transdermal permeation of caffeine out of several saturated vehicles 
(same thermodynamic activity), but different solubility parameters, different lipophilicities and 
varying saturation concentrations. Mineral oil and isopropyl myristate among others 
enhanced permeation by modulation of the barrier properties. It was concluded that the 
vehicles permeate into the skin lipids and alter the solubility properties in a favourable way. 
The degree to which the vehicles can achieve this depends on their uptake into the skin and 
their solubility of caffeine in the modified environment. The study indicated that although 
vehicles promote changes in partitioning and diffusion, it is likely to be the partitioning that is 
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the dominant factor. Drugs with a log P of about 2 have a higher permeation rate due to their 
lipophilicity [112]. 
Jaeckle et al. studied the permeation of the model drug ketoprofen through heat-separated 
human epidermis and artificial membranes with and without pre-treatment of ointment bases 
to test the influence of those dermatological ointments. It was possible to demonstrate an 
easy and cheap methodology to search for even relatively weak vehicle effects to influence 
drug permeation [113]. Tape stripping technique and in vitro skin permeation experiments 
are useful for comparing the percutaneous absorption kinetics of different formulations. The 
permeation parameters diffusivity inside a vehicle and partitioning from formulation to skin 
are easily altered by the composition of the formulation and are thus important factors 
affecting permeation kinetics. Diffusivity within the vehicle can be determined from in vitro 
release studies, whereas partitioning from a formulation to the skin can by measured by the 
tissue distribution of the drug (see 3.3.4.4). However, little is known about the relationship 
between these two parameters in practical study because mostly skin permeation of the drug 
has been analyzed assuming a well-stirred condition in the formulation.   
To summarize, the cause of skin permeation alteration from formulation has to be divided 
into diffusivity and partitioning in a formulation, diffusivity and partitioning in the skin and it 
has to be clarified which parameter has more effect on skin permeation – as presented in the 
work of Yamaguchi et al. [9]. 
 
3.3.3.6 Permeation Enhancer 
3.3.3.6.1 Definition and Mode of Action 
Methods for improving cutaneous delivery rely either on the use of chemical penetration 
enhancers, novel vehicle systems (e.g. microemulsions), liposome-based delivery systems, 
supersaturated formulations or more complex physical enhancement strategies such as 
iontophoresis, sonophoresis and electroporation. Skin penetration enhancers are molecules 
which reversibly remove the barrier resistance of the stratum corneum and, thus, allow drugs 
to penetrate more readily to the viable tissues and systemic circulation [114, 115]. Potential 
substances used need to fulfil several requirements [116]. 
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Table 4. Requirements of an ideal enhancer [116] 
Ideal Enhancer 
• Pharmacological and chemical inertness 
• Chemical stability 
• High degree of efficiency with specific activity and reproducibility 
• High compatibility with formulation and system ingredients 
• Possess no allergizing, sensitizing, phototoxic potential 
• Possess solubility parameters of the skin 
• Modification of barrier function in a reversible manner 
• Possess no odour, taste or colour: Acceptable for cosmetical purposes 
Generally, based of Fick’s first law of diffusion, the permeation enhancement strategies may 
be delineated: (i) increase of the diffusion coefficient, (ii) increase of the solubility of the drug 
in the stratum corneum, i.e. increase of the drug partition coefficient into the skin and, finally, 
(iii) increase of the drug concentration gradient vehicle-skin, that mainly acts as driving force 
for permeation, i.e. increase of the drug’s concentration inside the vehicle up to saturation or 
above (supersaturation approach) [115]. 
Barry tried to classify accelerant action by rationalizing various mechanisms responsible in 
the so-called lipid-protein-partitioning theory: Enhancers may interact with intercellular lipids, 
they may interact with intracellular protein (mainly keratin) and they may penetrate in high 
amounts as so-called co-solvents into stratum corneum with a resulting improved dissolving 
capacity of the barrier for the drugs [27, 117, 118]. 
 
Figure 12. Mode of action of permeation enhancers [84] 
 
Drug diffusion coefficient can be increased by disordering the stratum corneum lipids. It is 
assumed that accelerant molecules penetrate into and mix homogeneously with the lipids of 
the bilayers. Enhancers interact either with the polar head groups of the lipids (hydrophilic 
pathway) or with the long carbon chains (lipophilic pathway).  Interaction with polar head 
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groups of the lipids modifies hydrogen-bonding and ionic forces, disturbs hydration spheres 
and subsequently leads to an upset of the packing at the polar plane. The domain becomes 
more fluid and starts to promote diffusion, mainly of polar penetrants. More aqueous fluid 
may enter the tissue and increase the water volume between the lipid layers. An important 
secondary feature is that disruption of interfacial structure will also alter packing of lipid 
chains. The lipid hydrophobic route, thus, becomes more disordered and more readily 
traversed by lipid-like penetrants. Also, it is possible that accelerants insert themselves 
between the hydrophobic tails of the bilayers, upsetting their packing and, thus, increasing 
their fluidity, permitting easier diffusion. Through rotation, vibration and translocation micro 
cavities can be formed and free volume available for drug diffusion can again be increased. 
Fatty acids, azone, DMSO, oleic acid and terpenes are good examples for substances acting 
this way [27, 84, 115, 117]. 
Many solvents enter the stratum corneum, change its solution properties by altering the 
chemical environment and, thus, increase partitioning of a second molecule into the horny 
layer, i.e. increase of drug partitioning. Ethanol and propylene glycol are solvents that are 
known for this action, but, nevertheless, partition promotion is always specific for certain 
kinds of drugs. In theory, nonsolvent enhancers that mainly act by interaction with the lipids 
in the bilayer should also increase the partition coefficient for drugs. That is, by disordering 
the lipid interfacial domain they increase free volume and make a larger fraction of bilayer 
available for solute partitioning [27]. 
The drug concentration gradient vehicle-skin may be increased by increasing the degree of 
saturation inside the vehicle. This leads to an enhanced thermodynamic activity and 
therefore to an increased skin permeation. It is the drug’s thermodynamic activity that is more 
important than its absolute concentration. A saturated solution implies a thermodynamic 
activity of unity.  An increase in the degree of saturation to greater than one can be achieved 
via supersaturation. However, such formulations are thermodynamically unstable and drug 
crystallization occurs over time [115]. 
Additionally, the stratum corneum can be made more permeable for drug substances by the 
extraction of its lipids as the result of an interaction with chemical penetration enhancers. 
Polar penetration enhancers can also interact with intracellular keratin, leading to changes in 
the protein conformation, mainly opening up the dense structure and making it more 
permeable. However, intracellular route is usually not important in drug permeation and that 
is why this feature usually stays neglected in literature [27, 84]. 
Theoretical Section 
 
 
 
Miriam Reiser   University of Basel, 2008 
 
 
 - 61 - 
Panchagnula et al. tried to increase transdermal permeation of highly lipophilic paclitaxel 
(MW>500) by modifying stratum corneum with terpenes and fatty acids, but although bilayer 
was disrupted, permeation was not facilitated and this suggest that permeation of high-
molecular-weight can not be enhanced through bilayer and partitioning alteration [119]. 
 
3.3.3.6.2 Supersaturation 
As already mentioned above (3.3.3.4) supersaturation is a simple approach to increase drug 
permeation without alteration of stratum corneum structure. Higher drug concentrations in the 
vehicle lead to an increase in the concentration gradient of the Fick’s law and, thus, force the 
active principle out of the formulation and into or across the stratum corneum. Nevertheless, 
gaining a thermodynamic activity greater than 1 is always accompanied with thermodynamic 
unstable formulations and drug crystallization. The stability of supersaturated formulations 
can sometimes be prolonged by the addition of certain polymers but, even then, these 
systems are not stable enough for long-time storage. Supersaturation can be achieved by 
different methods directly before of during application of the formulation: (i) by water uptake 
from the skin, (ii) through evaporation of a volatile formulation components during 
application, (iii) by using the method of mixed cosolvent systems wherein vehicle changes 
are produced immediately prior to administration of the formulation and (iv) heating and 
subsequent cooling.  Theoretically, supersaturation offers an advantage over “traditional” 
enhancers in which the enhancement is specific to the compound of interest: There is no 
breakdown of the barrier function and the absorption of other compounds (e.g. excipients) is 
not enhanced [7, 86, 115]. 
 
3.3.3.6.3 Water as Penetration Enhancer 
The simplest means of penetration enhancement involves influencing the barrier function of 
the skin by increasing hydration of the stratum corneum. Retention of water in the horny layer 
leads to a loosening of its compact structure and, thus, makes it more permeable. The water 
content of the horny layer can either be increased by release of water from the vehicle or by 
(partial) occlusion that blocks transepidermal water loss [36, 86, 117]. 
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Table 5. Effect of carrier system on the stratum corneum water content and the penetration of active 
ingredients [120] 
Vehicle Example / Constituents 
Effects on skin 
hydration 
Effect on skin 
permeability 
Occlusive dressings plastic film, unperforated 
waterproof patch 
Prevent water loss, full 
hydration 
Marked increase 
Lipophilic vehicles paraffins, oils, fats, 
waxes, fatty acids, fatty 
alcohols, esters, silicones 
Prevent water loss, may 
produce full hydration 
Marked increase 
Absorption bases unhydrous lipids plus w/o 
emulsifiers 
Prevent water loss, 
marked hydration 
Marked increase 
Absorption bases Unhydrous lipids plus o/w 
emulsifiers 
Prevent water loss, 
marked hydration 
Marked increase 
W/O systems W/O creams, W/O 
emulsions 
Retard water loss, raised 
hydration 
Increase 
O/W systems O/W creams, O/W 
emulsions 
Can donate water, slight 
hydration increase 
Slight increase 
Humectants Water-soluble vehicles, 
glycerol, glycols 
Can withdraw water, 
decreased hydration 
Possible decrease or at 
as chemical enhancer 
Powder Clays, shake lotions As water evaporation, 
decreased excess 
hydration 
Negligible effect on 
stratum corneum 
 
Water as well as propylene glycol is thought to hydrogen bond to the polar head groups of 
the lipids in the stratum corneum. This leads to an enlargement of the distance between the 
lipid molecules in combination with a lateral extension of the alkyl chains. By hydration of the 
stratum corneum, the penetration of most of the drugs can be increased. Normally, the 
stratum corneum water content is 5-10%, but it can be in raised up to 50% under occlusive 
conditions. Furthermore, moisturizers such as urea can be used to increase the hydration of 
the stratum corneum and in consequence improve the diffusion of hydrophilic drugs [84, 93]. 
3.3.3.6.4 Chemical Enhancers 
Several excipients are able to promote the transport of an active substance across the skin 
barrier by a variety of mechanisms (see 3.3.6.3.1). Table 6 briefly summarizes the most 
commonly used enhancers and their mode of action [84].  
In general, permeation enhancers act by more than one mechanism and combing different 
enhancers can lead to synergistic effects. Nevertheless, one has to be aware that with an 
increasing potential to enhance permeation, also the risk for skin irritation is raised. 
In this section, special emphasis should be given to isopropyl myristate as permeation 
enhancers as it was one of the lipophilic bases selected for the w/o-emulsions examined in 
this work.  
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Isopropyl myristate belongs to the group of esters that may influence drug penetration by 
various mechanisms. Brinkmann et al. were able to show that isopropyl myristate 
incorporates within the densely packed bilayer lipids of stratum corneum leading to a loss of 
order of the corneocyte-bonded lipids and, thus, an increased fluidity with reduced diffusional 
resistances. The influence of isopropyl myristate on intercellular lipids can be demonstrated 
by several methods such as DSC, x-ray diffraction, SAXD and WAXD. While SAXD 
measurements show a slight decrease in intensity of the bilayer packing in the presence of 
isopropyl myristate, WAXD of isopropyl myristate pre-treated stratum corneum demonstrates 
a complete loss of order of the corneocyte-bonded lipid fraction and a decrease in the lateral 
packing distance of the hexagonally arranged lipid fraction. From these findings, an isopropyl 
myristate insertion into stratum corneum lipids has to be concluded, affecting both lipid 
fractions mentioned above. Isopropyl myristate insertion within the hydrocarbon chains 
results in a more densely packed arrangement and therefore in a higher permeation barrier. 
Obviously this strengthening of the stratum corneum barrier function counteracts the loss of 
order of the corneocyte-bonded lipid fraction [121-123]. 
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Table 6. Chemical enhancers and their mode of action [84] 
Enhancer Mode of Action 
Ethanol and higher 
alcohols 
• Increases solubility of the drug in the vehicle 
• Increases partition coefficient into the skin 
• Extract lipids and proteins, thereby increase porosity of stratum 
corneum 
• Disrupts bilayers structure of intercellular lipids 
• Displaces bound water at the lipid head-groups 
Sulphoxides, e.g. 
DMSO 
• Creates solvent-filled spaces in stratum corneum due to outstanding 
dissolving properties 
• Disturbs bilayers structure of stratum corneum (concentration above 
60% necessary) 
• Denaturises intercellular structural proteins 
• Changes intercellular keratin confirmation 
• High irritating potential 
• Extracts stratum corneum lipids 
Azone and 
derivatives 
• Low irritating potential 
• Low toxicity 
• No pharmacological activity 
• Mechanism under ongoing research 
• Intercalation into structured lipids of the stratum corneum 
• Disturbs lipid backing order of intercellular lipids 
• Increases fluidity of hydrophobic stratum corneum regions 
Pyrrolidones • Enhance hydrophilic and lipophilic drugs 
• Adverse effects like erythema and irritancy 
Urea and derivatives • Hydrating agent 
• Keratolytic properties 
• Moisturizing effects inducing hydrophilic diffusion channels 
Alkyl-N,N-
disubstituted 
aminoacetates 
• Interaction with stratum corneum keratin 
• Increases hydration 
Propylene glycol • Penetrates into skin and thereby drags drugs 
• Increases partition coefficient of the drug into the stratum corneum 
Surfactants • Potential to solubilize stratum corneum lipids 
• Interactions with keratin 
• Cationic surfactants are more effective than anionic and non-ionic 
compounds 
Terpens and 
terpenoids 
• Interact with intercellular lipids 
• Influences non-polar penetration route 
• Low toxicity and irritancy 
Fatty acids, e.g. oleic 
acid 
• Enhancement strongly dependent on fatty acid structure 
• Oleic acid forms pools within lipid bilayers of stratum corneum 
Esters • Enhance by affecting diffusion of the drug 
Cyclodextrines • Form inclusion complexes with lipophilic drugs 
• Increase solubility of the drug 
• Cannot penetrate skin 
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3.3.3.6.5 Liposomes and Microemulsions 
Liposomes are colloidal particles, typically consisting of phospholipids and cholesterol, with 
other possible ingredients such as niosomes (non-ionic surfactant), ethosomes (ethanol) and 
transferosomes (surfactants as “edge activators”). Most reports cite a localizing effect, 
whereby vesicles accumulate drugs in the stratum corneum or other upper skin layers. 
Generally, liposomes are not expected to penetrate into viable skin. Traditionally they are 
thought to confine themselves to the surface or upper layers of the stratum corneum, where 
they dehydrate and fuse with skin lipids [27, 124]. 
There has been a lot of controversial discussion and scepticism on the question whether 
vesicles penetrate the skin. Some authors claim that skin treated with liposomes reveals 
vesicle fusion, yielding a structural breakdown of the liposomal bilayers and hence, fusion of 
the phospholipids with the intercellular lipids of the stratum corneum. This can cause 
ultrastructural changes in the region with the consequence of reduced skin barrier function 
and permeation enhancement. A crucial factor may be the organization of phospholipids 
within the vesicle: highly ordered state (gel structure) or liquid crystalline state. Several 
studies underline the trend that more flexible liquid state liposomes are favoured to penetrate 
the skin. To summarize how liposomes interact with the skin, it is still not well understood 
whether they penetrate as entire liposomes or not [125-127]. 
Microemulsions are modern drug carrier systems for topical delivery that are 
thermodynamically stable, low viscous, transparent and optical isotropic with a dynamic 
microstructure that forms spontaneously by combining appropriate amounts of a lipophilic 
and a hydrophilic ingredients, as well as a surfactant and a co-surfactant. While emulsions 
consist of roughly spherical droplets of one phase dispersed in another (see 3.2.2), 
microemulsions may constantly evolve between various structures ranging form droplet like 
micelles to bicontinuous structures. The “particle” size in microemulsions lies in the range of 
10 -200 nm, whereas macroemulsions are at least one order of magnitude bigger (1-20 µm). 
Different mechanisms are responsible for the ability of microemulsions to increase the 
transdermal delivery: Important features are their high drug solubilization capacity which 
leads to high concentration gradients towards the skin and a microstructure that allows free 
and fast drug diffusion. Furthermore, the surfactants in the microemulsion may reduce the 
diffusional barrier of the stratum corneum altering both the lipophilic and the polar pathway 
by synergistic interaction of vehicle components with the stratum corneum.  Due to their 
ultra-low interfacial tension, an excellent surface contact between the skin and the vehicle is 
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ensured with the result of a faster penetration and permeation into deeper skin layers and a 
decreased lag-time, compared to conventional formulations, e.g. emulsions. However, the 
correlation between microemulsion structure/composition and drug delivery potential is not 
yet fully elucidated.  
It is assumed that the high content of lipophilic and aqueous phase fluctuate continuously, 
facilitating transition of both lipophilic and hydrophilic drugs from their typically hydrophilic-
vehicle to the lipophilic stratum corneum [128-131]. 
3.3.3.6.6 Stratum Corneum bypassed or removed 
Stratum corneum can be bypassed by injection and one development of this approach is a 
device of 400 microneedles which insert drug just below the barrier. The solid silicon needles 
(coated with drug) or hollow metal needles (filled with drug solution) penetrate the horny 
layer without breaking it or stimulating nerves in deeper tissues [27]. 
As the horny layer usually provides the permeation barrier, one could consider simply 
removing it. Chemical peels, micro-dermabrasion using a stream of aluminium oxide crystals 
and dermabrasion using a motor-driven abrasive fraise or cylinder are available. Adhesive 
tape can remove stratum corneum prior to drug application. Tape stripping techniques is also 
a frequently used method to determine drug uptake into the skin [27]. 
 
3.3.4 In Vitro Permeation Experiments 
3.3.4.1 Pig Ear Skin 
In search of a suitable animal model, two main options have to be considered: (a) use of an 
animal phylogenetically as close as possible to man or (b) use of an animal in which the 
process under investigation is as close as possible to that in man, considering its physiology, 
biochemistry and that the anatomy is similar. Various anatomical and physiological 
characteristics indicate that pig is a good model for man, but also dissimilarities do exist like 
vascularization (rich in man, poor in pig) and in the sebaceous glands. Humans have mostly 
eccrine sweat glands whereas pigs possess only apocrine glands. Percutaneous absorption 
in man and most probably in animals also varies depending on the area of the body on which 
the chemical resides. Most of the permeation studies conducted in pigs were performed on 
their back, on the ear and few on the flank or abdomen [132]. 
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Porcine skin, however, is a well-accepted and readily available model for human skin; 
especially excised porcine ears have become increasingly used for the assessment of 
dermatological formulations in vitro. The structure of porcine tissue, including hair follicles, 
has been studied qualitatively and quantitatively in comparison with human skin and results 
obtained underline the suitability of porcine tissues as a model for human skin.  
Significant similarities were found for lipid composition, epidermal thickness and 
permeabilities of the membranes to diverse compounds. Porcine ear skin shows even a good 
agreement in its histology as studied by Jacobi et al. [133, 134]. 
In addition, Lopez et al. investigated the composition and structure of pig stratum corneum 
tissues based on the action of different solubilizing agents and reported a strongly similar 
lipid composition and structural organisation of pig stratum corneum compared to human 
stratum corneum, described in 3.1.3 [135]. 
 
Table 7. Lipid composition of porcine and human stratum corneum (expressed in weight-%) [14] 
Component Epidermis Stratum Corneum 
 pig pig human 
Cholesterol esters 4.1 1.7 10 
Triglycerides 1.3 2.8 0.0 
Fatty acids 1.5 13.1 9.1 
Cholesterol 8.9 26.0 26.9 
Ceramide 1 21.8 4.1 3.2 
Ceramide 2 2.6 16.7 8.9 
Ceramide 3 9.1 6.9 4.9 
Ceramide 4 3.5 4.4 6.1 
Ceramide 5 2.4 4.5 5.7 
Ceramide 6 3.1 7.6 12.3 
Glucosylceramides 8.1 1.0 0.0 
Phospholipids 17.6 - - 
Cholesterol sulphate 
 3.9 1.9 
Protein-bound lipids 12.8   
Other 0.8 5.7 11.1 
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Table 8. Comparison of porcine ear skin with human skin [133] 
  
Pig ear skin Human skin 
Thickness [µm] Stratum Corneum 21 6 -19 
 Viable epidermis 72 70 (shoulder) 
 
  82 (buttock) 
 Dermis 1860 1800 - 1900 (back) 
Hair density [number / cm2] 
 20 14 - 32 
Diameter Hair [µm] 
 82 16 - 18 
Hair extension into skin [mm] 
 1.20 > 3 
 
Schmook et al. compared in vitro percutaneous absorption of human, pig, rat, GraftskinTM 
LSETM (living skin equivalent) and SkinethicTM HRE (human reconstructed epidermis) for 
dermatological drugs of widely varying polarity and concluded in agreement with already 
published data that pig skin appeared as the most suitable model [136]. 
In order to predict skin permeability and metabolism of human skin by extrapolating datas 
derived on animal skin, differences in skin metabolism have to be taken into consideration. 
Different dermal esterase activities and, subsequently, varying metabolism and transport 
rates were subject of studies conducted by Ngawhirunpat et al. in various species. Their 
investigations revealed that there was no significant difference in skin permeation and 
metabolism between human and pig skin [137]. 
Sekkat et al. examined stratum corneum barrier function during its progressive removal by 
adhesive tape-stripping using the techniques of transepidermal water loss (TEWL) and 
impedance spectroscopy. Comparing the results with in vivo data obtained from human 
strongly support the validity of the porcine membrane as a good in vitro model [134]. 
In general, rodent skin is more permeable than human skin. This can lead to an 
overestimation of permeation relative to that in human. This problem is partly associated with 
the effect of hydration wherein prolonged (generally 24h and more) exposure of skin to 
aqueous donor and receiver phases brings about a marked diminution in the barrier 
properties [138]. 
3.3.4.2 Franz-type Diffusion Cells 
There has been a wide variety of diffusion cells designed for in vitro measurements of skin 
permeation. Side-by-side diffusion cells (bichambers) can be used to delineate mechanisms 
of permeation under controlled conditions (e.g. iontophoresis). Vertical cells, like the Franz 
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diffusion cell, are more versatile because a wide variety of experimental conditions can be 
tested. The diffusion cell consists of a donor and a receiver compartment separated by a 
membrane, e.g. skin, that is mounted horizontally. The cell is suitable for measuring 
absorption from a range of dosage forms, including solutions, suspensions, powders, 
creams, gels, ointments, aerosols and solids. Furthermore, the delivery vehicle can be 
applied non-occlusively and in small amounts (finite dose) to simulate clinical situations as 
close as possible. For hydrophilic compounds, the receptor compartment should be a buffer 
solution, whereas for lipophilic compounds the use of solubilizing additive is sometimes 
necessary (e.g. cyclodextrine, bovine serum albumin) [115]. Sink conditions must be 
assured. The great advantage of performing in vitro permeation experiments is the 
avoidance of animal experiments and costs, experimental environment can be controlled and 
thereby individual factors modifying penetration can be elucidated. Nevertheless, only little 
information on metabolism and distribution after absorption can be gained, shedding as well 
as physiological and pharmacological responses do not occur. All of this can lead to an 
overestimation of total absorption [15, 138, 139]. 
 
 
Figure 13. Franz Diffusion Cell [140] 
 
 
3.3.4.3 Assessment of Skin Barrier Integrity 
In the course of performing in vitro percutaneous absorption studies, it is important to ensure 
the integrity of the stratum corneum. Based on OECD guidance document 28 three different 
methods are recommended for integrity testing: (a) measurement of transepidermal water 
loss (TEWL), (b) measurement of electrical resistance or (c) the use of tritiated water as 
permeation marker [141-143]. The principal of the TEWL-measurement is based upon an 
open chamber system with two humidity and two temperature sensors, placed at 2 and 4 mm 
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distance to the skin surface. This setup allows estimation of the evaporation gradient on the 
skin surface.  
The physical basis for this non-invasive and rapid alternative to tritiated water permeation is 
the first diffusion law discovered by Adolf Fick in 1855: 
dl
dsDA
dt
dm
−=   
where dm/dt denotes the diffusion stream across the open chamber, expressed as 
transported mass of water per time. A is the exposed area and ds/dl the change of density 
over the entire distance l. D is the diffusion coefficient of water vapour in the air. 
 
Figure 14. Sensor head for measurement of TEWL 
 
In general, TEWL values vary widely, dependent on the body site and the environmental 
conditions. Nevertheless, disturbance of the integrity of the skin barrier, leads to drastically 
increase in the loss of endogenous water [144]. TEWL measurements allow only the 
detection of severe damage of the stratum corneum, but not of small changes that already 
may influence drug diffusion as demonstrated by Netzlaff et al. [145]. 
3.3.4.4 Skin-Vehicle Distribution Coefficient 
The outer layer of the skin has been recognized for some time as the rate controlling 
membrane that acts predominantly as a lipophilic barrier and, thus, partitioning into the 
stratum corneum is a dominant physico-chemical determinant in controlling absorption [146]. 
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The partition coefficient for compounds between stratum corneum and water KSC can be 
estimated based on the drug octanol-water partition coefficient Koct : 
octSC KK log59.0024.0log +−=             according to Pugh et al. [147] 
octSC KK log514.0104.0log +=             according to Abraham et al. [148, 149]. 
If diffusion is straight through the cells, the pathlength is approximately 15µm, for transfer 
through the intercellular channels, the pathlength has been estimated to be between 350 and 
880 µm. It is possible to calculate KSC and D using various values for the pathlength. For a 
pathlength of 15 µm, for example, KSC for caffeine is assumed to be 1.79, for a pathlength of 
500 µm (tortuous pathway) KSC of caffeine is assumed to be 0.05 [150, 151]. 
One problem in the dermal field of research is inter- and intra-individual differences of the 
lipid composition of the skin that makes it very difficult to compare results obtained form 
numerous skin donors. In the last years, it was shown that the penetration of drugs into the 
stratum corneum mostly corresponds with the presence of various components of the lipid 
composition present in each skin specimen. For instance, Wagner et al. found a direct linear 
correlation between the stratum corneum/water partition coefficients and the amount of drug 
(flufenamic acid) penetrated into the stratum corneum [152].  Van der Merwe et al. tested 
various agricultural and chemicals with regard to their partitioning into and their permeability 
through stratum corneum. They concluded that, for the compounds tested, partitioning into 
the stratum corneum was determined by the relative solubility of the solute in the donor 
solvent and the stratum corneum lipids. However, composition of the lipoidal phase of the 
stratum corneum can be changed by the diffusion of e.g. components of an ointment base 
into the stratum corneum. This might have an impact on the drugs distribution coefficient and 
its solubility in stratum corneum, although they tend to parallel. The skin-vehicle distribution 
coefficient might be useful to delineate penetration and permeation, but it has to be 
considered that permeability always reflects the result of successive, complex processes and 
is not always predictable form stratum corneum partitioning alone [152, 153]. 
Several techniques can be used to determine the drug amount penetrated into stratum 
corneum and deeper skin layers and, thus, stratum corneum/drug-in-solution partition 
coefficient can be computed.  Typically, isolated, accurately weighted stratum corneum 
pieces are incubated with the specific substance dissolved in the vehicle over a validated 
time (equilibration).  Afterwards remnants in the vehicle and/or drug amount in the stratum 
corneum piece are quantified. Drug amount in stratum corneum can be received by tape-
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stripping technique and the subsequent quantification of each tape or by the extraction of 
cleaned, but whole stratum corneum piece with a suitable solvent (e.g. hexane). 
Furthermore, radiolabelled drugs can be used as the facilitate quantification, both in solution 
and skin sheets later on. A common method to isolate stratum corneum is based upon the 
treatment of excised skin with trypsin solution for several hours. Then, the stratum corneum 
may be carefully peeled off from the underlying epidermal cells and, after treatment with 
trypsin inhibitor solution in order to prevent further degradation, dried and stored in a 
desiccator over silica gel. For deeper skin layers, e.g. for the determination of stratum 
corneum/dermis partition coefficient cryo-sections can be used [152, 154, 155] 
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4 Transdermal Drug Skin Permeation with 
Lipophilic Vehicle: The Continuous Phase 
Drug Concentration Concept 
Abstract 
The purpose of this study was to investigate the influence of phase fraction, oil base and 
drug partitioning of occlusively applied w/o-emulsions on transdermal drug permeation for a 
hydrophilic and a lipophilic model drug (caffeine and ibuprofen) across pig ear skin in vitro. A 
concept for the interpretation of drug permeation is proposed that considers continuous 
phase drug concentration as the driving force for transdermal permeation. Drug distribution 
within the formulation and drug distribution between stratum corneum and continuous oil 
phase are determined in order to gain a full understanding of the examined absorption 
processes. 
The studied w/o-emulsions consisted of an oil phase into which water phase was dispersed 
in phase fractions of 70%, 50% and 30%, respectively (E70, E50, E30). Oil phase consisted 
of a single oil component (isopropyl myristate, miglyol 812N or paraffinum liquidum) and the 
polymeric emulsifier Isolan PDI. Water phase contained sodium chloride and was buffered to 
pH 4.5 in all emulsions containing ibuprofen. Pure oil with emulsifier was selected as 
reference formulation. Transport experiments were performed in Franz-type diffusion cells 
across pig ear skin with an infinite dose of 0.7 g/cm2. 
Dependence of apparent permeability coefficient Papp on fraction of drug concentration in the 
continuous phase was analyzed with a model taking into account the permeability coefficient 
of the skin Pm and the permeability coefficient of the diffusion boundary layer Pdbl. Pdbl reflects 
the diffusivity of the drug in the vehicle. By fitting this model to the experimental data using 
non-linear regression, parameter values for Pm and Pdbl were deduced. Pm values were 
consistent with the drug partitioning between stratum corneum and continuous oil phase. For 
isopropyl myristate a permeation enhancement was found in agreement with literature. Pdbl 
values were compared with calculated values using a literature model for diffusion in 
heterogeneous matrix systems. These were found in most cases to be in fairly good 
agreement with the Pdbl values.  
The proposed concept can be used to explain experimentally measured apparent 
permeability coefficient Papp for lipophilic vehicles. Applying this concept to w/o-emulsions 
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comprising varying mass fractions provides a predictive tool to delineate the effect of 
physicochemical formulations parameters and for transdermal drug delivery rate.  
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4.1 Introduction 
In clinical practice, a drug is rarely applied to the skin in form of a pure chemical, but instead, 
is incorporated into a carrier system, the vehicle, to guarantee efficient topical or systemic 
therapy. This carrier system, however, has to fulfil a host of requirements like suitable 
applicability, compatibility, adequate stability and foremost efficacy that comprises duration 
and strength of the desired pharmacological action. Thus, development and optimization of 
these dermatological formulations is a challenging task [1].  
Common vehicles usually comprise several components that are often not mutually miscible, 
thus, separate phases are formed that, on the microscopic level, are intermixed with each 
other. From the macroscopic point of view a homogeneous system is apparent that disguises 
different microstructures arising inside the formulation [2, 3]. 
It is widely acknowledged that transdermal permeation is regulated by the formulation of the 
drug product. This regulation may take place not only based on physico-chemical principles 
such as diffusion and partitioning of the active ingredient, but also by an interaction with the 
absorptive epithelium, i.e. the epidermis, affecting the permeability of the drug. However, a 
variety of factors combine to complicate a correct interpretation of how drug transport across 
the skin depends on the delivery formulation. A solid knowledge of the composition, including 
its physico-chemical properties, dynamic properties (evaporation) and present 
microstructures, is therefore crucial in terms of achieving optimal topical delivery.  
However to date, there is no uniform and comprehensive recommendation or guideline 
available that takes into consideration the multifaceted complexity present in dermatological 
formulations in order to quantitatively understand mechanisms being decisive for transdermal 
absorption processes [1, 6]. 
The group of Coldman et al. noticed that increasing concentration of a drug within a vehicle 
due to evaporation processes can strongly affect overall drug permeation. Thus, total drug 
concentration of a formulation seems to be a crucial parameter for transdermal delivery [8]. 
Little is known about the relationship between drug diffusivity inside the formulation and drug 
skin permeation in practical studies, although molecular mobility of a drug within a 
formulation is reportedly a further aspect that may contribute to drug delivery [131, 156]. The 
cause of skin permeation alteration from formulation has to be divided into partitioning and 
diffusivity within the formulation and partitioning and diffusivity within the skin and it has to be 
clarified which parameter has a larger effect on skin permeation. Yamaguchi et al., for 
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example, studied the in vitro skin permeation of 22-oxacalcitriol from ointments having 
different compositions and considered the diffusion coefficients of the drug inside the 
vehicles. Drug diffusion coefficient within the ointment differed significantly depending on the 
amount of medium chain triglycerides present [9]. However, permeation parameters such as 
diffusivity in a formulation and partitioning from formulation to skin are easily altered by the 
composition of the formulation [10]. For instance, the microstructure of modified water 
containing hydrophilic ointment DAB 1997 with suspended hydrocortisone-21-acetate on in 
vitro drug release showed distinct vehicle effects. Both, the colloidal structure of the cream 
and the presence of specific vehicle compounds, i.e. penetration enhancers, are likely to 
influence the drug permeation through the skin rather than the total drug concentration in the 
cream dose [11]. 
Previous work of our group proposed the continuous phase drug concentration concept as a 
model to delineate regulation of skin permeation considering drug distribution among distinct 
phases of multi-phasic hydrophilic formulations. Validity of this concept was confirmed for 
lipophilic (ibuprofen) and hydrophilic (sodium nicotinate) drugs applied under occlusive and 
non-occlusive conditions even though vehicles underwent considerable changes in their 
composition and microstructure due to evaporation of volatile ingredients [2, 3]. 
The goal of the present work was to implement this continuous phase drug concentration 
concept to lipophilic vehicle systems under occlusive conditions, i.e. w/o-emulsions of 
varying phase fraction and oil phases, in order to confirm its validity and, importantly, use it 
as a tool to delineate the contribution of drug diffusivity within the vehicle and drug 
permeability through the skin to overall apparent permeability coefficient. The combined 
efficiency of different parameters influencing the transdermal absorption process was to be 
clarified.   
The studied w/o-emulsions consisted of an oil phase into which water phase was dispersed 
in phase fractions of 70%, 50% and 30%, respectively (E70, E50, E30). Oil phase consisted 
of a single oil component (isopropyl myristate, miglyol 812N or paraffinum liquidum) and 
polymeric emulsifier Isolan PDI. Water phase contained sodium chloride and was buffered to 
pH 4.5 in all emulsions containing ibuprofen. Pure oil with and without emulsifier was 
selected as reference formulation. These formulations were designed specifically for 
elucidating the effect of differing continuous phase drug concentrations, microstructures and 
oil bases on transdermal delivery. Benzyltrimethylammonium chloride (salt, hydrophilic), 
caffeine (hydrophilic) and ibuprofen (lipophilic) were applied as model drugs, owning different 
solubility properties. Permeation experiments were carried out in vitro using pig ear skin as a 
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model for human skin [134]. A practically infinite amount of formulations was applied in order 
to determine steady state flux values that facilitate the data evaluation. This was deemed 
appropriate for reaching the specific goals of this study. Additionally, drug partitioning 
between distinct phases of transdermal absorption processes were considered. Continuous 
phase drug concentration was determined experimentally by ultracentrifugation of the 
corresponding formulations and theoretically by calculation. Gaining deeper understanding of 
the mode of interaction and the dependence on physicochemical structures of the 
formulations rounds up the goal of the present work. 
In a separate manuscript (Part III), the continuous phase drug concentration concept was 
applied to w/o-emulsions considering non-occlusive transport conditions. Evaporation pattern 
and consequently water loss of w/o-emulsions was studied over time and implemented on 
changes in the continuous phase drug concentration. Microstructure of the formulations was 
additionally examined by freeze fracture scanning electron microscopy. 
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4.2 Materials and Methods 
4.2.1 Materials  
Caffeine was a gift from Boehringer Ingelheim (Ingelheim, Germany) and ibuprofen was 
obtained from Glatt GmbH (Binzen, Germany). Miglyol 812N® (Migl), medium chain 
triglycerides, was a gift from Hüls AG (Witten, Germany) and the polymeric emulsifier Isolan 
PDI (INCI: Diisostearoyl Polyglycerly-3 dimer dilinoleate) was donated from Goldschmidt 
GmbH (Essen, Germany). Isopropyl myristate (IPM), paraffinum liquidum (Para), sodium 
chloride, sodium dihydrogenphosphate dihydrate and phosphoric acid 85% were purchased 
from Haenseler AG (Herisau, Switzerland). Benzyltrimethylammonium chloride (BTA-Cl), 
sodium azide, sodium acetate, 1-octanesulfonic acid sodium salt monohydrate, puriss.p.a., 
and trypsin inhibitor from soybean were purchased from Fluka Chemie GmbH (Buchs, 
Switzerland). Methanol was obtained from Merck KGaA (Darmstadt, Germany). Acetonitrile 
(HPLC, gradient grade) was ordered from Biosolve (Valkeensward, Netherlands). Trypsin 
2.5% was received from LuBioScience (Lucerne, Switzerland). All other chemicals and 
reagents used in this study were of analytical grade. Bidistilled water was used in all cases. 
4.2.2 Methods 
4.2.2.1 Manufacturing of the Formulations 
The study formulations (for composition see Table 9, 10 and 11) were prepared by first 
mixing water and oil phase separately. In case of hydrophilic drugs the water phase 
consisted of the model drug (benzyltrimethylammonium chloride BTA-Cl or caffeine, 
respectively), sodium chloride and bidistilled water. Oil phase consisted of emulsifier Isolan 
PDI (Iso) and the selected oil component, isopropyl myristate (IPM), miglyol 812N (Migl) or 
paraffinum liquidum (Para), respectively. In case of lipophilic model drug the water phase 
consisted of sodium chloride, bidistilled water and was buffered to pH 4.5 using sodium 
acetate (buffer capacity β = 0.01). Oil phase consisted of lipophilic ibuprofen, emulsifier 
Isolan PDI (Iso) and the selected oil component, isopropyl myristate (IPM), miglyol 812N 
(Migl) or paraffinum liquidum (Para), respectively. First, all components of the oil phase were 
mixed and heated to 80-100°C until complete dissolu tion occurred. Second, water phase was 
added to the hot oil phase gradually with intense homogenization using a polytron PT 3000 
(Kinematica AG Littau, Switzerland) for 5 minutes. Before further use, formulations remained 
at room temperature for 24h to ensure complete partitioning of the model drug between 
water and oil phase. Different emulsion formulations with varying amounts of dispersed 
phase of 30, 50 and 70 weight-% were prepared as formulation E (E30, E50 and E70). If 
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other total concentrations of caffeine were chosen than the concentrations listed in table 10, 
the amount of caffeine increase/decreased in as much as the corresponding amount of water 
decrease/increase, but fraction of the complete water phase remained the same within the 
whole formulation. If other total concentrations of ibuprofen were selected than the ones 
listed in table 11, the amount of ibuprofen increase/decrease in as much as the 
corresponding amount of oil decreased/increased, but fraction of the complete oil phase 
remained the same within the whole formulation.  Pure saturated caffeine oil with or without 
emulsifier Isolan PDI (Iso) was obtained by adding an excess of caffeine to the 
homogeneous oily base. These solutions were stirred for 24h at 32°C and filtrated 
afterwards. The saturated oils were kept at 32°C to  avoid drug precipitation before further 
use.  
All formulations applied in transport experiments were previously tested for stability. After 
manufacturing the formulations were filled into falcon tubes, closed to avoid any possible 
water loss and left at room temperature for 24h (equilibration time) and at 32°C (water bath) 
for 48h (duration of the permeation experiment). No phase separation was allowed to occur. 
w/o-character of the formulations was confirmed with conductivity measurements before and 
after stability testing. Therefore, a conductometer 660 and a conductivity-measuring cell 
60323110 with a cell constant of 0.8cm-1 (Metrohm AG, Herisau, Switzerland) were used. 
 
Table 9. Composition of the study formulations (in weight-%) for benzyltrimethyammonium chloride 
BTA-Cl 
BENZYLTRIMETHYLAMMONIUM CHLORIDE E701 E301 
Benzyltrimethylammonium chloride2 1 0.5 
Sodium Chloride 0.5 0.5 
Water 68.5 29 
Oil (IPM, Migl or Para) 27 65 
Isolan PDI 3 5 
TOTAL 100 100 
1
 w/o-emulsion with 70% and 30% of dispersed phase, respectively 
2
 for paraffinum liquidum only E70 was examined 
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Table 10. Composition of the study formulations (in weight-%) for caffeine 
CAFFEINE E701 E501 E301 Oil Oil with Isolan PDI2 
Caffeine3,4,5,6 0.2 0.2 0.2 Saturated saturated 
Sodium Chloride 0.5 0.5 0.5   
Water 69.3 49.3 29.3   
Oil (IPM, Migl or Para) 27 45 65 100 92.86 
Isolan PDI 3 5 5 - 7.14 
TOTAL 100 100 100 100  
1 
 w/o-emulsion with 70%, 50% and 30% of dispersed phase, respectively 
2
 ratio of Isolan PDI to oil is in the same order of magnitude than the examined emulsions E70, E50 and E30, respectively 
3
 for IPM a total drug concentration of 0.08% and 0.25% for E70, 0.08% for E50 and E30 was chosen 
4
 for Migl a total drug concentration of 1% and 0.2% for E70, 0,2% for E50 and 0.2% and 0.5% for E30 was chosen 
5
 for Para a total drug concentration of 0.2% for E70, E50 and E30 was chosen 
6
 for saturation procedure see 4.2.2.1 
 
 
 
Table 11. Composition of the study formulation (in weight-%) for ibuprofen 
IBUPROFEN E701 E501 E301 Oil Oil with Isolan PDI2 
Sodium Chloride 0.5 0.5 0.5 - - 
Sodium Acetate Buffer pH 4.5 69.5 49.5 29.3 - - 
Ibuprofen3 1 1 0.5 1 1 
Oil (IPM, Migl or Para) 26 44 64.5 99 91.84 
Isolan PDI 3 5 5 - 7.12 
TOTAL 100 100 100 100 100 
1
 w/o-emulsion with 70%, 50% and 30% of dispersed phase, respectively 
2
 ratio of Isolan PDI to oil is in the same order of magnitude than the examined emulsions E70, E50 and E30, respectively 
3
 for paraffinum liquidum also a total concentration of 0.5% and 1% for E50 was chosen 
 
4.2.2.2 Ultracentrifugation and Chemical Analysis of the Formulations 
Ultracentrifugation was applied to fractionate intact structures of the formulations as 
previously demonstrated as a good methodology to investigate multi-phase dermatological 
formulations by separation of the comprising dispersed phase structures [3]. The study 
formulations were fractionated using an ultracentrifuge type Centricon T-1075 and a rotor 
TFT 7013 (Kontron Instruments, Mailand, Italy). Quick-seal centrifuge tubes, 5/8X3 
(Beckmann Instruments, Palo Alto, USA) were used. All emulsion formulations were 
centrifuged for 2 hours at 222000-450000 g. The operation time was optimized to achieve 
total breaking of the emulsions. Following this treatment, the received fractions were carefully 
isolated by a syringe or spattle and analyzed for model drug content (caffeine or ibuprofen). 
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All model drugs were assayed by HPLC (Hewlett Packard, series 1050, Waldborn, 
Germany). For BTA-Cl a reversed phase RP-18 column (CC125/2 LiChrospher 100-5 RP-18) 
was used. The mobile phase consisted of 15% acetonitrile and 85% phosphate buffer (pH 
3.5; buffer capacity β = 0.05) containing 5 mM 1-octanesulfonic acid sodium salt. For 
caffeine, a reversed phase RP-8 column was used (CC 125/2 Nucleosil 100-5 C8 ec). The 
mobile phase consisted of 10% acetonitrile and 90% phosphate buffer (pH 7.4; buffer 
capacity β = 0.01). For ibuprofen a reversed phase RP-18 column (CC125/2 LiChrospher 
100-5 RP-18) was used. The mobile phase consisted of 55% acetonitrile and 45% phosphate 
buffer (pH 2.1; buffer capacity β = 0.02). Detection was performed UV-spectrophotometrically 
at 210nm, 275nm and 214 nm for BTA-Cl, caffeine and ibuprofen, respectively. The flow rate 
was 0.25 ml/min and injection volume was 10 µl in all cases. For the determination of drug 
content in the formulation or the oil fraction after ultracentrifugation, the samples were 
prepared by extraction with an at least 100-fold amount of phosphate buffer pH 7.4 (buffer β 
= 0.05) in the case of caffeine or methanol in the case of ibuprofen. Diluted samples were 
sonificated for 5 minutes and subsequently centrifuged at 15800 g for 10 minutes. Clear 
samples were obtained and injected.  
4.2.2.3 Determination of Drug Distribution Coefficient Oil / Water 
The drug distribution of model drug between oil (IPM, Migl or Para) and water or buffer pH 
4.5 (buffer capacity β = 0.01), respectively, was determined by shake-flask method. Briefly, in 
case of caffeine 1 weight-% of drug was dissolved in water with 0.5% sodium chloride to 
simulate the water phase of the formulations. This solution was transferred into a separation 
funnel together with equal amount of selected oil (IPM, Migl or Para). In case of ibuprofen, 1 
weigth-% of model drug was dissolved in the selected oil (IPM, Migl or Para) and transferred 
into a separation funnel together with equal amount of sodium acetate buffer pH 4.5 (buffer 
capacity β = 0.01). This mixture was extensively shaken for 10 minutes. The two phases 
were allowed to separate over night before drug content in each phase was quantitatively 
determined. Therefore, the phases were separated and diluted with an at least 100-fold 
amount of water or methanol (for conditions see 4.2.2.2).  Validity of the procedure was 
proven by equally determining drug distribution out of saturated caffeine oil into water. 
Partition coefficient KL/W was calculated as the ratio of drug concentration in the lipophilic oil 
phase CL over drug concentration in the hydrophilic phase CW.  
)(
)(
/ DrugC
DrugCK
W
L
WL =    [equation I] 
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4.2.2.4 Determination of Drug Distribution Coefficient Stratum Corneum / Oil 
Stratum corneum sheets were prepared from porcine skin by trypsin treatment. In particular, 
full-thickness skin samples were cut to a thickness of 200 µm with a pneumatic dermatome 
(Zimmer, Dover, OH, USA) and then spread, stratum corneum side up, on filter paper soaked 
with 0.5% crude trypsin in phosphate buffered saline (pH 7.4, buffer capacity β = 0.005) 
inside a petri dish. After incubation at 37°C for 7 5 minutes stratum corneum was carefully 
peeled off from the underlying epidermal cells and washed three times with bidistilled water 
to prevent further degradation. The isolated stratum corneum sheets were incubated with 
phosphate buffered trypsin inhibitor solution from soy bean (pH 7.4, buffer capacity β = 
0.005) at 37°C for further 120 minutes. The stratum  corneum sheets were washed again with 
bidistilled water three times and then stored on wire mesh as support in a desiccator over 
silica gel for at least 2 days until mass remained constant, but not longer than two weeks 
before use [157]. 
Originally, the idea was to determine drug distribution between (continuous) oil (phase) and 
dried stratum corneum. Some experiments were performed, but failed as it was not possible 
to remove adherent oil entirely for stratum corneum pieces without loosing drug substance or 
destroying the skin sheets. Thus, an indirect method had to be used. Therefore, first drug 
distribution between stratum corneum and water was determined and corrected for drug 
partition coefficient between stratum corneum and oil with the help of drug distribution 
coefficient between oil and water KL/W previously determined by shake-flask method (4.2.2.3): 
L
SC
L
W
W
SC
LSC C
C
C
C
C
CK =⋅=/     [equation II] 
Dried stratum corneum pieces (mass between 1.5 and 3 mg) were weighted, transferred into 
an Eppendorf tube and additionally an exactly determined amount of caffeine in water or 
ibuprofen in sodium acetate buffered solution (pH 4.5, buffer capacity β = 0.01) was added 
(1ml). Entire contact of the solution with the area of stratum corneum sheets was obligatory. 
The Eppendorf cups were incubated at 32°C for 25h u ntil equilibration. Different 
concentrations of caffeine or ibuprofen solutions, respectively, were examined. The 
concentration range was 1.1 – 147.9 µg/g for caffeine and 14.56 – 128.19 µg/g (saturated) 
for ibuprofen. Every single concentration was examined on at least three different stratum 
corneum sheets. To determine possible adsorption of small amounts of the drug by the 
Eppendorf tubes themselves, experiments were carried out by incubating caffeine or 
ibuprofen solutions under the same conditions as in the distribution coefficient 
measurements, but without stratum corneum (blank solutions). No influence of the test 
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conditions on drug concentrations could be detected (data not shown).  After incubation 
solutions were removed, centrifuged for 10 minutes at 15800 g (Eppendorf centrifuge 5415C, 
Dr. Vaudaux AG, Schönenbuch, Germany) and analyzed using HPLC (for conditions see 
4.2.2.2). The difference in drug amount present in drug solutions with stratum corneum and 
drug amount present in solutions of blank cups after 25h of incubation represented the 
amount of penetrated drug into the stratum corneum. For calculation of drug concentration 
within stratum corneum a density of 1000 mg/g was assumed. According to Parry, the 
stratum corneum/water partition coefficient was determined over the slope of regression line 
which was obtained by plotting the concentration of caffeine in supernatant of the solutions 
incubated with stratum corneum pieces (mg/g) against caffeine concentration in stratum 
corneum (mg/g) [82, 152, 154] . 25 hours of incubation time were chosen because 
equilibrium was established between the drug amount penetrated into the stratum corneum 
pieces and the drug amount still present in the solutions. The time needed to reach 
equilibrium was investigated by collecting samples at varying incubation times (data not 
shown). 
4.2.2.5 Determination of Continuous Phase Drug Concentration  
 (Occlusive Conditions) 
Continuous phase drug concentration was determined by two different approaches. The 
experimental approach used ultracentrifugation experiments in order to break the formulation 
into its two distinct phases. Subsequently, the oil phase was analysed quantitatively for its 
containing model drug concentration. The theoretical approach applied the formula derived in 
4.3.1.3 for calculation of continuous phase drug concentration taking into consideration the 
drug distribution coefficient between the selected oil component (IPM, Migl or Para) and the 
corresponding water phase KL/W. For a multi-phase formulation with mass fraction of the 
continuous phase ФL and mass fraction of the dispersed phase ФW this continuous phase 
drug concentration CL is given by: 
LK
tot
L
WL
W
CC φφ +=
/
    [equation III] 
where Ctot denotes the total drug concentration of the formulation. Mass concentrations 
(mg/g) and mass fractions (weight-%/100) were considered [2, 3].  
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4.2.2.6 Permeation Experiments 
In all cases, drug permeation was studied in Franz-type diffusion cells with a diffusion 
surface area between 2.99 – 4.05 cm2 at 32°C across excised full thickness pig ear skin . The 
ears of domestic pigs were obtained from a local slaughter house directly post-mortem. The 
skin was separated from the cartilage tissue with a scalpel, stored in a freezer at -75°C and 
used within 4 weeks. To overcome the effect of individual skin variability, every single 
formulation was examined in at least three permeation experiments. For a single permeation 
experiment skin of the same pig was used. The receiver medium for the permeation 
experiments with a volume of 8.5 to 9 ml consisted of an aqueous phosphate buffer solution 
(pH 7.4, buffer capacity β = 0.05) and 0.1% sodium azide. Skin integrity was tested by 
measurements of transepidermal water loss (TEWL) (Tewameter TM 210, Courage & 
Khazaka electronic GmbH, Cologne, Germany) after 4 hours of equilibration. Then, a 
practically infinite dose of 700 mg/cm2 formulation was applied onto the skin to ensure that 
donor compartment would not become poor of model drug over the entire duration of the 
transport experiment. For occlusive conditions the donor compartment was covered with a 
rubber stopper. At predetermined time intervals, samples of the receiver compartment were 
collected and replaced with fresh buffer. The entire duration of an experiment was 48 hours. 
The samples were analyzed for model drug concentration by HPLC (for conditions see 
4.2.2.2) without further treatment except centrifugation for 10 minutes at 15800 g (Eppendorf 
centrifuge 5415C, Dr. Vaudaux AG, Schönenbuch, Germany). 
For caffeine and ibuprofen three different series of permeation experiments were performed 
in which the applied oil was the discriminating factor. A series consisted of the formulations 
E70, E50, E30 and pure oil with emulsifier, respectively.  
Table 12. Overview on the permeation series performed 
Drug Oil SERIES 
Isopropyl myristate A 
Miglyol 812N B Caffeine 
Paraffinum liquidum C 
Isopropyl myristate D 
Miglyol 812N E Ibuprofen 
Paraffinum liquidum F 
In order to compare the different formulations of one series against each other, the 
composition of the vehicles was arranged in a way that the ratio of emulsifier content over oil 
content was in the same order of magnitude, i.e. E70 comprising 3%, E50 and E30 
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comprising 5% and pure oil comprising 7% of emulsifier. For more detailed discussion, see 
Part III. Table 12 summarizes the series performed. 
4.2.2.7 Data Analysis of the Permeation Experiments  
4.2.2.7.1 Theory (Papp, Pm, Pdbl) 
For interpretation of permeation data, it is postulated that continuous phase drug 
concentration of a multi-phasic formulation governs permeation kinetics alone [2, 3]. This 
concentration is given by equation III (see 4.2.2.5). Assuming the conditions of a perfect sink 
(receiver concentration negligible), an infinite donor reservoir, assuring a constant continuous 
phase drug concentration CL, rate limiting membrane (skin) diffusion with the diffusion 
coefficient D and drug distribution between the skin and the continuous phase of the 
formulation with the distribution coefficient KSC/L, drug flux J may be described by Fick’s first 
diffusion law. Drug flux J is defined as the amount of drug permeated through the skin per 
unit time and unit area and is given by: 
LCPJ ⋅=     with    h
KDP LSC /⋅=  
where P is the permeability coefficient (cm/s) and h as thickness of the diffusion rate limiting 
membrane. 
Combining the formulas leads to equation IV:  
h
KDCJ LSCL /⋅⋅=    [equation IV] 
In general, apparent permeability coefficient Papp is dependent on several processes 
proceeding in parallel, whereas the slowest is decisive and determinant. Concerning the w/o-
emulsions examined, it is mainly the diffusivity of the drug within the vehicle, reflected by the 
permeability coefficient of the diffusion boundary layer, Pdbl, and the permeability through the 
membrane/skin, reflected by the permeability coefficient Pm, that determine apparent 
permeability coefficient Papp. Hence, for a reasonable discussion of the permeation results, it 
is obligatory to have an idea about Pdbl and Pm. Equation V, derived in 4.3.2.1, delineates the 
relation among these parameters. 
mC
C
dblapp PPP totL
111
+=    [equation V] 
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4.2.2.7.2 Easy Fit® 
Based on the permeation data derived from the transport experiments across pig ear skin, 
namely apparent permeability coefficient Papp and continuous phase drug concentration over 
total drug concentration CL / Ctot, the corresponding values for permeability coefficient of 
diffusion boundary layer Pdbl and permeability coefficient of the membrane Pm can be 
computed for every single transport series using non linear regression (EasyFit® software; 
Prof. Schittkowski, University of Bayreuth).   
For analysis the model type EXPLICIT and the numerical method SQP-Gauss-Newtonian 
were applied. Scaling was -1 in case of caffeine and +1 in case of ibuprofen.  
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4.3 Results 
4.3.1 Characterization of the Formulations 
4.3.1.1 Oil / Water Drug Distribution Coefficient [KL/W] 
Drug distribution coefficients between oil and water phase were determined for caffeine and 
ibuprofen in order to calculate continuous phase drug concentration of the formulations 
applied according to equation III (see 4.3.1.3). Table 13 shows the values obtained by shake-
flask method (see 4.2.2.3). 
Table 13. Drug partition coefficient between oil and water phase KL/W 
 Caffeine1 Ibuprofen2 
Isopropyl myristate 0.040 ± 0.005 883.40 ± 11.84 
Miglyol 812N 0.129 ± 0.006 841.35 ± 44.04 
Paraffinum liquidum 0.00265 ± 0.0001 122.65 ± 1.24 
All values denote mean ± standard deviation.  n = 4-12 
1
 water phase consisted of pure water with 0.5% sodium chloride 
2
 water phase consisted of a sodium acetate puffer (pH 4.5, buffer capacity β = 0.01) 
The values depicted in table 13 clearly demonstrate the hydrophilic nature of caffeine (values 
below unity; pKa = 0.6) and the lipophilic nature of ibuprofen (values above unity, pKa = 5.2) 
if, in the case of ibuprofen, water phase was buffered to pH 4.5. Furthermore, it is obvious 
that, for both drugs, the oil components isopropyl myristate and miglyol 812N differed greatly 
from paraffinum liquidum. This can be attributed to differences in the chemical structure and 
polarity. Isopropyl myristate and miglyol 812N possess ester bonds, whereas paraffinum 
liquidum consists only of saturated carbon chains. 
4.3.1.2 Stratum Corneum / Oil Drug Distribution Coefficient [KSC/L] 
In order to gain a deeper understanding of the different drug permeation behaviour as a 
function of physicochemical properties of the formulation, drug distribution coefficients KSC/L 
between stratum corneum (SC) and, according to the proposed concept, continuous oil 
phase of the formulation (L) were determined (see equation II and 4.2.2.4). 
Table 14. Drug distribution coefficient KSC/L between stratum corneum SC and continuous oil phase L1 
 Caffeine2 Ibuprofen3 
Isopropyl myristate 73.75 0.101 
Miglyol 812N 22.87 0.106 
Paraffinum liquidum 1113.21 0.724 
1 all values denote mean.  n = 3 
2
 KSC/W(caffeine) = 2.95 for pure water with 0.5% sodium chloride selected as water phase 
3
 KSC/W(ibuprofen) = 88.8 for sodium acetate buffer pH 4.5 (buffer capacity β = 0.01) selected as water phase 
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For both drugs distribution into the stratum corneum was favoured from paraffinum liquidum.  
For caffeine drug distribution coefficients between stratum corneum and oil differed only 3-
fold between isopropyl myristate and miglyol, but almost 50-fold between paraffinum liquidum 
and miglyol 812N. For ibuprofen drug distribution coefficients KSC/L were almost the same for 
isopropyl myristate and miglyol, but 7 times smaller than for paraffinum liquidum. Distribution 
into stratum corneum is favoured for caffeine compared to ibuprofen. This is due to different 
solubility properties in the lipophilic vehicle and, consequently, varying escaping tendencies 
into the partly hydrophilic and partly lipophilic stratum corneum.  Nevertheless, as 
determination was performed indirectly (see 4.2.2.4), this method masked the direct effect oil 
might have on skin such as changes in skin structure or extraction of lipids. Comparison of 
the distribution coefficient between stratum corneum and water KSC/W for caffeine with values 
available in literature underlined the accuracy of the performed measurement. KSC/W 
determined for caffeine was 2.95. Hansen et al. found values between 2.92 and 4.70, 
depending on the equilibration time selected [158]. Dias et al. studied the topical delivery of 
caffeine from some commercial formulations and computed values of 0.05 and 1.79 for KSC/W 
depending on path of diffusion through stratum corneum [151]. 
4.3.1.3 Calculated and Experimentally Determined Continuous Phase Drug 
Concentration CL  
Total drug concentration Ctot is connected to the drug concentration in continuous phase CL 
with phase fraction ФL and to the drug concentration in the dispersed phase CW with phase 
fraction ФW by equation VI: 
LLWWtot CCC ⋅+⋅= φφ    [equation VI] 
with  1=+ LW φφ ;   
tot
W
W V
V
=φ   and 
tot
L
L V
V
=φ  
where, Vtot denotes total volume of the formulation, VL volume of the continuous phase and 
VW volume of the dispersed phase. 
Drug distribution coefficient between oil and water phase KL/W is defined by equation I (see 
4.2.2.3): 
W
L
WL C
CK =/    [equation I] 
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Connecting both equations and solving for CL leads to the following equation III: 
LK
tot
L
WL
W
CC φφ +=
/
   [equation III] 
Continuous phase drug concentrations for caffeine and ibuprofen were calculated based on 
equation III and drug partition coefficient KL/W (see 4.3.1.1) for all formulations studied in 
permeation experiments in order to find a correlation between apparent permeability 
coefficient Papp and continuous phase over total drug concentration CL/Ctot. Besides, 
calculated values for CL were compared to the values derived experimentally by 
ultracentrifugation and subsequent quantification of drug in the oil phase (see figure 15).  
 
Figure 15. Distinct phases within w/o-emulsions of 
varying phase fractions after ultracentrifugation 
(top part: oil fraction, bottom part: complex 
mixture of water and further emulsion 
ingredients; E70, E50 and E30 denote emulsion 
with 70%, 50% and 30% of dispersed water 
phase) 
 
Data are shown in table 15 for caffeine and in table 16 for ibuprofen.  
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Table 15. Calculated and measured values of continuous phase drug concentration for caffeine in w/o-
emulsions of varying phase fractions (units µg/g) 
 E701,2 E501,2 E301,2 
 Calculated Measured3 Calculated Measured3 Calculated Measured3 
Isopropyl 
myristate 44.94 111.78±12.14 61.54 151.01±5.42 97.56 211.45±6.01 
Miglyol 812N 349.26 479.98±13.62 457.04 613.88±20.2 661.03 806.32±3.13 
Paraffinum 
liquidum 7.58 20.28±1.95 10.58 29.42±1.60 17.92 34.98±0.27 
1
  w/o-emulsion with 70%, 50% or 30% of dispersed phase, respectively. 
2
 total drug concentration was 2000 µg/g for all formulations on the basis of miglyol 812N or paraffinum liquidum and 800 µg/g 
for all formulations on the basis of isopropyl myristate 
3
 all values denote mean ± standard deviation. n = 3 – 6 
 
 
Table 16. Calculated and measured values of continuous phase drug concentration for ibuprofen in w/o-
emulsions of varying phase fractions (units mg/g) 
 E701,2 E501,2 E301,2 
 Calculated Measured3 Calculated Measured3 Calculated Measured3 
Isopropyl 
myristate 33.25 31.5±1.81 19.98 19.73±0.41 7.14 7.56±0.91 
Miglyol 812N 33.24 34.58±1.56 19.98 19.5±0.45 7.14 7.65±0.13 
Paraffinum 
liquidum 32.71 n.m.
4
 19.84 n.m.4 14.245 11.95±0.84 
1
 w/o-emulsion with 70%, 50% or 30% of dispersed phase, respectively. 
2
 for E70 and E50 a total concentration of 10000 µg/g caffeine, for E30 a total concentration of 5000 µg/g was selected 
3
 all values denote mean ± standard deviation. n = 3 - 6 
4
 not measured. 
5
 a total concentration of 10000 µg/g was selected. 
 
Calculated and measured values agreed very well for all formulations and all oils examined 
in case of ibuprofen. Additionally, the values clearly indicate that the studied emulsions with 
varying phase fractions (E70, E50 and E30) possessed different continuous phase drug 
concentrations. Ibuprofen concentrations within an emulsion of defined phase fraction but 
formulated on the basis of different oils did not show any influence on the resulting drug oil 
concentration. 
However, for caffeine, the agreement between calculated and measured continuous phase 
drug concentration was not as good as compared to ibuprofen. Best values were achieved 
for caffeine in E70, E50 and E30 manufactured on the basis of miglyol 812N. In general, the 
concentrations examined were up to 1500-fold smaller (unit µg/g instead of mg/g). The 
emulsions E70, E50 and E30 varied in their continuous phase drug concentration for all oils 
studied. Contrary to the results obtained for ibuprofen, emulsions with the same phase 
fraction also possessed different continuous phase drug concentrations, depending on the oil 
selected. Based on the determination of saturation concentration of caffeine in oil with or 
without Isolan PDI, it can be excluded that the drug distribution and consequently the drug 
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content was influenced by the presence of any free emulsifier in the oil phase (see Part III, 
5.3.1.3). 
Generally, total drug concentration and partitioning of caffeine into the continuous phase of 
the formulation was lower if compared to ibuprofen and, thus, achieved continuous phase 
drug concentrations were smaller. The solubility of caffeine in oily vehicles was limited; 
hence, in terms of manufacturing the formulations, it had to be assured that no saturation of 
the continuous phase occurred. Neither for caffeine, nor for ibuprofen saturation of the 
continuous oil phase was achieved (for saturation concentration see Part III, 5.3.1.3). 
Equation III uses mass fractions of continuous and dispersed phase, ФL and ФW, 
respectively, for calculation of continuous phase drug concentration CL. To test how much 
continuous phase drug concentration CL is affected by the emulsifier content, emulsions with 
varying amounts of Isolan PDI were manufactured and subjected to ultracentrifugation 
experiments. Measured continuous phase drug concentrations were compared to calculated 
values, assuming that Isolan PDI was either part of continuous phase or part of dispersed 
phase. The values obtained are depicted in table 17. 
 
Table 17. Isolan PDI and its influence on continuous phase drug concentration by ultracentrifugation 
experiments of ibuprofen formulations (units mg/g) 
 E30 Miglyol1 E70 Miglyol1 
Isolan 
PDI Measured
2
 Calculated3 Calculated4 Measured2 Calculated3 Calculated4 
3% 15.80±0.18 14.28 14.92 34.07±2.44 33.24 36.92 
5% 17.86±2.14 14.28 13.33 38.76±0.94 33.24 39.86 
10% 15.32±0.45 14.28 12.50 33.75±1.48 33.24 49.76 
1
 a total drug concentration of 10000 µg/g was selected for w/o-emulsion containing 30% and 70% of dispersed phase, 
respectively 
2
 all values denote mean ± standard deviation. n = 3 
3
 assumption that continuous phase is formed by the oil component and emulsifier Isolan PDI. 
4
 assumption that continuous phase is formed only by the oil component. 
 
The values clearly show that best agreement was achieved if emulsifier is accounted for 
continuous phase. Furthermore, for E30 and E70, the continuous phase drug concentration 
did not differ strongly between formulations that were manufactured with 3%, 5% or 10% of 
emulsifier if calculation is based on the assumption that external phase is composed of oil 
and emulsifier. This is consistent with determined saturation concentrations of ibuprofen in 
miglyol 812N with varying amounts of Isolan PDI (see part III, 5.3.1.3) which did not influence 
saturation concentration to any great extent. 
Part II 
 
 
 
Miriam Reiser   University of Basel, 2008 
 
 
 - 94 - 
To summarize, the good agreement between calculated and measured values strongly 
indicates the validity of the equation III derived in 4.3.1.3. 
In terms of correlating apparent permeability coefficient Papp of the different formulations (see 
4.3.2.3 and 4.3.2.4) with the continuous phase drug concentration CL, calculated values were 
used (see equation III, 4.2.2.5). As the formulations differed in their total concentrations, the 
fraction continuous phase drug concentration over total drug concentration CL/Ctot was 
introduced (see table 18 and 19). 
Table 18. Continuous phase caffeine concentration over total concentration CL/Ctot of all formulations 
used in permeation experiments (total concentration in weight-%) 
Vehicle base Formulation Total Concentration CL/Ctot 
E70 0.08% 0.06 
E50 0.08% 0.08 
E30 0.08% 0.12 
Isopropyl myristate 
Oil + 7% Isolan PDI Saturated 1.00 
E70 0.25% 0.18 
E70 0.2% 0.18 
E50 0.2 % 0.23 
E30 0.2% 0.33 
Miglyol 812N 
Oil + 7% Isolan PDI Saturated 1.00 
E70 0.2% 1.43·10-3 
E50 0.2% 2.00·10-3 
E30 0.2% 3.33·10-3 Paraffinum liquidum 
Oil + 7% Isolan PDI Saturated 1.00 
 
 
 
Table 19. Continuous phase ibuprofen concentration over total concentration CL/Ctot for all formulations 
examined in permeation experiments (total concentration in weight-%) 
Vehicle base Formulation Total Concentration CL/Ctot 
E70 1% 3.32 
E50 1% 2.00 
E30 0.5% 1.43 Isopropyl myristate 
Oil + 7% Isolan PDI 1% 1.00 
E70 1% 3.32 
E50 1% 2.00 
E30 0.5% 1.43 Miglyol 812N 
Oil + 7% Isolan PDI 1% 1.00 
E70 1% 3.27 
E50 0.5% 1.98 
E30 0.5% 1.42 Paraffinum liquidum 
Oil + 7% Isolan PDI 1% 1.00 
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4.3.2 Permeation Experiments 
4.3.2.1 Equations of Transport Kinetics 
It is postulated that a drug has to diffuse through the diffusion boundary layer of the vehicle, 
until it reaches the interface vehicle-skin. The relatively fast partitioning of drug from 
continuous phase into stratum corneum is followed by diffusion through the skin.  
 
Figure 16. Drug diffusion through a fictitious diffusion boundary layer and  skin membrane - adapted 
from [2]: Ctot denotes total drug concentration, CL denotes continuous phase drug concentration, subscript 
r denotes concentration directly present on the membrane surface, subscript R denotes concentration 
present in the receiver compartment 
 
 
Ctot denotes total drug concentration of the formulation, CL is the continuous phase drug 
concentration. The subscript r is equivalent to the corresponding concentration directly on the 
skin membrane surface. The subscript R is equivalent to the corresponding concentration in 
the receiver phase. For steady-state conditions, it is assumed that the flux through diffusion 
boundary layer Jdbl is equal to the flux through the skin membrane Jm. 
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mdbl JJ =     and accordingly 
rLmrtottotdbl CPCCP ,, )( =−    [equation VII] 
where, Pdbl denotes permeability coefficient of diffusion boundary layer and Pm denotes 
permeability coefficient of the skin membrane. Pdbl reflects the diffusivity of the drug in the 
vehicle. Ctot,r is the total drug concentration and CL,r the continuous phase drug concentration 
directly on the surface of the membrane r. Ctot,R is assumed to be zero (sink conditions). 
If equation VI for the calculation of total drug concentration (see 4.3.1.3) is considered and 
drug partition coefficient KW/L is introduced as drug concentration in the water phase over 
drug concentration in the oil phase 
L
W
C
C
LWK =/    [equation VIII] 
the total drug concentration Ctot,r  at the membrane surface r can be replaced by the term 
( )[ ]11/,, +−= LWWrLrtot KCC φ    [equation IX]         
 leading to equation X 
rLmLWWrLdbltotdbl CPKCPCP ,/, )1))1((( =+−− φ    [equation X] 
Simplifying and dissolving this equation for CL,r gives  
)1)1(( /, +−+
=
LWWdblm
totdbl
rL KPP
CPC φ    [equation XI] 
Inserting the term for CL,r into  J = PmCL,r (equation VII) gives 
( )[ ]11/, +−⋅+= LWWrLdblm
totdblm
KCPP
CPPJ φ    [equation XII]. 
As apparent permeability coefficient is defined as the quotient of flux J over the total drug 
concentration Ctot, this can be applied to equation XII. Replacing CL,r[ФW(KW/L-1)+1] by Ctot/CL 
(equation IX) gives equation V. This formula shows the correlation between apparent 
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permeability coefficient Papp with the permeability coefficient of the diffusion boundary layer 
Pdbl and the permeability coefficient of the membrane Pm, respectively. 
mC
C
dblapp PPP totL
111
+=    [equation V] 
 
Depending on the contribution of Pdbl and   (CL/Ctot)Pm to the value of Papp three different 
cases can be distinguished: 
 
a) mCCdbl PP totL>>  
b) mCCdbl PP totL<<  
c) mCCdbl PP totL≈  
 
 
The interplay is demonstrated in Figure 17. If diffusion through the membrane is rate limiting 
for overall permeation, the correlation between apparent permeability coefficient Papp and 
continuous phase drug concentration over total concentration CL/Ctot will be linear. A line 
parallel to the x-axis will appear if permeation within the vehicle is slower than permeation 
through the skin. If the values of Pdbl and (CL/Ctot)Pm are comparable, the correlation will 
result in a curve.  
It has to be assumed that permeability coefficient of the diffusion boundary layer Pdbl may be 
different for emulsions comprising a drug that is mainly present in the dispersed phase 
(caffeine) and a drug that is mainly present in the continuous phase (ibuprofen). Additionally, 
Pdbl may also differ for emulsions comprising the same oil component/oil phase, but varying 
phase fractions due to arising changes in the microstructure, i.e. droplet size and density of 
droplet packing. Considering these differences, macroscopic permeation through an 
emulsion is described as effective permeability coefficient Pe. Following the Maxwell-
 
Figure 17. Correlation between apparent permeability Papp and 
continuous phase drug concentration over total drug concentration 
CL/Ctot in terms of Pdbl and Pm contribution 
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Rayleigh-Lorentz-Clausius-Mosotti-Wagner-Wiener relation, this Pe may be calculated by the 
following equation: 
W
LW
LW
Le
Le V
PP
PP
PP
PP






+
−
=
+
−
22
   [equation XIII] 
 
where, the subscripts e, W and L denote effective, dispersed and continuous. P denotes 
permeability coefficient and VW is the volume fraction of the internal water phase [159-161].  
Based on equation XIII effective diffusion coefficient De can be calculated, if the following 
assumptions are set: 
(1) Diffusion coefficients for caffeine and ibuprofen are identical. 
(2) Dispersed particles do not interact with each other. 
(3) Drug diffusion coefficient in the oil phase is estimated based on drug diffusion coefficient 
in the water phase (DW ≈ 7·10-6 cm2/sec at 32°C, viscosity 1 mPas) and viscosity of th e oil 
phase (see table 20)  
Table 20. Measured oil viscosity and estimation of the diffusion coefficients DL for the different oils – 
based on diffusion coefficient D for water (DW ≈ 7·10-6 cm2/sec at 32°C assuming a viscosity of 1 mPas) 
 Viscosity at 32°C [mPas] 1    Estimated DL 
Isopropyl myristate 7  9.8·10-7 
Miglyol 812N 25  2.8·10-7 
Paraffinum liquidum 77  9.1·10-8 
1
 for viscosity measurement see Part III, 5.3.1.1 
(4) According to Higuchi [159], it holds: 
e
e
e K
PD =   [equation XIV]  
and 
LWLWe VVKK += /    [equation XV] 
where, KW/L denotes drug partition coefficient between water and oil phase, VW and VL denote 
volume fractions of internal (subscript W) and continuous phase (subscript L), respectively. 
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Taken together, effective diffusion coefficient De can be calculated based on equation XVI: 
W
LWLW
LWLW
Lee
Lee V
DDK
DDK
DKD
DKD
⋅
+
−
=
+
−
22 /
/
      [equation XVI] 
From effective diffusion coefficient De effective permeability coefficient Pe can be calculated 
using equation XIV.  
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4.3.2.2 Transdermal Permeation of Caffeine 
4.3.2.2.1 Apparent permeability coefficient Papp (Experimental Data) 
For caffeine the partition coefficients between oil and water phase were always below unity, 
indicating that most of the drug is entrapped within the water droplets of the w/o-emulsion. 
Therefore, also the ratio of continuous phase drug concentration over total concentration 
CL/Ctot possessed values below unity. However, as confirmed by ultracentrifugation 
experiments and calculation, continuous phase drug concentration was not zero and differed 
among the formulations studied. Accordingly, different values for Papp were received (see 
table 21). 
Table 21.  Apparent permeability coefficient Papp (cm/sec) and continuous phase caffeine concentration 
over total concentration CL/Ctot  
Isopropyl myristate Ctot (µg/g) cL / ctot Papp ± SEM1 [cm/sec] 
E702 800 0.06 4.62·10-7 ± 3.25·10-8 
E502 800 0.08 7.98·10-7 ± 4.98·10-8 
E302 800 0.12 1.15·10-6 ± 1.11·10-7 
Oil + 7% Isolan PDI Saturated 1.0 3.05·10-6 ± 4.45·10-7 
Miglyol 812N 
   
E702 2500 0.17 2.60·10-7 ± 1.57·10-8  
E702 2000 0.18 2.65·10-7 ± 2.09·10-8 
E502 2000 0.23 2.41·10-7 ± 1.77·10-8 
E302 2000 0.33 3.47·10-7 ± 3.21·10-8 
Oil + 7% Isolan PDI Saturated 1.0 6.32·10-7 ± 1.46·10-7 
Paraffinum Liquidum 
   
E702 2000 1.43·10-3 1.77·10-7 ± 3.28·10-8 
E502 2000 2.00·10-3 1.60·10-7 ± 2.37·10-8 
E302 2000 3.33·10-3 2.21·10-7 ± 4.75·10-8 
Oil Saturated 1.0 1.86·10-6 ± 2.05·10-7 
1
 all values denote mean ± standard error of mean. n = 3 - 9 
2
 w/o-emulsion with 70%, 50% or 30% dispersed phase, respectively 
The correlation between Papp and CL/Ctot is illustrated graphically in figure 18. Depending on 
the oil selected different curve progressions are observed. For isopropyl myristate correlation 
was non-linear, whereas for miglyol 812N a nearly linear correlation was observed. For 
paraffinum liquidum no clear statement was possible. The single data points are not evenly 
distributed along the x-axis and it turned out that combination of caffeine with paraffinum 
liquidum was not suitable due to the low drug distribution coefficient KL/W between oil and 
water phase (see 4.3.1.1).  
Permeation of caffeine was strongly dependent on the oil base selected. Highest permeation 
was achieved for isopropyl myristate, followed by paraffinum liquidum and miglyol 812N. 
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Figure 18. Correlation of apparent permeability coefficient Papp and continuous phase caffeine 
concentration over total concentration  CL/Ctot for lipophilic vehicles of varying phase fractions on the 
basis of different oils    (n = 3 - 9; error bars not shown) 
 
 
4.3.2.2.2 Permeability coefficients of the vehicle Pdbl and the skin Pm (non-linear regression) 
To delineate the contribution of permeability through diffusion boundary layer Pdbl and 
permeability through skin Pm to overall apparent permeability Papp of each transport series 
(isopropyl myristate, miglyol 812N or paraffinum liquidum, see table 12), the individual values 
were calculated. For this purpose equation V was fitted to the data of Papp versus CL/Ctot. 
EasyFit® curves are shown in figure 19 and demonstrate a good agreement of the curve with 
experimental data for all studied series. The deduced values for Pdbl and Pm are shown in 
table 22. 
Concerning the permeability coefficient of the skin Pm large differences between the oils were 
obtained. Largest Pm was obtained for the paraffinum liquidum series. It was 9-fold higher 
compared to the IPM series and 56-fold higher compared to the miglyol series. Concerning 
the permeability coefficient of the diffusion boundary layer Pdbl, the differences between the 
oils were smaller than for Pm. IPM series had an almost 2.4-fold higher value of Pdbl 
compared to paraffinum liquidum series and an almost 4.5-fold higher value of Pdbl compared 
to miglyol series.  It is noted that Pdbl values obtained from the fit are average values of all 
four formulations of a transport series. 
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For a deeper understanding of the received Pdbl values, effective permeability Pe in the w/o-
emulsion formulations was considered. 
 
Table 22. Representative values for permeability coefficients of the diffusion boundary layer Pdbl and the 
skin Pm derived by easy fit® software for the caffeine transport series (n = 3 - 9) with isopropyl myristate 
(IPM), miglyol 812N (Migl) and paraffinum liquidum (Para) 
Oil Formulation CL/C tot1 Papp2 [cm/sec] Pdbl3 [cm/sec] Pm4 [cm/sec] 
E705 0.06 4.62·10-7 
E505 0.08 7.98·10-7 
E305 0.12 1.15·10-6 
IPM 
Oil+7% Isolan PDI 1 3.05·10-6 
4.50·10-6 1.03·10-5 
E705 0.18 2.65·10-7 
E505 0.23 2.41·10-7 
E305 0.33 3.47·10-7 Migl 
Oil+7% Isolan PDI 1.0 6.32·10-7 
1.01·10-6 1.61·10-6 
E705 1.43·10-3 1.77·10-7 
E505 2.00·10-3 1.60·10-7 
E305 3.33·10-3 2.21·10-7 Para 
Oil 1.0 1.86·10-6 
1.87·10-6 9.04·10-5 
1
 continuous phase caffeine concentration over total  caffeine concentration 
2
 apparent permeability coefficient 
3 
 permeability coefficient of the diffusion boundary layer 
4
 permeability coefficient of the membrane / skin 
5
 emulsion E with 70%, 50% or 30% of dispersed phase, respectively 
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Figure 19. EasyFit® plot for the caffeine formulations (× denotes isopropyl myristate, ∆ denotes 
paraffinum liquidum and □ denotes miglyol 812N) 
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4.3.2.2.3 Effective Permeability Coefficient Pe of the vehicle (non-linear regression) 
Effective permeability coefficient Pe reflects the diffusivity of the drug in the vehicle and was 
calculated by equation XIV and XVI. For all three oils studied permeability coefficient for the 
vehicle increased as the phase fraction of dispersed water phase was increased. 
Additionally, following increasing viscosity (see Part III, 5.3.1.1) of isopropyl myristate, 
miglyol 812N and paraffinum liquidum, effective permeability coefficient Pe was decreased. 
 
Table 23. Effective permeability coefficient Pe(cm/sec) of caffeine in w/o-emulsions of varying phase 
fractions and for different oils 
 
Pe(IPM)1 [cm/sec] Pe(Migl)2 [cm/sec] Pe(Para)3 [cm/sec] 
E704 5.40·10-6 2.13·10-6 7.21·10-7 
E504 3.73·10-6 1.07·10-6 3.64·10-7 
E304 3.46·10-6 6.16·10-7 2.08·10-7 
1
 isopropyl myristate 
2
 miglyol 812N 
3
 paraffinum liquidum 
4
 w/o-emulsion with 70%, 50% and 30% of dispersed phase, respectively 
 
Effective permeability coefficient Pe of the formulations based on different oils agreed on 
average very well with the corresponding permeability coefficient Pdbl values for isopropyl 
myristate and miglyol. For paraffinum liquidum an approximately 5-fold difference was 
observed.
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4.3.2.3 Transdermal Permeation of Ibuprofen 
4.3.2.3.1 Apparent Permeability Coefficient Papp (Experimental Data) 
For ibuprofen the drug distribution coefficient between oil and sodium acetate buffer pH 4.5 
was always bigger than unity, indicating that the majority of the drug was present in the 
continuous phase. Therefore also the ratio of continuous phase drug concentration over total 
concentration possessed values bigger than unity. Ultracentrifugation experiments and 
calculation revealed that continuous phase drug concentration over total concentration CL/Ctot 
differed for all formulations studied, depending on the phase fraction and the oil base 
selected. Accordingly, different values for Papp were received (see table 24).  
The correlation between Papp and CL/Ctot is illustrated in figure 20. Depending on the oil 
selected different correlation behaviour was observed. Again, ibuprofen showed best 
permeability for formulations comprising isopropyl myristate. Permeability of formulations 
comprising paraffinum liquidum was higher compared to miglyol 812N. Considering the 
range examined, correlation appeared linear at first sight for all three oils, but none of the 
regression lines hit the point of origin. 
 
Table 24. Correlation between apparent permeability coefficient Papp and continuous phase ibuprofen 
concentration over total concentration CL/Ctot  
Isopropyl myristate Ctot (ug/g) CL/Ctot Papp ± SEM (cm/sec)1 
E702 10000 3.32 3.54·10-7 ± 4.79·10-8  
E502 10000 2.00 2.82·10-7 ± 2.79·10-8 
E302 5000 1.43 2.68·10-7 ± 8.41·10-9 
Oil + 7% Isolan PDI 10000 1.00 2.52·10-7 ± 1.57·10-8 
Miglyol 812N 
   
E702 10000 3.32 2.06·10-7 ± 2.80·10-8  
E502 10000 2.00 1.39·10-7 ± 2.74·10-8 
E302 5000 1.43 1.10·10-7 ± 1.04·10-8 
Oil + 7% Isolan PDI 10000 1.00 1.07·10-7 ± 1.86·10-8 
Paraffinum Liquidum 
   
E702 10000 3.27 2.68·10-7 ± 3.97·10-8 
E502 5000 1.98 2.24·10-7 ± 1.70·10-8 
E302 5000 1.42 1.89·10-7 ± 1.90·10-8 
1
 all values denote mean ± standard error of mean. n = 5 - 11 
2
 emulsion with 70%, 50% and 30% of dispersed phase, respectively 
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Figure 20. Correlation between apparent permeability coefficient Papp and continuous phase ibuprofen 
concentration over total concentration CL/Ctot  of lipophilic vehicles with varying phase fractions on the 
basis of different oils (n = 5 - 11; error bars not shown) 
 
 
4.3.2.3.2 Permeability coefficients of the vehicle Pdbl and the skin Pm (non-linear regression) 
To delineate the contribution of permeability through diffusion boundary layer Pdbl and 
permeability through skin Pm to overall apparent permeability Papp of each transport series 
(isopropyl myristate, miglyol 812N or paraffinum liquidum, see table 12), the individual values 
were calculated. For this purpose equation V was fitted to the data of Papp versus CL/Ctot. 
EasyFit® curves are shown in figure 21 and demonstrate a good agreement of the curve with 
experimental data for all studied series. The deduced values for Pdbl and Pm are shown in 
table 25. 
 Considering a wider range for CL/Ctot, it turned out that correlation for all three transport 
series / oils studied was non-linear. Permeation was best for isopropyl myristate series. 
Paraffinum liquidum series showed higher permeability than miglyol 812N series. 
Considering permeability coefficient of the skin Pm, values differed at most 5-fold. Contrary to 
the values received for caffeine transports, permeability coefficient of the diffusion boundary 
layer Pdbl for ibuprofen did not show a difference for all three oil selected. It is noted that Pdbl 
values obtained from a fit are average values of all four formulations of a transport series. 
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For a deeper understanding of the received Pdbl values, effective permeability Pe in the w/o-
emulsion formulation was considered. 
 
Table 25. Representative values for permeability coefficient of the diffusion boundary layer Pdbl and the 
skin Pm derived by easy fit® software for the ibuprofen transport series (n = 5 - 11) with isopropyl 
myristate (IPM), miglyol 812N (Migl) and paraffinum liquidum (Para) 
Oil Formulation CL / C tot Papp (cm/sec)1 Pdbl (cm/sec) Pm (cm/sec) 
E702 3.32 3.54·10-7 
E502 2.00 2.82·10-7 
E302 1.43 2.68·10-6 
IPM 
Oil+7% Isolan PDI 1.00 2.52·10-6 
4.18·10-7 5.53·10-7 
E702 3.32 2.06·10-7 
E502 2.00 1.39·10-7 
E302 1.43 1.10·10-7 Migl 
Oil+7% Isolan PDI 1.00 1.07·10-7 
4.20·10-7 1.16·10-7 
E702 3.27 2.68·10-7 
E502 1.98 2.24·10-7 Para 
E302 1.42 1.89·10-7 
3.93·10-7 2.59·10-7 
1 mean value. Standard error not shown. n = 5 – 11 
2
 emulsion with 70%, 50% and 30% of dispersed phase, respectively 
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Figure 21. EasyFit® plot of the ibuprofen formulations (× denotes isopropyl myristate, ∆ denotes 
paraffinum liquidum and □ denotes miglyol 812N) 
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4.3.2.3.3 Effective Permeability Coefficient Pe within the vehicle (non-linear regression) 
Effective permeability coefficient Pe reflects the diffusivity of a drug in a vehicle and was 
calculated by equation XIV and XVI. For all three oils studied permeability coefficient for the 
diffusion boundary layer Pdbl decreased as the phase fraction of dispersed water phase was 
increased. Additionally, following increasing viscosity (see Part III, 5.3.1.1) of isopropyl 
myristate, miglyol 812N and paraffinum liquidum, effective permeability coefficient Pe was 
decreased in all cases. 
 
Table 26. Effective permeability coefficient Pe(cm/sec) of ibuprofen in emulsions with varying phase 
fractions and for of different oils 
 
Pe(IPM)1 [cm/sec] Pe(Migl)2 [cm/sec] Pe(Para)3 [cm/sec] 
E704 2.25·10-7 6.3·10-8 6.65·10-8 
E504 3.99·10-7 1.19·10-7 7.21·10-8 
E304 6.03·10-7 1.75·10-7 7.84·10-8 
1
 isopropyl myristate 
2
 miglyol 812N 
3
 paraffinum liquidum 
4
 emulsion with 70%, 50% and 30% of dispersed phase, respectively 
 
Permeability coefficient of the diffusion boundary layer Pdbl is a representative value for all 
emulsion of a transport series, i.e. emulsions of different phase fractions and different droplet 
sizes (see Part III, 5.3.1.2). Effective permeability coefficient Pe, however, is a specific value 
for the oil and the mass fractions selected. Comparison of the permeabilities Pdbl and Pe of 
the corresponding transport series yielded a good correlation only for the isopropyl myristate 
series. 
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4.3.2.4 Transdermal Permeation of Benzyltrimethylammonium Chloride 
For benzyltrimethylammonium chloride (BTA-Cl) the drug distribution coefficient between oil 
and water phase is supposed to be zero, as salts do not possess solubility in oil. According 
to the proposed concept that continuous drug phase concentration governs skin permeation, 
no permeation should occurr as drug substance remaines entrapped in water droplets 
dispersed in oil. In all cases studied, occlusive application of BTA-Cl formulations with an 
infinite dose of 0.7 g/cm2 did not yield a steady-state flux within 48h or no permeation was 
observed at all. The comparatively low amounts that permeated through the skin can be 
attributed to possible damages of the skin, permeation through shunt routes or instabilities of 
the formulations occurring directly at the emulsion – stratum corneum surface within 48h. 
Furthermore, it is possible that ion pair complexes were formed with anions resulting from the 
skin or the vehicle that enabled distribution and consequently permeation. Figure 22 is a 
representative and averaged permeation pattern of the studied formulations. 
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Figure 22. Averaged permeation pattern of Benzyltrimethylammonium Chloride (1% and 0.5% of total 
drug concentration for E70 and E30, respectively; error bars not shown; n = 4 - 11) 
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4.4 Discussion 
The efficiency, tolerability and applicability of topical agents are directly related to employed 
vehicles. Thus, to achieve optimum topical therapy, a solid knowledge of the vehicles, their 
composition, and their physical and dermato-pharmacological actions is important [36]. 
The overall topical delivery process is extremely complex in that competitive effects 
proceeding in parallel or consecutively are not easily separated since components of the 
vehicle themselves may dramatically alter the permeability of the skin to the drug. Clearly, 
the relative importance of each of these determinants is a function of the physicochemical 
properties of the drug, its vehicle and the membrane, i.e. the skin [6]. 
Transdermal permeation of a hydrophilic and a lipophilic model drug (caffeine and ibuprofen, 
respectively) out of w/o-emulsions of varying phase fractions (E70, E50 and E30) and 
differing oil components (isopropyl myristate IPM, miglyol 812N Migl, paraffinum liquidum 
Para) was studied.  Additionally, these formulations also differed in their microstructure 
showing decreasing droplet sizes and denser droplet packing as the fraction of the dispersed 
water phase was increased. Microscopic pictures obtained by freeze fraction scanning 
electron microscopy (see Part III, 5.3.1.2) revealed that this observation was consistent for all 
formulations studied. The formulations were designed specifically to quantitatively 
understand the mechanisms that determine absorption processes across the skin. For that 
purpose, continuous phase drug concentration of the formulation was considered, according 
to a proposed concept, which postulates that this concentration is the driving force governing 
permeation kinetics [2, 3]. 
Continuous phase drug concentration was determined experimentally by ultracentrifugation 
experiments and theoretically by calculation based on equation III taking into consideration 
total drug concentration, phase fractions and drug partitioning between the corresponding oil 
and water phase. Drug distribution coefficients between oil and water phase did not only 
disclose the hydrophilic and lipophilic nature of the model drugs studied, but additionally 
showed that distribution was different depending on the oil selected. Concerning the drug 
distribution coefficient for caffeine and ibuprofen, the values for IPM and Migl were closer to 
each other than the values of Para.  
For ibuprofen formulations, the calculated and measured continuous phase drug 
concentration correlated impressively well. The continuous phase ibuprofen concentrations 
differed within one transport series (E70, E50, E30 and oil) according to the phase fraction, 
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but were similar for w/o-emulsions of the same phase fraction, although different oil 
components were selected. This is because continuous phase drug concentration for a w/o-
emulsion is calculated based on formula III. For a lipophilic drug, the term volume fraction of 
dispersed phase over drug partition coefficient between oil and water phase ФW / KL/W can be 
neglected compared to the volume fraction of the continuous phase ФL due to the high values 
of partition coefficient KL/W for lipophilic model compounds. 
For caffeine the total drug concentration applied in formulations was smaller compared to 
ibuprofen in order to prevent any possible saturation or drug precipitation within the 
continuous oil phase (for saturation concentration, see Part III, 5.3.1.3 and [3]). Accordingly, 
the continuous phase drug concentration was up to 1500-fold smaller.  The agreement 
between calculated and measured values was not as good as for ibuprofen. The reason for 
this is presently not clear, might be related though to experimental error due to the much 
smaller drug concentration. Continuous phase drug concentration differed within the 
transport series (E70, E50, E30 and oil), but also had different values for w/o-emulsions of 
the same phase fraction, but different oil components. This is because equation III was 
applied for calculation of caffeine concentration in the oil phase. For hydrophilic drug 
components possessing a drug distribution coefficient KL/W below unity, the term ФW / KL/W 
outweighs ФL.  
To summarize, validity of equation III for calculation of continuous phase drug concentration 
in w/o-emulsions under occlusive conditions is given for hydrophilic and lipophilic model 
drugs (see table 15 and 16) and, therefore can be used with other lipophilic vehicle systems. 
Varying amounts of emulsifier Isolan PDI in emulsions comprising the same phase fractions 
did not affect continuous phase drug concentration examined with ibuprofen for which 
emulsifier in the oil phase could, in theory (equation III), have a measurable effect. Further 
studies revealed that emulsifier did also not affect saturation concentration of the drugs in the 
oils (see Part III, 5.3.1.3). 
Transdermal absorption processes with lipophilic vehicle systems were studied with transport 
experiments across full-thickness pig ear skin. Correlation of apparent permeability 
coefficient Papp for steady-state conditions with continuous phase drug concentration over 
total concentration CL/Ctot was examined (see figure 19 for caffeine and 21 for ibuprofen).  
To consider possible effects Isolan PDI could exert with respect to transdermal permeation, 
its influence was studied more in detail (discussed in an additional publication, see part III). 
No effect of Isolan PDI was found. With respect to the transdermal permeation of the 
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formulations discussed here, w/o-emulsions were designed in a way that ratio of emulsifier 
content over oil content ranged in the same order of magnitude. Consequently, for reference 
formulation pure oil was mixed with a corresponding amount of emulsifier so as to be 
comparable to the emulsion applied. 
In the situation of transdermal drug delivery from a multi-phasic dermatological formulation, 
two diffusion-related processes take place: drug diffusion within the skin and drug diffusion 
within the formulation to the skin. Apparent permeability coefficient Papp was determined by 
transport experiments across full-thickness pig ear skin using Franz-type diffusion cells and 
is therefore dependent on permeability coefficient of the diffusion boundary layer (vehicle) 
Pdbl and of the membrane (skin) Pm. Dependent on the contribution of these two determinants 
to overall measured apparent permeability coefficient Papp, correlation between Papp and 
CL/Ctot resulted in a non-linear relationship, except for caffeine/Migl transport series (see 
4.3.2.1). 
By plotting apparent permeabilities Papp of all caffeine formulations studied (series IPM, Migl, 
Para) against corresponding continuous phase drug concentration over total concentration 
CL/Ctot, obtained correlation differed for all three oils selected. A linear correlation for miglyol 
based formulations and a nonlinear correlation for IPM based formulation was observed. A 
clear statement for paraffinum liquidum based formulations was not possible. The single data 
points are not evenly distributed along the x-axis and it turned out that combination of 
caffeine with paraffinum liquidum was not suitable due to the low drug distribution coefficient 
KL/W between oil and water phase (see 4.3.1.1). Depending on the oil selected, apparent 
permeability coefficients Papp were different. Highest permeability was found for caffeine/IPM 
series, followed for caffeine/Para series and caffeine/Migl series.  
Considering apparent permeabilities Papp of all examined ibuprofen formulations and the 
corresponding continuous phase drug concentration over total concentration CL/Ctot, 
correlation pattern was similar, but not identical. In the examined range of values correlation 
appeared linear at first sight for all three oils, but none of the regression lines hit the point of 
origin. As already observed for the hydrophilic drug caffeine, ibuprofen possessed highest 
apparent permeability coefficients Papp in formulations comprising IPM, followed by Para and 
Migl based formulations, thus, the ranking of drug permeabilities with respect to the oils was 
the same. 
To delineate the contribution of permeability through diffusion boundary layer Pdbl and 
permeability through the skin Pm to overall apparent permeability Papp of each transport 
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series, the individual values were calculated. Equation V was fitted to the data of Papp versus 
CL/Ctot. 
Taking into account caffeine distribution coefficient between stratum corneum and oil (see 
4.3.1.2), the values, determined indirectly without any direct interaction of the oil with the 
stratum corneum, could only explain the permeability coefficient Pm of Migl and Para. 
Contrary, IPM possessed a low drug distribution coefficient KSC/L of all three oils, but showed 
highest permeation. Permeability coefficient of the skin Pm differed 6.4-fold between IPM and 
Migl series, 8.8-fold between Para and IPM series, and 56-fold between Para and Migl 
series. Considering the ratios of Pm values for the caffeine series and the ratio of the 
corresponding distribution coefficients of caffeine partitioning between stratum corneum and 
oil, there is a good correlation for the Para and Migl series (ratios almost identical), whereas 
ratios differed 2-fold for IPM and Migl series and 1.7-fold for Para and IPM series (see table 
27). 
Taking into account ibuprofen distribution coefficient between stratum corneum and oil (see 
4.3.1.2), the values, determined indirectly without any direct interaction of the oil with the 
stratum corneum, could only explain the ranking of permeation for Migl and Para. Ibuprofen 
distribution between stratum corneum and oil was similar for IPM and Migl, but IPM series 
showed highest permeation. Drug distribution coefficient between stratum corneum and oil 
was 7-fold smaller for IPM than for Para, but permeability coefficient of the skin Pm differed 2-
fold between IPM and Para. 
For Migl and Para, there was an almost linear correlation for permeability coefficient of the 
skin Pm and caffeine distribution coefficient between stratum corneum and oil KSC/L, whereas 
for ibuprofen only the ranking of the distribution for Pm and KSC/L was similar. 
Concerning the oils, it is important to note that according to literature IPM acts as a 
permeation enhancer. For instance, Dias et al. studied the transdermal permeation of 
caffeine out of several saturated vehicles. Mineral oil and isopropyl myristate among others 
enhanced permeation by modulation of the barrier properties. It was concluded that the 
vehicles permeate into the skin lipids and alter the solubility properties in a favourable way. 
The degree to which the vehicles can achieve this depends on their uptake into the skin and 
their solubility of caffeine in the modified environment [112]. Other researcher claim that IPM 
places itself within lipid bilayers present in stratum corneum (intercalation), thus, the high 
ordered structure is disturbed, bilayers get more liquid and diffusion velocity is increased [36, 
118, 122, 123]. Potentially, IPM also extracts lipophilic components of the skin and therefore 
disturbs skin barrier function [138]. As determination of the partition coefficient for caffeine 
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between stratum corneum and IPM was performed indirectly, direct effects IPM might exert 
on stratum corneum were masked and, thus, lower values than effectively present were 
obtained. For ibuprofen transport series with IPM, the received drug distribution values for 
KSC/L did also not correlated with permeability coefficient Pm. Consequently, the permeation 
enhancement of ibuprofen is not limited to hydrophilic drug, but also valid for lipophilic drugs. 
 
Table 27. Permeability coefficient of the membrane Pm for caffeine and ibuprofen taking into account 
drug distribution between stratum corneum and oil phase KSC/L  
 
Isopropyl myristate 
[cm/sec] 
Miglyol 812N 
[cm/sec] 
Paraffinum liquidum 
[cm/sec] 
CAFFEINE series A B C 
Pm 1.03·10-5 1.61·10-6 9.04·10-5 
KSC/L 73.75 22.87 1113.21 
IBUPROFEN 
series 
D E F 
Pm 5.53·10-7 1.16·10-7 2.59·10-7 
KSC/L 0.101 0.106 0.724 
 
The deduced permeability coefficient of the diffusion boundary layer Pdbl is a representative 
values for lipophilic emulsions of varying phase fractions and varying droplet sizes and does 
not consider the microstructure present in each formulation. Consequently, the theoretically 
calculated effective permeability coefficient Pe was introduced taking into account different 
phase fractions and drug distribution coefficients between oil and water phase.  
Concerning the hydrophilic drug caffeine in all series studied (IPM, Migl, Para), in most cases 
permeability coefficient of diffusion boundary layer Pdbl were in the same order of magnitude 
as effective permeability coefficient Pe (see table 28). Pdbl values differed 4.5-fold between 
IPM and Migl series, 2.5-fold between IPM and Para series and 1.8-fold between Para and 
Migl series. For IPM and Migl series, effective permeability coefficient Pe showed a good 
agreement with estimated permeability coefficients of the diffusion boundary layer Pdbl. 
Effective permeability coefficient Pe of the formulation increased as phase fraction of the 
dispersed water phase is increased. Additionally, within one formulation of defined phase 
fraction, effective permeability coefficient increased as viscosity of the formulation or the oil 
was decreased.  
Caffeine incorporated in w/o-emulsions of varying phase fractions is mainly entrapped inside 
water droplets. As fraction of internal phase is increased, droplet size decreases and packing 
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becomes denser. It is likely that these changes in microstructure facilitate diffusion of a 
hydrophilic drug within w/o-emulsions.  
Concerning the lipophilic drug ibuprofen in all series studied, permeability coefficients of the 
diffusion boundary layer Pdbl were almost identical for all three series studied (see table 28). 
In most cases computed values for Pe are in the same order of magnitude as permeability 
coefficient of the diffusion boundary layer Pdbl. Best agreement was found for IPM series.  
Ibuprofen, in contrary, is mainly present in the continuous oil phase. If the fraction of the 
internal phase is increased, resulting in a denser droplet packing and reduced droplet size, 
diffusion of ibuprofen slows down. The path of diffusion is becoming more and more tortuous 
and ibuprofen has to circumvent more and more droplet “obstacles”. 
The tendency of effective permeability coefficient Pe was different compared to caffeine with 
respect to the phase fractions, but not with respect to viscosity. The smaller the dispersed 
phase fraction of water in oil was, the higher the calculated effective permeability coefficient 
Pe became. Within one formulation of defined phase fraction, effective permeability coefficient 
Pe increased as the viscosity of the formulation or oil, respectively, was decreased. 
Table 28. Effective permeability coefficient Pe ·106 and permeability coefficient of the diffusion boundary 
layer Pdbl·106 [units cm/sec] 
 CAFFEINE IBUPROFEN 
 
Isopropyl 
myristate 
Miglyol 
812N 
Paraffinum 
liquidum 
Isopropyl 
myristate 
Miglyol 
812N 
Paraffinum 
liquidum 
E701 5.40 2.13 0.72 0.23 0.06 0.067 
E501 3.73 1.07 0.36 0.40 0.12 0.072 
E301 3.46 0.62 0.21 0.60 0.18 0.078 
Pdbl 4.50 1.01 1.87 0.42 0.42 0.39 
1
 emulsions with 70%, 50% and 30% of dispersed phase, respectively 
 
Previous work that focused on multi-phasic hydrophilic formulations figured out that diffusion 
within the vehicle was at least two orders of magnitude faster than diffusion within stratum 
corneum [3]. This finally indicated that diffusion in the skin dominated permeation kinetics, 
confirming a published work where diclofenac permeation from different phospholipids-based 
formulations was investigated [162]. In contrary, Clément et al. studied the effect of 
formulation parameters on the in vitro release of caffeine from concentrated w/o-emulsions 
obtaining four different emulsifiers across a polysulfone membrane. The concentration of the 
emulsifier did not have a significant effect on the release of caffeine, but in contrast, diffusion 
of caffeine from w/o-emulsions was found to be highly dependent on the internal phase 
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volume. The flux of caffeine increased with the percentage of the dispersed water phase. 
The droplet diameter decreased and also apparent viscosity increased with the percentage 
of dispersed phase. Results further suggested that the shape factor of dispersed phase may 
also have an influence on the release of caffeine from concentrated emulsions [45, 163]. 
Izquierdo et al. examined the influence of emulsion droplet size on skin penetration of 
tetracaine using 3 macro-emulsions with droplet-sizes > 1 µm and 3 nano-emulsions with 
droplet sizes < 100 nm, but could not confirm the general anticipated increase in 
(transdermal) drug delivery with reduced emulsion droplet size [164-166]. Thus, it is likely 
that besides droplet size also drug properties and drug partitioning have to be considered. 
The above citations show that literature is conflicting with respect to phase fraction and 
particle size. Our findings could confirm the work of Clément et al.. 
Based on the data derived for Pdbl and Pm of all series studied, caffeine possessed an up to 
10-fold higher permeability coefficient Pdbl of the diffusion boundary layer and an up to 350-
fold higher permeability coefficient Pm of the skin compared to ibuprofen. The drug 
distribution coefficients between stratum corneum und oil phase were up to 1500-fold higher 
for caffeine than for ibuprofen which is consistent with the data for permeability coefficients 
Pm (see table 27). 
Additionally, w/o-emulsions containing benzyltrimethylammonium chloride as a model drug 
were examined to confirm the postulated concept. Formulations comprising 
benzyltrimethylammonium chloride did not establish a steady state flux within 48h, if they 
showed any permeation at all. This observation is consistent with the assumption that no salt 
was present in the continuous oil phase of the formulations and, accordingly, no driving 
concentration gradient existed. Benzyltrimethylammonium chloride remained entrapped in 
the water droplets. If permeated drug was detected, however, steady-state conditions were 
not established and transported drug amount was very low (see figure 22). This was most 
probably due to transport through shunt routes, emulsion instabilities and ion pairing 
complexes occurring within 48h. 
To conclude, a correlation between apparent permeability coefficient Papp and continuous 
phase drug concentration over total concentration CL/Ctot was established taking into account 
permeability coefficient of the diffusion boundary layer Pdbl and permeability coefficient of the 
skin Pm. These values are in general comparable indicating that depending on the ratio of 
CL/Ctot both can be rate controlling. Deduces values of Pdbl and Pm were reasonably 
consistent with independent theoretical calculation (in case of Pdbl), independent 
experimental and literature data (in case of Pm). This supports validity of the established 
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correlation. The proposed concept can be used to predict drug delivery rates of lipophilic 
vehicle systems under occlusive conditions. 
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5 Influence of Emulsifier Content, Thickener, 
Dose and Evaporation on Transdermal Drug 
Skin Permeation with Lipophilic Vehicles 
Abstract 
A concept for the interpretation of drug permeation was proposed that considered continuous 
phase drug concentration as the driving force for transdermal permeation of w/o-emulsions if 
occlusive conditions are assumed (see Part II). In order to implement this concept to the 
situation of non-occlusive application, changes vehicle undergo in the course of their 
application like evaporation of volatile components were studied. The extent of water loss 
and consequently the degree of occurring compositional changes is dependent on the 
applied dose. Continuous phase drug concentration can further be influenced by the 
presence of free emulsifier or an interaction with additives such as thickener Aerosil 200.  
The purpose of this study was to elucidate the effect of these (formulation) parameters on 
transdermal absorption of a hydrophilic and a lipophilic model drug (caffeine or ibuprofen) 
incorporated in w/o-emulsions. 
The studied w/o-emulsions consisted of an oil phase into which water phase was dispersed 
in mass fractions of 70%, 50% and 30% (E70, E50 and E30, respectively). Oil phase 
consisted of an oil component (isopropyl myristate, miglyol 812N or paraffinum liquidum) and 
of polymeric emulsifier Isolan PDI. Water phase contained sodium chloride and was buffered 
to pH 4.5 for all emulsions containing ibuprofen. Transport experiments were carried out in 
Franz-type diffusion cells across pig ear skin at 32°C under occlusive and non-occlusive 
conditions with the infinite dosing of 0.3 g/cm2 and 0.7 g/cm2. 
Freeze fracture scanning electron microscopy revealed a decreasing droplet size and denser 
droplet packing as phase fraction of dispersed water phase was increased. Additionally, 
viscosity increased with the amount of dispersed water phase.  
A reduction of applied dose did not affect apparent permeability coefficient, but extent of 
water loss, as confirmed by studies on skin and in beaker. For implementing continuous 
phase drug concentration concept to non-occlusive conditions, a formula was derived that 
considered observed water loss and permeated drug amount in order to calculate the 
calculate the resulting drug concentration in the continuous formulation phase over time. An 
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increase of the drug concentration in the continuous oil phase was estimated which, 
however, did not lead to a measurable increase of the apparent permeability coefficient. 
Free emulsifier present in the continuous oil phase neither affected saturation concentration 
nor transdermal absorption of the model drugs. Thickener Aerosil strongly decreased 
transdermal permeation of caffeine, but did not show any interaction with ibuprofen. 
The performed characterisations demonstrate the possible influence of formulations 
parameters on regulation of drug skin permeation. Continuous phase drug concentration 
concept for lipophilic vehicles is expanded to the situation of non-occlusive application, but 
confirmation requires further investigations. 
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5.1 Introduction 
In clinical practice, a drug is barely applied to the skin in form of a pure chemical, but instead, 
is incorporated into a carrier system, the vehicle, to guarantee efficient topical or systemic 
therapy. Convincing and suitable applicability, compatibility, adequate stability and above all 
efficacy with respect to duration and strength of the desired pharmacological action are 
requirements directly related to the employed vehicle. Thus, development and optimization of 
these dermatological formulations is a challenging task [1, 36].  
Nowadays, it is widely acknowledged that transdermal permeation is regulated by the 
formulation of the drug product. This regulation may take place not only based on physico-
chemical principles such as diffusion and partitioning of the active ingredient, but also by an 
interaction with the absorptive epithelium, i.e. the epidermis, affecting the permeability of the 
drug. Hence, a solid knowledge of the composition, including its physico-chemical properties 
and present microstructures is crucial in terms of achieving optimal topical delivery. 
However, if a finite dose of dermatological formulation is applied onto the skin, the physico-
chemical and thermodynamic conditions of the freshly applied emulsion change radically. 
Initial structural matrix and quantitative composition will most likely change during and after 
mechanical agitation associated with the application of the product (e.g. rubbing) and/or 
evaporation of ingredients (phase inversion).  Medications are typically applied to the skin as 
a thin layer under non-occlusive conditions and are intended to deliver the active ingredient 
for hours. A change in the composition due to evaporation likely elicits alterations of the 
phase structure of the system and of the concentration and distribution of the active 
ingredient in it. These alterations can in turn affect delivery performance. Consequently, the 
transformation of the formulation while on the skin surface may be a crucial factor 
determining drug delivery. Possible evaporation of the volatile components of some vehicles, 
for instance o/w-emulsions, can result in an appreciable increase in solute drug 
concentration, first leading to saturation condition and then to a supersaturation or drug 
precipitation. Yet, it is still the beginning to research the complicating effects of vehicle 
metamorphosis on the entire clinical picture. On the contrary, if an infinite dose is applied, the 
formulation does not involve at the skin surface and the thermodynamic parameters are not 
altered [1, 3, 5]. 
A comprehensive and uniform theory that considers this multifaceted complexity present in 
dermatological formulations in order to quantitative understand the mechanisms of 
transdermal absorption is consequently a valuable contribution to research and development. 
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Previous work of our group proposed the continuous phase drug concentration concept as a 
model to delineate regulation of skin permeation considering drug distribution among distinct 
phases of multi-phasic hydrophilic formulations. Validity of this concept was confirmed for 
occlusive and non-occlusive conditions even though vehicles underwent considerable 
changes in their composition and microstructure due to evaporation of volatile ingredients [2, 
3]. In a separate manuscript this concept was applied to w/o-emulsions of varying phase 
fractions and oil components and confirmed for occlusive conditions. Concerning lipophilic 
vehicle systems, resulting apparent permeability coefficients were not only dependent on 
drug permeability through the skin, but also on drug diffusivity within the vehicle itself. To 
date, drug diffusion inside the vehicle and its overall contribution to transdermal permeation 
has received too little attention. Permeability through the vehicle is mainly dependent on 
vehicle and drug properties, but also on phase fractions intermixed with each other and on 
arising microstructures (Part II). Additionally, drug concentration in the external oil phase can 
be influenced by the presence of free emulsifier, interaction with additives like thickeners or 
changes vehicle undergo in the course of their application like evaporation of volatile 
components. The extent of water loss and consequently the degree of occurring 
compositional changes is furthermore dependent on the applied dose . 
Thus, the goal of the present work was to investigate the dependence of drug skin 
permeation of w/o-emulsions on (formulation) parameters like emulsifier and thickener 
content, dose and evaporation. The studied vehicles consisted of an oil phase into which 
water phase was dispersed in phase fractions of 70%, 50% and 30%, respectively (E70, E50 
and E30). Oil phase consisted of a single oil component (isopropyl myristate, miglyol 812N or 
paraffinum liquidum) and polymeric emulsifier Isolan PDI. Water phase contained sodium 
chloride and was buffered to pH 4.5 in case of ibuprofen. Pure oil with and without emulsifier 
were selected as reference formulations. These formulations were designed specifically to 
elucidate the effect of differing continuous phase drug concentrations, microstructures and oil 
bases on transdermal delivery (see Part II). Caffeine (hydrophilic) and ibuprofen (lipophilic) 
were applied as model drugs, owning different solubility and permeation properties. 
Permeation experiments were carried out in vitro using Franz-type diffusion cells and pig ear 
skin as a model for human skin [134]. 
The influence of a reduced though still infinite dose (0.3 g/cm2 instead of 0.7 g/cm2) on 
apparent permeability coefficient was studied under occlusive conditions. Additionally, the 
reduced dose appeared handy and practical in terms of studying evaporation and 
transdermal permeation in parallel for non-occlusive conditions. Evaporation was examined 
in beaker and on skin mounted in Franz-type diffusion cells. Different experimental setup 
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allowed investigating any possible water uptake resulting from upward diffusion of the 
receiver compartment. Furthermore evaporation was studied in dependence of time and 
phase fraction present. Taking into account continuous phase drug concentration concept as 
a model to delineate transdermal drug delivery (see Part II), a formula is derived that 
considers observed water loss in the course of non-occlusive application and drug amount 
permeated in order to calculate new arising drug concentration in the external oil phase. 
Isopropyl myristate and miglyol 812N were mixed with Isolan PDI in varying ratios being in 
the same order of magnitude or even similar to the situation present in the study formulation 
in order to examine the influence of free available emulsifier on the model drugs in terms of 
saturation concentration, continuous phase drug concentration and absorption process. The 
effect of thickener Aerosil 200 on macroscopic viscosity and apparent permeability coefficient 
for both model drugs was additionally investigated. 
Besides, particle size of the examined formulations was approximated by freeze fracture 
scanning electron microscopy in order to gain a deeper understanding for the present 
microstructures and, thus, the entire absorption process. The understanding was completed 
through viscosity measurements of the examined formulations. 
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5.2 Materials and Methods 
5.2.1 Materials 
Caffeine was a gift from Boehringer Ingelheim (Ingelheim, Germany) and ibuprofen was 
obtained from Glatt GmbH (Binzen, Germany). Miglyol 812N® (Migl), medium chain 
triglycerides, was a gift from Hüls AG (Witten, Germany) and the polymeric emulsifier Isolan 
PDI (INCI: Diisostearoyl Polyglycerly-3 dimer dilinoleate) was donated from Goldschmidt 
GmbH (Essen, Germany). Isopropyl myristate (IPM), paraffinum liquidum (Para), sodium 
chloride, sodium dihydrogenphosphate dihydrate and phosphoric acid 85% were purchased 
from Haenseler AG (Herisau, Switzerland). Sodium azide and sodium acetate were 
purchased from Fluka Chemie GmbH (Buchs, Switzerland). Methanol, CombiTitrant5, a one-
component reagent for the volumetric Karl Fischer titration and CombiSolventOil, the basic 
solution for Karl Fischer titration, consisting of methanol and toluol, were obtained from 
Merck KGaA (Darmstadt, Germany). Acetonitrile (HPLC, gradient grade) was ordered from 
Biosolve (Valkeensward, Netherlands). Aerosil 200, used as a stabilizer and thickener for 
oleogels, was obtained from Degussa (Düsseldorf, Germany). All other chemicals and 
reagents used in this study were of analytical grade. Bidistilled water was used in all cases. 
5.2.2 Methods 
5.2.2.1 Manufacturing of the Formulations 
The study formulations (for composition see table 29 and 30) were prepared by first mixing 
water and oil phase separately. In case of hydrophilic model drug water phase consisted of 
caffeine, sodium chloride and bidistilled water. Oil phase consisted of emulsifier Isolan PDI 
(Iso) and the selected oil component, i.e. isopropyl myristate (IPM), miglyol 812N (Migl) or 
paraffinum liquidum (Para), respectively. In case of lipophilic model drug water phase 
consisted of sodium acetate buffer (pH 4.5, buffer capacity β = 0.01) and sodium chloride. Oil 
phase consisted of ibuprofen as model drug, emulsifier Isolan PDI (Iso) and the selected oil 
component, i.e. isopropyl myristate (IPM), miglyol 812N (Migl) or paraffinum liquidum (Para), 
respectively. First, all components of the oil phase were mixed and heated to 80-100°C until 
complete dissolution occurred. Second, water phase was added to the hot oil phase 
gradually with intense homogenization using a polytron PT 3000 (Kinematica AG Littau, 
Switzerland) for 5 minutes. Before further use, formulations remained at room temperature 
for 24h to ensure complete partitioning of the model drug between water and oil phase. 
Different emulsion formulations comprising varying amounts of dispersed phase (30, 50 and 
70 weight-%, respectively) were prepared as formulation E (E30, E50 and E70). If other total 
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concentrations of caffeine were chosen than the listed concentrations in table 29, the amount 
of caffeine increased/decreased in as much as the corresponding amount of water 
decreased/increased, but fraction of the complete water phase remained the same within the 
whole formulations. If other total concentrations of ibuprofen were selected that the 
concentrations listed in table 30, the amount of ibuprofen increased/decreased in as much as 
the corresponding amount of oil decreased/increased, but fraction of the complete oil phase 
remained the same within the whole formulation. If other emulsifier concentrations were 
selected (3%, 5% or 10%), the concentration of oil also changed, but fraction of the lipophilic 
phase remained the same within the whole formulation. If thickener Aerosil 200 was added to 
the oil formulations in order to form organogels, the added percentage referred to the ratio of 
emulsifier Isolan PDI to oil component. Pure saturated caffeine oil with or without emulsifier 
Isolan PDI was obtained by adding an excess of caffeine to the homogeneous oily base. 
These solutions were stirred for 24h at 32°C and fi ltrated afterwards. The saturated oils were 
kept at 32°C to avoid drug precipitations before fu rther use.  
 
Table 29. Composition of the study formulations (in weight-%) for caffeine 
 E701 E501 E301 Oil2 Oil + 
4.5% 
Isolan 
PDI 
Oil + 
7.7% 
Isolan 
PDI 
Oil + 
11.1% 
Isolan 
PDI 
Oil + 
20.0% 
Isolan 
PDI 
Caffeine3,4,5 0.2 0.2 0.2 Saturated Saturated Saturated Saturated Saturated 
Sodium 
Chloride 0.5 0.5 0.5 - - - - - 
Water 69.3 49.3 29.3 - - - - - 
Isolan PDI 3 5 5 - 4.29 7.14 10 16.67 
Oil6,7,8,9 27 45 65 100 95.71 92.86 90 83.33 
TOTAL 100 100 100 100 100 100 100 100 
[ ]OilIsolanPDI  in % 11.1 11.1 7.69 0 4.48 7.7 11.1 20 
1
 emulsion with 70%, 50% and 30% of dispersed phase, respectively 
2
 for isopropyl myristate and paraffinum liquidum oil formulations an addition of 5% Aerosil 200 was examined, for miglyol oil 
formulations an addition of 3%, 5% and 10% Aerosil 200 was studied (viscosity, apparent permeability) 
3
 for isopropyl myristate a total concentration of 1%, 0.25% and 0.08% for E70, 0.08% for E50 and 0.5%, 0.3% and 0.08% for  
E30 were studied 
4
 for miglyol a total concentration of 1%, 0.2% and 0.25% for E70, 0.2% for E50 and 0.3% and 0.5% for E30 were studied 
5
 for paraffinum liquidum a total concentration of 0.2% for E70, E50 and E30 were studied 
6
 isopropyl myristate (IPM), miglyol 812N (Migl) or paraffinum liquidum (Para) 
7
 for isopropyl myristate oil formulations the influence of 7.7%, 11.1% and 20% Isolan PDI was studied 
8
 for miglyol oil formulations the influence of 4.5%, 7.7%, 11.1% and 20.0% Isolan PDI was studied 
9
 for paraffinum liquidum the influence of Isolan PDI in oil formulations could not be studied (solubility problem) 
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Table 30. Composition of the study formulations (in weight-%) for ibuprofen 
 E701,2 E501 E301,3 Oil4,5 Oil +  
4.5% 
Isolan PDI 
Oil +  
7.7% 
Isolan PDI 
Oil + 
11.1% 
Isolan PDI 
Oil + 
20.0% 
Isolan PDI 
Sodium 
Chloride 0.5 0.5 0.5 - - - - - 
Buffer pH 
4.56 69.5 49.5 29.5 - - - - - 
Ibuprofen7 1 0.5 0.5 1 1 1 1 1 
Isolan PDI 26 44.5 64.5 - 4.28 7.12 10.24 17.08 
Oil8 3 5 5 99 94.72 91.84 88.76 81.92 
TOTAL 100 100 100 100 100 100 100 100 
[ ]OilIsolanPDI  
in % 
11.5 11.24 7.75 0 4.5 7.75 11.5 20.84 
1
 emulsion with 70%, 50% and 30% of dispersed phase, respectively 
2
 for E70 the influence of 3%, 5% and 10% Isolan PDI on viscosity and apparent permeability were studied with miglyol as oil 
component 
3
 for E30 the influence of 3%, 5% and 10% Isolan PDI on viscosity and apparent permeability were studied with miglyol as oil 
component, all formulations additionally contained 3% Aerosil 200 as thickener component 
4
 for miglyol oil formulations the influence of additional 5% and 7% Aerosil 200 on viscosity and apparent permeability were 
studied 
5 for isopropyl myristate and paraffinum liquidum oil formulations the influence of 5% Aerosil 200 on apparent permeability was 
examined 
6
 sodium acetate puffer pH 4.5 (buffer capacity β = 0.01) 
7 the influence of 4.5%, 7.7%, 11.1% and 20.0% Isolan PDI for miglyol oil formulations and 7.7% and 20% Isolan PDI for 
isopropyl myristate oil formulations were studied 
8  isopropyl myristate (IPM), miglyol 812N (Migl) or paraffinum liquidum (Para)  
 
All formulations employed for transport experiments were previously tested for stability. After 
manufacturing, the formulations were filled into falcon tubes, closed to avoid any possible 
water loss and left at room temperature for 24h (equilibration time) and at 32°C (water bath) 
for 48h (duration of the permeation experiment). No phase separation was allowed to occur. 
w/o-character of the formulations was confirmed by conductivity measurements before and 
after stability testing. Therefore, a conductometer 660 and a conductivity-measuring cell 
60323110 with a cell constant of 0.8cm-1 (Metrohm AG, Herisau, Switzerland) were used. 
5.2.2.2 Chemical Analysis of the Formulations 
Water was assayed by Karl Fischer titration using a KF 701 Titrino (Metrohm AG, Herisau, 
Switzerland) and a one-component reagent CombiTitrant5. The titrations were performed in 
CombiSolventOil, a mixture of methanol and toluol to guarantee complete dissolution of the 
formulation. The titer was exactly determined with double distilled water prior to every 
analytical run. For water content of 1000 ppm a relative standard deviation between 0.5-1 % 
has to be assumed. For water content > 1000 ppm a relative standard deviation of < 0.5% 
has to be assumed. 
All model drugs were assayed by HPLC (Hewlett Packard, series 1050, Waldborn, 
Germany). For caffeine, a reversed phase RP-8 column was used (CC 125/2 Nucleosil 100-5 
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C8 ec). The mobile phase consisted of 10% acetonitrile and 90% phosphate buffer (pH 7.4, 
buffer capacity β = 0.01). For ibuprofen a reversed phase RP-18 column (CC125/2 
LiChrospher 100-5 RP-18) was used. The mobile phase consisted of 55% acetonitrile and 
45% phosphate buffer (pH 2.1, buffer capacity β = 0.02). Detection was performed UV-
spectrophotometrically at 275nm and 214 nm for caffeine and ibuprofen, respectively. The 
flow rate was 0.25 ml/min and the injection volume 10 µl in all cases. For the determination of 
drug content in the formulation or the oil fraction after ultracentrifugation, samples were 
prepared by extraction with an at least 100-fold amount of buffer pH 7.4 in the case of 
caffeine or methanol in the case of ibuprofen. Diluted samples were sonificated for 5 minutes 
and subsequently centrifuged at 15800 g for 10 minutes. Clear samples were obtained and 
injected. 
5.2.2.3 Viscosity Measurement  
Viscosity and flow behaviour of emulsions, oils and organogels with varying amounts of 
thickener Aerosil 200 and emulsifier Isolan PDI was measured with a rheometer at 32°C 
(Rotovisco RV 12, Haake, Elektro-Wiget GmbH, Arth, Switzerland). A suitable measuring 
cylinder and head were selected and filled with formulation. After 1 hour of temperature 
equilibration, measurement was performed and viscosity was determined for a shear rate of 
γ = 100 s-1 so that different formulations possessing non-newtonian flow behaviour could be 
compared against each other. For experimental setup, an increase in shear stress was 
defined for the first 8 minutes and a decrease in shear stress for the following 8 minutes. 
Maximum shear stress was selected depending on the formulations examined. 
5.2.2.4 Freeze Fracture Scanning Electron Microscopy 
Freeze fracture scanning electron microscopy was performed in order to estimate the particle 
size of the dispersed phase droplets within formulations of different phase fractions (70%, 
50% and 30% of dispersed phase, respectively) and on the basis of different oils (isopropyl 
myristate, miglyol 812N and paraffinum liquidum). For specimen preparation a small droplet 
of the formulation is placed on a specimen table and rapidly frozen in liquid propane / liquid 
nitrogen. The samples are rapidly cryo-transferred into a freeze-fracturing device, where the 
fracture is performed at low temperature under high vacuum. The sample will cleave along a 
fracture plain with the least cohesion. The fracture plane is finally coated with a metal-carbon 
film before scanning electron microscopic inspection.  
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5.2.2.5 Saturation Concentration 
The solubility of caffeine in water, phosphate buffer (pH 7.4, buffer capacity β = 0.05), 
isopropyl myristate (IPM), miglyol 812N (Migl) and paraffinum liquidum (Para) with and 
without emulsifier Isolan PDI was determined as well as the solubility of ibuprofen in sodium 
acetate buffer (pH 4.5, buffer capacity β = 0.01), phosphate buffer (pH 7.4, buffer capacity β 
= 0.05), isopropyl myristate (IPM), miglyol 812N (Migl) and paraffinum liquidum (Para) with 
and without emulsifier Isolan PDI (Iso). Therefore an excess of drug substance was 
equilibrated with each vehicle. The solutions were left under magnetic stirring overnight at 
32°C. Upon equilibration, excess of drug was allowe d to sediment / filtered off and all 
samples were diluted and assayed for model drug as described in 5.2.2.2. Every solubility 
analysis was performed in replicates of three or more. 
5.2.2.6 Evaporation Analysis 
In order to figure out if evaporation takes place within w/o-formulations, beakers with 
predetermined surfaces where placed in water bath (32°C, 48h) and filled with study 
formulations using a dose of 0.7 g/cm2 and 0.3 g/cm2, respectively. Caffeine emulsions that 
comprised 70%, 50% and 30% of dispersed water phase (E70, E50 and E30, respectively) in 
miglyol 812N (0.2% total concentration) were selected as study formulation. Ibuprofen 
emulsions that comprised 70% and 30% of dispersed sodium acetate buffer pH 4.5 in miglyol 
812N (1% and 0.5% total concentration for E70 and E30, respectively) were additionally 
examined. At predetermined time points (0h, 16h, 25h, 40h, 48h) formulations were removed 
from the beaker and analyzed for water content with Karl Fischer titration. Every single 
formulation was examined at least three times. 
In order to compare evaporation pattern, further evaporation studies were performed using 
pig ear skin in Franz-type diffusion cells (32°C, 4 8h). The same formulations were examined, 
but this time only a dose of 0.3 g/cm2 under open and occlusive conditions was applied. 
Again, at predetermined time points water content was assayed by Karl Fischer titration. 
Every single formulation was examined at least three times on skin sheets from three 
different donors.  
5.2.2.7 Permeation Experiments 
In all cases, drug permeation was studied in Franz-type diffusion cells with a diffusion 
surface area between 2.99 - 4.05 cm2 at 32°C across excised full thickness pig ear skin . The 
ears of domestic pigs were obtained from a local slaughter house directly post-mortem. The 
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skin was separated from the cartilage tissue with a scalpel, stored in a freezer at -75°C and 
used within 4 weeks. To overcome the effect of individual skin variability, every single 
formulation was examined in at least three permeation experiments. For a single permeation 
experiment skin of the same pig was used. The receiver medium for the permeation 
experiments with a volume of 8.5 to 9 ml consisted of an aqueous phosphate buffer solution 
(pH 7.4, buffer capacity β = 0.05) and 0.1% sodium azide. Skin integrity was tested by 
measurements of transepidermal water loss (TEWL) (Tewameter TM 210, Courage & 
Khazaka electronic GmbH, Cologne, Germany) after 4 hours of equilibration. Then, a 
practically infinite dose of 0.3 g/cm2 or 0.7 mg/cm2 formulation, respectively, was applied onto 
the skin. A dose of 0.3 g/cm2 was selected in terms of studying evaporation profiles and 
dosing effects, a dose of 0.7 g/cm2 was selected in terms of studying occlusive conditions 
and dosing effects. For occlusive conditions the donor compartment was covered with a 
rubber stopper. At predetermined time intervals, samples of the receiver compartment were 
collected and replaced with fresh buffer. The entire duration of one experiment was 48 hours. 
The samples were analyzed for model drug concentration by HPLC (for conditions see 
4.2.2.2) without further treatment except centrifugation for 10 minutes at 15800 g (Eppendorf 
centrifuge 5415C, Dr. Vaudaux AG, Schönenbuch, Germany).  
5.2.2.8 Data Analysis of the Permeation Experiments  
For interpretation of permeation data, it is postulated that continuous phase drug 
concentration CL of a multi-phase formulation governs permeation kinetics alone. This 
concentration is given by equation III (see Part II) 
LK
tot
L
WL
W
CC φφ +=
/
   [equation III] 
where Ctot denotes overall drug concentration, ФW and ФL phase fractions of dispersed and 
continuous phase, respectively, and KL/W drug partition coefficient between oil and water 
phase. Assuming the conditions of a perfect sink (receiver concentration negligible), an 
infinite donor reservoir, assuring a constant continuous phase drug concentration CL, rate 
limiting membrane (skin) diffusion with the diffusion coefficient D and drug distribution 
between the skin and the continuous phase of the formulation with the distribution coefficient 
KSC/L, drug flux J may be described by Fick’s first law of diffusion. Drug flux J is defined as 
the amount of drug permeated through the skin per unit time and unit area and is given by: 
L
CPJ ⋅=  
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with P as the permeability coefficient (cm/s) and h as thickness of the diffusion rate limiting 
membrane. 
h
KDP LSC /⋅=  
Combining both formulas lead to equation IV (see Part II): 
h
KDCJ LSCL /⋅⋅=    [equation IV] 
Due to possible evaporation of volatile formulation components following a non-occlusive 
application, the composition of the vehicle may change. A model is developed to interpret the 
permeation data that considers the situation within the formulations, i.e. partitioning of the 
drug and phase ratio of dispersed to continuous phase of a multi-phase formulation 
subjected to non-occlusive conditions (see 5.3.2.4.1). 
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5.3 Results 
5.3.1 Characterization of the Formulations 
5.3.1.1 Viscosity Measurement 
To guarantee a long-life stability of emulsions, the addition of thickeners or the alteration of 
emulsifier content can be advisable. Hence, various vehicles with varying amounts of Aerosil 
200 and Isolan PDI were manufactured. The altered viscosity was measured and correlations 
were established (Table 31). For non-newtonian flow behaviour viscosity η at D = 100 1/s is 
shown. 
 
Table 31. Measured viscosity of isopropyl myristate, miglyol, paraffinum liquidum and emulsions 
comprising 30% and 70% of dispersed water in miglyol (E30 and E70) in dependence of emulsifier 
content and thickener content  
 Isolan PDI (%) Aerosil 200 (%) η measured at  D = 100 s-1 (average) SD
1 Flow behaviour 
IPM2 - - 6.71 5.44 Newtonian 
Migl3 - - 22.78 9.51 Newtonian 
Para4 - - 72.35 7.97 Newtonian 
Migl - 5 423.97 33.51 Newtonian 
Migl - 7 847.93 18.59 Newtonian 
E30 Migl 5 - 67.98 3.10 Non-Newtonian 
E30 Migl 3 3 279.96 22.50 Non-Newtonian 
E30 Migl 5 3 343.47 47.80 Non-Newtonian 
E30 Migl 10 3 252.23 9.30 Non-Newtonian 
E70 Migl 3  1075.48 90.65 Non-Newtonian 
E70 Migl 5  1179.33 183.86 Non-Newtonian 
E70 Migl 10  2397.65 155.33 Non-Newtonian 
E70 IPM 3 - 233.52 55.60 Non-Newtonian 
1
 standard deviation (n = 3 – 4) 
2 
 isopropyl myristate 
3 
 miglyol 812N 
4
 paraffinum liquidum 
 
As illustrated in table 31 oils with newtonian flow behaviour differed strongly in their viscosity. 
Isopropyl myristate possessed the smallest viscosity, whereas the viscosities were 
approximately 3-fold and 10-fold higher for miglyol 812N and paraffinum liquidum, 
respectively. Macroscopically, this difference could also be observed for formulations E70, 
E50 and E30 manufactured with these oils. Formulations on the basis of isopropyl myristate 
possessed lotion like appearance, while emulsions on the basis of miglyol and paraffinum 
liquidum had cream or paste like appearance. Within one series comprising the same oil 
component (E70, E50, E30 and oil), viscosity always increased as the amount of dispersed 
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phase was raised. Emulsifier content only exerted an influence on an emulsion comprising 
70% of dispersed water phase. 
If Aerosil 200 was added to miglyol 812N in order to produce organogels, the observed 
viscosity increased with the amount of thickener added (see data table 31). For E70 miglyol 
812N with increasing amounts of added emulsifier an increase of viscosity was observed, but 
not for E30 Miglyol 812N.  
Isolan PDI possesses long polymeric carbon chains that, within w/o-emulsions, project into 
continuous oil phase if interface is enriched with emulsifier. Within E70, packing of the 
droplets is denser than in E50 and E30, respectively (see 5.3.1.2). The close alignment of 
the droplets facilitates possible interaction of the polymeric carbon chains with the 
consequence of an increased viscosity and subsequently a better stability. 
5.3.1.2 Estimation of Particle Size by Freeze Fraction Scanning Electron 
Microscopy 
Freeze fracture scanning electron microscopy was performed to reveal the microstructure 
present within the studied formulations and especially to gain an idea about the particle 
sizes. Freeze fracture scanning electron microscopy was performed for E70 using isopropyl 
myristate, miglyol 812N and paraffinum liquidum as oil components. Concerning E50 and 
E30, only miglyol 812N and paraffinum liquidum as oil components were analyzed as probes 
with isopropyl myristate did not form a droplet on the specimen table and therefore could not 
be subjected to freeze fracture. Figure 23 shows the microscopic pictures obtained with a 
roughly approximation of particle sizes (see table 32). 
 
Table 32. Estimation of particle size based on freeze fracture scanning electron microscopy pictures 
(diameter in µm) 
 Isopropyl myristate Miglyol 812N Paraffinum liquidum 
E701 2 1.5 1 
E501 n.m.2 2 1.5 
E301 n.m.2 3 1.5 
1
 emulsion with 70%, 50% and 30% of dispersed phase, respectively 
2 not measurable 
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Figure 23. Microscopic pictures of the study formulations by freeze fracture scanning electron microscopy 
(see also appendix) 
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5.3.1.3 Saturation Concentration 
The values obtained for saturation concentration determination are depicted in table 33 for 
caffeine and table 34 for ibuprofen, respectively. 
Table 33. Saturation concentration of caffeine in various vehicles determined at 32°C  
Vehicle Emulsifier (%) Saturation concentration   
± SD(µg/g) 1 
Isopropyl myristate 0 1248.06 ± 26.23 
Isopropyl myristate 4 1482.13 ± 15.00 
Isopropyl myristate 7 1482.72 ± 127.19 
Isopropyl myristate 10 1393.46 ± 21.01 
Isopropyl myristate 16 1607.77 ± 31.66 
Miglyol 812 N 0 2476 ± 127.14 
Miglyol 812 N 4 2707.11 ± 84.76 
Miglyol 812 N 7 2659.07 ± 144.78 
Miglyol 812 N 10 2514.18 ± 235.22 
Miglyol 812 N 16 2776.18 ± 257.36 
Paraffinum liquidum 0 120.14 ± 5.28 
Water 0 30789.47 ± 633.10 
Phosphate buffer pH 7.4 (acceptor solution) 0 25628.10 ± 260.36 
1
 all values denote mean ± standard deviation. n = 3 - 15 
 
Concerning saturation concentration of caffeine in various vehicles, it is obvious that its 
solubility is much higher in hydrophilic solutes (water, phosphate buffer pH 7.4) than in 
lipophilic solutes. Saturation concentration of caffeine in oily vehicles showed highest 
solubility in miglyol 812N, followed by isopropyl myristate and paraffinum liquidum. For 
isopropyl myristate and miglyol 812N saturation concentration of caffeine was not affected by 
the presence of varying amounts of emulsifier Isolan PDI (table 33). 
 
Table 34. Saturation concentration of ibuprofen in various vehicles at 32°C  
Vehicle Emulsifier (%) Saturation concentration  
 
± SD1(mg/g) 
Isopropyl myristate 0 163.72 ± 7.80 
Isopropyl myristate 4 153.23 ± 1.87 
Isopropyl myristate 7 159.55 ± 7.17 
Isopropyl myristate 20 147.19 ± 4.41 
Isopropyl myristate 52 152.14 ± 2.42 
Miglyol 812 N 0 142.03 ± 2.66 
Miglyol 812 N 4 149.94 ± 1.35 
Miglyol 812 N 7 188.09 ± 5.97 
Miglyol 812 N 11 142.90 ± 12.19 
Paraffinum liquidum 0 25.50 ± 1.19 
Sodium acetate buffer pH 4.5 0 0.127±0.0003 
Phosphate buffer pH 7.4 (acceptor solution) 0 n.m.2 
1
 all values denotes mean ± standard deviation. n = 3 - 4 
2
 not measured 
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Saturation concentration of ibuprofen possessed highest values for isopropyl myristate and 
was similar to saturation concentration in miglyol 812N. Nevertheless, these concentrations 
were approximately 6 times greater than the concentrations observed for paraffinum 
liquidum. Concerning solubility in hydrophilic solutes, e.g. sodium acetate buffer pH 4.5 
representing the dispersed phase of all ibuprofen formulations, saturation was quickly 
achieved (127.19 µg/g). Isolan PDI did not strongly affect saturation concentration neither in 
case of isopropyl myristate nor in case of miglyol 812N (table 34). The influence of emulsifier 
was not studied for paraffinum liquidum as solubility of Isolan PDI was very low. 
5.3.1.4 Evaporation as a function of Time and Dose  
Evaporation of w/o-emulsions was studied as a function of time and dose with miglyol 812N 
as a representative oil component. Beakers of defined surfaces were filled with the 
formulation and remained at 32°C (water bath heatin g) for 48 hours under non-occlusive 
conditions. Figure 24 describes the water content as a function of time and dose for E70 and 
E30 received from these examinations. Concerning a dose of 0.7 g/cm2 and 0.3 g/cm2, water 
loss was observed, although it is more pronounced for E70 than for E30. The percentage of 
water loss related to original water content is 16.27% and 18.55% for E70 and E30, 
respectively, if a dose of 0.7g/cm2 was applied. Reduction of the dose and, hence, vehicle 
layer thickness resulted in an approximately 2-fold greater water loss related to original water 
content (%): 44.06% for E70 and 33.48% for E30, respectively. Besides, figure 24 nicely 
describes continuing water loss over 48h which is equal to the duration of performed 
transport experiments. Similar results were obtained if ibuprofen formulations using miglyol 
812N as oil component were studied instead of caffeine (datas not shown). 
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Figure 24. Evaporation in dependence of time and dosage for caffeine emulsions comprising 70% and 
30% of dispersed water phase in miglyol oil (E70, E30) studied in beaker under non-occlusive conditions. 
Error bars denote standard deviation (n = 3 - 5). 
 
Due to the results obtained in figure 24, a dose of 0.3 g/cm2 was selected for all further 
evaporation studies. Evaporative changes within dermatological vehicles may differ, 
dependent on whether water loss of a formulation is studied in beaker or on skin mounted in 
Franz-type diffusion cells. In the transport cells, water resulting from an upward diffusion out 
of the receiver compartment can be emulsified by the formulations applied onto the skin. 
Figure 25 compares the changes formulations undergo in dependence of experimental 
setup, i.e. beaker or skin, using a dose of 0.3 g/cm2. For all three formulation types 
examined, E70, E50 or E30, there was a clear difference between occlusive and open 
conditions. Water loss in dependence of time was the same for experiments performed in 
beaker or on skin (t-test, two-sided, p=0.95). If water is lost within a formulation due to 
evaporative processes, this water is not replaced by water uptake from an upward diffusion 
process. Additionally, possible alteration oil vehicles may undergo was studied. Miglyol 812N 
was applied onto skin mounted into diffusion cells with a dose of 0.1 g/cm2. The vehicle 
contained 7.75% of emulsifier and, hence, was similar to continuous phase of formulation 
E30 comprising 30% dispersed water phase and 5% Isolan PDI (ratio emulsifier content over 
oil content). The mixture of oil and emulsifier facilitates possible emulsification of water 
received from upward diffusion from the receiver compartment. However, neither under 
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occlusive nor under open conditions, a significant water uptake was observed (datas not 
shown). This result is in good agreement with the conclusion drawn from figure 25.  
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Figure 25. Absolute water content (%) after 48h studied in dependence of experimental setup for caffeine 
emulsions comprising 70%, 50% and 30% of dispersed water phase in miglyol oil (E70, E50, E30). Dose: 
0.3 g/cm2. Error bars denote standard deviation (n = 3 - 6). 
 
Knowledge about alteration of water content within dermatological vehicles is necessary in 
terms of determining continuous phase drug concentration CLt taking into consideration 
evaporative processes and drug permeation behaviour over time (see 5.3.2.4). Table 35 and 
36 depict the absolute water loss of various formulations within 48h applied under open 
conditions: 
Table 35. Water loss (%)of dermatological caffeine vehicles  (total drug concentration 0.2%) applied non-
occlusively onto skin (dose 0.3 g/cm2, application time 48h) compared to original value 
Original formulation E701 E501 E301 
Water loss [%]2 41.95 36.86 37.54 
New formulation E38 E31 E18 
1
 emulsions comprising 70%, 50% and 30% of dispersed phase, respectively, in miglyol oil 
2
 percentage related to original water content 
 
 
Table 36. Water loss (%) of dermatological ibuprofen vehicles (total drug concentration 1% for E70 and 
0.5% for E30, respectively) applied non-occlusively (dose 0.3 g/cm2, application time 48h) compared to 
original value 
Original formulation E701 E50 E301 
Water loss [%]2 45.16 n.m.2 39.55 
New formulation E36 n.m.3 E18 
1
 emulsions comprising 70%, 50% and 30% of dispersed phase, respectively, in miglyol oil 
2
 percentage related to original water content 
3
 not measured 
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Independently of the amount of water dispersed in oil, the percentage of water loss related to 
original water content was approximately 40% within 48h. Obviously, kinetic of evaporation is 
similar for w/o-emulsions comprising different droplet sizes and droplet arrangements. 
5.3.2 Permeation Experiments 
5.3.2.1 Influence of Thickener Aerosil 200 on Transdermal Permeation 
The influence of thickener Aerosil 200 on apparent permeability coefficient Papp was studied 
for caffeine and ibuprofen in pure oil formulations. Results obtained are shown in table 37 
and 38. 
Aerosil 200 did not exert any statistically significant effect on apparent permeability 
coefficient Papp regarding ibuprofen in isopropyl myristate, miglyol 812N or paraffinum 
liquidum vehicles as confirmed by a two-sided t-test (p=0.95). For paraffinum liquidum Papp 
was 1.5-fold bigger if transport experiments were performed without Aerosil 200. Concerning 
the oils alone, apparent permeability coefficient Papp of ibuprofen was in the same order of 
magnitude for isopropyl myristate and paraffinum liquidum and approximately two times 
greater than miglyol 812N. 
Table 37. Aerosil 200 and its influence on apparent permeability coefficient Papp of ibuprofen in oil 
formulations 
 Aerosil 200 [%] Papp ± SEM (cm/sec)1 
IPM2 0 3.08·10-7 ± 2.47·10-8 
IPM2 5 2.70·10-7 ± 1.30·10-8 
Migl3 0 1.30·10-7 ± 1.13·10-8 
Migl3 5 1.18·10-7 ± 1.70·10-8 
Migl3 7 1.30·10-7 ± 1.14·10-8 
Para4 0 2.96·10-7 ± 2.36·10-8 
Para4 5 1.96·10-7 ± 1.51·10-8 
1
 all values denote mean ± standard error. n = 5 – 22 
2
 isopropyl myristate 
3
 miglyol 812N 
4
 paraffinum liquidum 
 
Table 38. Aerosil 200 and its influence on apparent permeability coefficient Papp of caffeine  
 Aerosil 200 [%] Papp  ± SEM1 (cm/sec) 
IPM2 0 3.81·10-6 ± 5.91·10-7 
IPM2 5 3.89·10-7 ± 3.27·10-8 
Migl3 0 8.26·10-7 ± 2.58·10-7 
Migl3 5 1.26·10-7 ± 1.07·10-8 
Para4 0 1.86·10-6 ± 2.05·10-7 
Para4 5 No permeation measured 
1  all values denote mean ± standard error. n = 5 – 21 
2
 isopropyl myristate 
3
 miglyol 812N 
4
 paraffinum liquidum 
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Concerning Papp of caffeine, Aerosil 200 exerted an effect on transdermal permeation. The 
thickener led to a 10-fold reduction of Papp in case of isopropyl myristate and an 8-fold 
reduction in case of miglyol 812N. Caffeine dissolved in paraffinum liquidum possessed a 
comparably high permeability, but after addition of Aerosil 200, no permeation could be 
observed at all. Concerning the oils alone, apparent permeability coefficients of isopropyl 
myristate was 2-times greater than for paraffinum liquidum and 4.5-fold greater than for 
miglyol 812N.  
Additionally, influence of Aerosil 200 was studied in two w/o - formulations with a dispersed 
phase content of 30% (E30), as these vehicles showed a tendency for instability and, thus, 
increased viscosity would have been favoured. However, Aerosil 200 reduced Papp here as 
well, although reduction was at most 2-fold (see table 39). 
 
Table 39. Aerosil 200 and its influence on apparent permeability coefficient Papp of caffeine in E301  
 Aerosil 200 [%] Papp  ± SEM2 (cm/sec) 
E30 IPM3 0 1.11·10-6 ± 1.57·10-7 
E30 IPM3 3 5.89·10-7 ± 3.50·10-8 
E30 Migl4 0 3.47·10-7 ± 3.21·10-8 
E30 Migl4 3 2.42·10-7 ± 1.66·10-8 
1
 emulsion with 30% of dispersed phase 
2
 all values denote mean ± standard error. n= 4 – 7 
3
 isopropyl myristate 
4
 miglyol 812N 
 
 
5.3.2.2 Influence of Emulsifier Content on Transdermal Permeation 
5.3.2.2.1 Caffeine and Isolan PDI 
In the w/o-emulsions studied, Isolan PDI enriches itself at the interfaces between continuous 
oil phase and dispersed water droplets. As it is not clear if free emulsifier is also present in 
the continuous oil phase, its possible influence on drug permeation was studied. For that 
purpose, varying amounts of emulsifier were dissolved in either isopropyl myristate (IPM) or 
miglyol 812N (Migl). The amounts selected were in the same order of magnitude or similar to 
the ratio of Isolan PDI content over oil content of the studied formulations (see table 29). 
Neither in case of IPM nor in case of Migl, a statistically significant difference was observed 
for the vehicles studied (t-test, 2-sided, p=0.95). Papp values are shown in table 40. As 
Paraffinum liquidum possessed only small solubility for Isolan PDI, studies could not be 
carried out with an oil-emulsifier mixture. 
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Table 40. Isolan PDI and its influence on apparent permeability coefficient Papp of caffeine studied in oil 
formulations comprising varying amounts of emulsifier Isolan PDI 
 
Isolan PDI [%] appP ± SEM1 
IPM2 0 3.81·10-6 ± 5.91·10-7 
IPM2 7.7 3.05·10-6 ± 4.45·10-7 
IPM2 11.1 2.83·10-6 ± 4.97·10-7 
Migl3 0 8.26·10-7 ± 2.58·10-7 
Migl3 4.3 6.97·10-7 ± 7.55·10-8 
Migl3 7.7 6.32·10-7 ± 1.46·10-7 
Migl3 11.1 8.07·10-7 ± 2.02·10-7 
1
 all values denote mean ± standard error. n = 4 – 5 
2
 isopropyl myristate 
3
 miglyol 812N 
 
5.3.2.2.2 Ibuprofen and Isolan PDI 
Varying amounts of emulsifier were dissolved in either isopropyl myristate (IPM) or miglyol 
812N (Migl). Again, the ratio of Isolan PDI content over oil content was in the same order of 
magnitude as for the studied formulations (see table 30). Neither in case of IPM nor in case 
of Migl, a statistically significant difference was seen for the vehicles studied (t-test, 2-sided, 
p=0.95). Papp values are shown in table 41. As Paraffinum liquidum possesses only small 
solubility for Isolan PDI, studies could not be carried out with this oil component. 
 
Table 41. Isolan PDI and its influence of apparent permeability coefficient Papp of ibuprofen in oil and 
emulsion comprising varying amounts of Isolan PDI  
 
Isolan PDI [%] appP ± SEM (cm/sec)1 
IPM2 0 3.08·10-7 ± 3.20·10-8 
IPM2 7.75 2.52·10-7 ± 1.57·10-8 
IPM2 20.83 2.75·10-7 ± 1.28·10-8 
Migl3 0 1.33·10-7 ± 1.29·10-8 
Migl3 4.5 1.18·10-7 ± 7.79·10-9 
Migl3 7.75 1.07·10-7 ± 1.86·10-8 
Migl3 11.5 1.08·10-7 ± 1.95·10-8 
Migl3 20.83 9.96·10-8 ± 1.53·10-8 
E30 Migl3,4 3 1.28·10-7 ± 2.79·10-8 
E30 Migl3,4 5 1.10·10-7 ± 1.04·10-8 
E30 Migl3,4 10 8.19·10-8 ± 1.66·10-8 
E70 Migl3,5 3 2.09·10-7 ± 2.80·10-8 
E70 Migl3,5 5 2.23·10-7 ± 4.28·10-8 
E70 Migl3,5 10 1.69·10-7 ± 2.80·10-8 
1
 all values denote mean ± standard error. n = 4 - 11 
2
 isopropyl myristate 
3 
 miglyol 812N 
4
 emulsion with 30% of dispersed water phase 
5
 emulsion with 70% of dispersed water phase 
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5.3.2.3 Influence of Dose on Transdermal Permeation 
Transdermal permeation behaviour was studied with two infinite doses of 0.7 g/cm2 and 0.3 
g/cm2, respectively. The idea was to evaluate whether a reduced vehicle layer thickness 
might affect apparent permeability coefficient Papp. A dose below 0.3 g/cm2 was not feasible 
in terms of assuring constant continuous phase drug concentration of the vehicle over the 
entire duration of a transport experiment, i.e. 48h. Furthermore, this dose was handy with 
respect to determining water loss in the remaining formulations if non-occlusive conditions 
were examined (see 5.3.2.4). 
Neither for caffeine nor for ibuprofen an alteration in apparent permeability coefficient Papp 
was observed for all examined formulations if dose and, hence, vehicle layer thickness 
applied onto the skin, was reduced (occlusive conditions, see figure 26 und 27). This was 
confirmed by a two-sided t-test (p=0.95). 
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Figure 26. Effect of dose on transdermal permeation of occlusive applied caffeine emulsions comprising 
70%, 50% and 30% of dispersed phase in miglyol (E70, E50, E30). Error bars denote standard error of 
mean (n = 3 - 6). 
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Figure 27. Effect of dose on transdermal permeation of occlusive applied ibuprofen emulsions comprising 
70% and 30% of dispersed phase in miglyol. Error bars denote standard error of mean (n = 3 - 9). 
 
 
5.3.2.4 Influence of Evaporation on Transdermal Permeation 
5.3.2.4.1 Transport Kinetic 
The influence of dermatological w/o-formulations on in vitro caffeine and ibuprofen 
permeation was investigated taking especially into consideration alterations these 
formulations undergo due to evaporation of volatile components following a non-occlusive 
application. As continuous phase drug concentration is the decisive parameter for skin drug 
permeation (see Part II), an equation is derived that allows estimation of the change of 
continuous phase drug concentration in w/o-emulsions caused by the evaporation of volatile 
ingredients, i.e. water. 
The drug concentration within distinct phases of a multi-phase formulation is given by: 
WLWWtot CCC ⋅+⋅= φφ    [equation VI] 
where Ctot is the overall drug concentration in the formulation, CW and CL are the 
concentrations of the dispersed water and the continuous lipid phase, respectively, with ФW 
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and ФL as the mass-fraction of the dispersed and continuous phase, respectively. These 
mass fractions are given by: 
tot
L
L V
V
=φ      and     
tot
W
LW V
V
=−= φφ 1  
where Vtot, VW and VL denote the volume of the total formulation, of the dispersed and of the 
continuous phase, respectively. The distribution of a drug between the dispersed and the 
continuous phase can be expressed as the partition coefficient KW/L (see Part I, 4.2.2.3): 
L
W
LW C
CK =/    [equation VIII] 
By combination of equation VI and VIII the term for calculation of continuous phase drug 
concentration is derived (see also Part I, 4.3.1.3): 
1)1( / +−
=
LWW
tot
L K
CC φ    [equation IX] 
Equation IV is of general validity. Some additional considerations are necessary to apply 
them to the situation of non-occlusive application. Over time the fractions ФW and ФL may 
change, which, in turn, affects the concentrations Ctot, CW and CL. Hence, the superscript t is 
introduced to denote the arising conditions during evaporation, and the superscript 0 will 
symbolize the situation in the according original formulation for further discussion. Then, 
during evaporation, the following correlations may be set up: 
LW
tot
tot VV
MC
+
=  [equation XVII] 
 
with     
tot
w
W V
V
=φ ; 
tot
L
L V
V
=φ       and      1=+ LW φφ . It follows: 
00 1
1
W
t
w
tot
t
tot
C
C
φ
φ
−
−
=    [equation XVIII] 
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Finally, the combination of equations IX, XVII and XVIII offers a general term that allows 
calculating continuous phase drug concentration at a specific state during evaporation of a 
multi-phase w/o-formulation: 
[ ]
[ ]1)1(
1)1(
1
1
/
/
0
00
0
+−
+−
⋅
−
−
⋅⋅=
LW
t
W
LWW
W
t
W
tot
t
tot
L
t
L K
K
M
MCC φ
φ
φ
φ
    [equation XIX] 
This formula was applied to the permeation data of caffeine in E70, E50 and E30 (0.2% total 
drug concentration) and to the permeation data of ibuprofen in E70 and E30 (1% and 0.5% 
total drug concentration, respectively) both using miglyol 812N as oil component in order to 
calculate new arising continuous phase drug concentration. Transport experiments were 
performed non-occlusively with a dosing of 0.3 g/cm2. 
5.3.2.4.2 Ibuprofen 
Concerning the permeation of ibuprofen in E70 and E30 (1% and 0.5% total drug 
concentration, respectively) with miglyol 812N as oil component, following values in view of 
to equation XIX were obtained (table 42). 
 
Table 42. Alteration of continuous phase ibuprofen concentration (mg/g) due to evaporation and 
permeation in w/o-formulations (dose: 0.3 g/cm2) 
E701,2,3 E301,2,3 Ibuprofen Average ± SD Average ± SD 
0
tot
t
tot
M
M
 0.92 ± 0.02 0.94 ± 0.02 
0
LC  33089.33 ± 45.56 6954.59 ± 129.62 
t
LC  40806.59 ± 822.71 6950.47 ± 275.82 
Change of CL  + 23.32 % - 0.06 % 
1
 emulsion with 70% and 30% dispersed phase in miglyol 812N oil, respectively 
2  total concentration of ibuprofen was 1% for E70 and 0.5% for E30, respectively 
3
 al values denote mean ± standard deviation. n = 4 - 5 
 
In total, only 8% of ibuprofen for E70 and 6% for E30 permeated into and through the skin 
within 48h. In the same time, formulations lost 45.16% of water referred to the original water 
content for E70 and 39.55% for E30, altering them to an E36 and an E18 (see table 36). 
Accordingly, phase fraction of the continuous phase increased as well as continuous phase 
drug concentration of ibuprofen which led in part to an increase of continuous phase drug 
concentration. This consideration is confirmed by the calculated values for CLt (see table 42) 
showing an increase of 23.32% for E70. Apparent permeability coefficient Papp did not show 
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any statistically significant difference for all formulations examined if a dose of 0.3 g/cm2 for 
occlusive and non-occlusive conditions was applied (see table 43). This findings were 
confirmed by a two-sided t-test (p=0.95). 
 
Table 43. Apparent permeability coefficient Papp of ibuprofen for open and occlusive conditions  
 Open conditions Occlusive conditions 
 appP ± SEM (cm/sec)1 appP ± SEM (cm/sec)1 
E302 1.28·10-7 ± 1.91·10-8 1.29·10-7 ± 2.74 ·10-8 
E702 1.78·10-7 ± 1.80·10-8 1.74·10-7 ± 2.51·10-8 
1
 all values denote mean ± standard error. n = 3 - 5 
2
 emulsion with 30% and 70% of dispersed phase in miglyol oil 
 
5.3.2.4.3 Caffeine 
Concerning the permeation of caffeine in E70, E50 and E30 (0.2% of total drug 
concentration) with miglyol 812N as oil component, following values were obtained after 
application of equation XIX (see table 44). 
Table 44. Alteration of continuous phase drug concentration due to evaporation and permeation of w/o-
formulations (dose: 0.3 g/cm2) 
E701,2,3 E501,2,3 E301,2,3 Caffeine Average ± SD Average ± SD Average ± SD 
0
tot
t
tot
M
M
 0.90 ± 0.43 0.89 ± 0.05 0.87 ± 0.06 
0
LC  350.61 ± 1.57 456.32 ± 3.14 667.95 ± 5.34 
t
LC  530.21 ± 26.22 765.98 ± 88.61 847.32 ± 55.48 
Change of CL + 51.23% + 67.86% +26.85% 
1
 emulsion with 70%, 50% and 30% of dispersed phase in miglyol 812N oil 
2
 
 total concentration of caffeine was 0.2% for E70, E50 and E30, respectively 
3 all values denote mean ± standard deviation. n = 5 
 
Water loss of the studied caffeine formulations was 41.95%, 36.86% and 37.54% for E70, 
E50 and E30, respectively, if referred to the original water content (see table 35). In the 
course of evaporation continuous oil phase was increased with the consequence that also 
CL0 increased to CLt. Continuous phase drug concentration increased 51.23% for E70, 
67.86% for E50 and 26.85% for E30. In view of the hypothesis that continuous phase drug 
concentration governs skin permeation alone, an increased apparent permeability coefficient 
should be expected (see part II). Observed apparent permeabilities Papp for occlusive and 
non-occlusive conditions did not show any statistically significant difference, if emulsions of 
the same phase fractions were compared against each other (t-test, two-sided, p=0.95, see 
table 45). However, overall drug depletion within every caffeine formulation was 
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underestimated because of drug remaining in the skin. For E70, E50 and E30 depletion was 
10%, 11% and 13%, respectively (see table 44), but this depletion was based only on 
calculation of drug amount in the receiver compartment and did not consider drug amount 
remaining in the skin. 
Table 45. Apparent permeability coefficient of caffeine for open and occlusive conditions  
 Open conditions Occlusive conditions 
 appP ± SEM (cm/sec)1 appP ± SEM (cm/sec)1 
E302 2.74·10-7 ± 5.95·10-8 2.61·10-7 ± 2.86·10-8 
E502 2.98·10-7 ± 4.47·10-8 2.63·10-7 ± 4.36·10-8 
E702 2.64·10-7 ± 4.88·10-8 2.52·10-7 ± 2.25·10-8 
1
 All values denote mean ± standard error. n = 4 – 6 
2
 emulsion with 30%, 50% and 70% of dispersed phase in miglyol oil 
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5.4 Discussion 
Microscopic pictures obtained by freeze fraction scanning electron microscopy (see 5.3.1.2) 
revealed that these formulations differed in their microstructure showing a small decrease of 
droplet size and denser droplet packing as the fraction of the dispersed water phase was 
increased. This observation was consistent for all formulations studied. The approximated 
droplet diameters ranged between 0.5 and 4 µm (see figure 23 and table 32). These findings 
are not astonishing, because already in 1933, Langevin noticed that variation of the 
proportions of emulsion ingredients influences the size of droplets. Particle size distribution of 
emulsions is altered by the adjustment of the phase volume ratio, the method of 
manufacture, temperature and viscosity [42]. It is a general rule that, regarding w/o-
emulsions, the larger the water content, the more viscous the systems are [44]. Clément et 
al. noticed that phase volume ratio in w/o-emulsions plays a role in the variation of apparent 
viscosity and droplet diameter. An increase in the percentage of disperse phase caused a 
reduction in droplet diameter and an increase in apparent viscosity. These findings were 
confirmed by characterization of the formulations used in this study [45]. 
In addition to decreasing droplet size as the amount of dispersed water was raised, an 
increase pf viscosity was observed (see table 31). A reduction of the oil content in w/o-
emulsions is equivalent to reducing the continuous phase and, by doing so, increasing the 
interaction between the water droplets in the emulsion. An increase in viscosity is the direct 
consequence of that. Additionally, the risk of coalescence of water droplets increases as the 
average distance between the water droplets further decreases [46]. Formulations 
comprising same phase fractions but different oil components possessed macroscopically 
different viscosity, following the increasing viscosity of isopropyl myristate, miglyol 812N and 
paraffinum liquidum. 
Thickener Aerosil was able to increase viscosity and therefore also stability. However, it 
turned out that Aerosil showed strong interaction with hydrophilic model drug caffeine, 
leading to a tremendous decrease of apparent permeability coefficient Papp. Permeation 
parameters such as diffusivity in a formulation and partitioning from formulation to skin are 
easily altered by the composition of the formulation, as already stated by Diez-Sales et al. 
who studied the in vitro percutaneous penetration of acyclovir form solvent systems and 
carbopol hydrogels in order to figure out the extent of changed viscosity and varying 
propylene glycol amounts on apparent permeability coefficient[10]. 
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All formulations examined were previously arranged in transport series comprising same 
ingredients but different ratios these components were intermixed with each other (E70, E50, 
E30 and oil as reference formulation). In order to implement continuous phase drug 
concentration concept to the formulations of a transport series (see Part II), particular 
attention had to be paid to the emulsifier content present in each vehicle. 
In this context there are two options how to consider emulsifier content in each vehicle. First, 
emulsifier content employed in each vehicle is related to the specific surface area of the 
emulsion droplets present in each emulsion. Second, ratio of emulsifier content over oil 
content is calculated for each vehicle employed. 
Specific surface area of the water droplets present in the w/o-emulsions of varying phase 
fractions was computed after the following equation XX: 
W
r
r φ⋅
Π
Π
3
3
4
24
   [equation XX] 
where the counter denotes droplet surface and the denominator denotes droplet volume with 
radius r. ФW represents the phase fraction of dispersed water phase. Equation XXI was 
obtained after simplifying and relating to the emulsifier content ФISO employed: 
Iso
Wr
φ
φ⋅3
   [equation XXI] 
Particle sizes were estimated based on microscopic pictures obtained by freeze fracture 
scanning electron microscopy. Table 46 depicts the values obtained after calculation, 
approximated particle sizes are shown in table 32. 
Concerning the specific droplet surface area approach, values should be comparable. 
Consequently, in order to adjust formulation E70 to the situation present in E50 and E30, this 
would require that emulsifier content has to be in a range of 9 – 23%, although total oil 
phase, consisting of oil and emulsifier, comprises only 30%. This approach is not practical as 
adapted emulsions would then contain emulsifier concentrations far from reality and 
compatibility. Additionally, specific droplet surface area approach does not reflect real 
situation existing inside the emulsions, as emulsifiers will not only enrich themselves at the 
interface between dispersed water globules and continuous oil phase, but also be present in 
the oil phase. The extent to which the amount of free available emulsifier in the oil phase will 
be altered due to absorption at the interface oil - water, is much stronger for E70 than for E50 
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or E30, as it possesses the smallest droplets that are more densely packed and, thus, offers 
more interface.  
The ratio of emulsifier content over oil content (see table 46) was deemed appropriate, as 
values are in the same order of magnitude. Keeping in mind that emulsifier concentration 
was originally dispensed empirically following requirements like stability, lipophilic vehicle 
character and manufacturer’s recommendations, small variations from uniformity can be 
accepted. Pure oil was chosen as reference formulation, but for adjustment to the discussed 
situation, it was intermixed with 7.7% Isolan PDI for both drugs.  
 
Table 46. Emulsifier approach for the w/o-emulsions studied (oil base: miglyol 812N) 
 
E701 E501 E301 
ISOφ  2 0.03 0.05 0.05 
Wr φ⋅3  3 2.8 1.5 0.6 
Iso
Wr
φ
φ⋅3
 
4
 93 30 12 
L
Iso
φ
φ
 5
 0.11 0.11 0.077 
1
 emulsions with dispersed phases of 70%, 50% or 30%, respectively 
2
 Isolan PDI content of the emulsions, considering for instance caffeine 
3
 specific surface of the globules 
4
 specific surface of the globules related to emulsifier content 
5
 Isolan PDI content over oil content of the studied emulsions 
 
Determination of saturation concentration and apparent permeability coefficient across pig 
ear skin for both drugs was performed in order to profound understanding of the interplay 
between oil, emulsifier Isolan PDI and model drug. Therefore, varying ratios of Isolan PDI 
were added to isopropyl myristate and miglyol 812N PDI being in the same order of 
magnitude or similar to the situation present in the examined w/o-emulsions. The procedure 
failed for paraffinum liquidum as only small amounts of Isolan PDI were dissolvable in this oil. 
Neither in case of caffeine nor in case of ibuprofen presence of Isolan PDI could strongly 
affect determined saturation concentration. Solubility clearly demonstrated the hydrophilic 
nature of caffeine and the lipophilic nature of ibuprofen.  
For caffeine solubility was best in water/phosphate buffer pH 7.4 and displayed an up to 250-
fold difference compared to oil solubility. Miglyol 812N showed highest affinity for caffeine 
that was 2-fold greater than for isopropyl myristate and 20-fold greater than for paraffinum 
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liquidum. The order of oil saturation concentration is in good agreement with the order of 
caffeine partition coefficient oil/water determined in a previous manuscript (see 4.3.1.1, Part 
II).  
For ibuprofen, solubility was highest in isopropyl myristate and miglyol 812N that were similar 
to each other. Solubility was approximately 6-times smaller in paraffinum liquidum and 1200-
times smaller in sodium acetate buffer pH 4.5. The order of the oil saturation concentrations 
was again in good agreement with the order of ibuprofen partition coefficient oil/water 
determined before (see 4.3.1.1, Part II). 
In a previous manuscript emulsions of varying phase fractions and varying emulsifier 
contents (3%, 5% and 10%) were subjected to ultracentrifugation experiments with 
subsequent quantification of continuous phase drug concentration. The determined 
concentrations revealed that Isolan PDI does not influence drug partitioning and 
consequently decisive drug concentration in the external formulation phase (see 4.3.1.3, Part 
II). 
Intermixing isopropyl myristate or miglyol 812N with different amounts of Isolan PDI did 
neither affect transdermal permeation behaviour of caffeine nor ibuprofen. Additionally, 
ibuprofen emulsions comprising 30% and 70% of dispersed phase in miglyol 812N, 
respectively, possessed the same apparent permeability coefficient Papp, independent 
whether 3%, 5% or 10% of emulsifier were selected for the studied vehicle of defined phase 
fraction. These findings were all confirmed by a two-sided t-test (p=0.95) (see 5.3.2.2.1 for 
caffeine and 5.3.2.2.2 for ibuprofen). 
To summarize, it can be assumed that Isolan PDI does not affect continuous phase drug 
concentration independent of its presence as free available ingredient in the external oil 
phase or enriched ingredient at the interface water-oil. Any further microstructures present 
inside the emulsions that are formed due to free Isolan PDI can be excluded as 
ultracentrifugation experiment only displayed two distinct phases, i.e. dispersed water phase 
and continuous oil phase [3]. 
 Contrary, literature also reports on emulsifier affecting transdermal permeation. Presence of 
free emulsifier in the continuous or dispersed phase can change thermodynamic activity and 
solubility properties of a drug. For instance, Lalor et al. studied transdermal permeation of 
lipophilic p-aminobenzoate incorporated in o/w-emulsions. The effective activity of any 
permeant is connected to the state of saturation of the drug in the vehicle. Surfactants led to 
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a substantial solubilization of the drug in the external phase, thus, lowering the appreciable 
thermodynamic activity with the net result of decreased transport rate over a membrane. 
Partitioning of the drug into the internal phase led to an even lower concentration in the 
external phase and, hence, apparent permeability coefficients for o/w-emulsions were lower 
than for w/o-emulsions. Besides interaction with the drug, surfactants can also alter skin 
structure and consequently skin permeability [6, 167].  
No statistic significant difference for apparent permeability coefficient Papp was evident in 
terms of testing two infinite doses (0.3 g/cm2 and 0.7 g/cm2). Considering caffeine transport 
experiments using w/o-emulsions with miglyol 812N as oil component, these results are not 
astonishing. In a previous work, it already turned out that for these systems (dose: 0.7 g/cm2) 
permeability coefficient of the skin Pm was rate-limiting compared to permeability coefficient 
of the vehicle Pdbl (see Part II, 4.3.2.3.2, series B). In contrary, for ibuprofen transport 
experiments using w/o-emulsions with miglyol 812N as oil component, an impact of reduced 
vehicle layer thickness could have occurred. Regarding a dose of 0.7 g/cm2, the impact of 
permeability coefficient of the diffusion boundary layer gained increasing influence on the 
overall apparent permeability coefficient as demonstrated before (see Part II, 4.3.2.4.2, 
series D). 
In a separate manuscript a concept for the interpretation of transdermal drug permeation 
using w/o-emulsions of varying phase fractions and oil phases was presented by the authors 
considering drug distribution among distinct phases and it was postulated that continuous 
phase drug concentration alone governs drug permeation kinetics. With the derived 
quantitative model it was possible to explain in vitro skin permeation of 
benzyltrimethylammonium chloride, caffeine and ibuprofen as model drugs that were applied 
under occlusive conditions. The proposed concept was further shown to be consistent for 
multi-phasic hydrophilic formulations comprising different microstructures and phase 
fractions in previous works [3]. The model was confirmed for hydrophilic and lipophilic drugs 
applied under occlusive and non-occlusive conditions taking into account changes these 
vehicles underwent in the course of evaporation of volatile components [2, 3]. Thus, the 
concept was implemented on the same w/o-emulsions studied before (see Part II), but 
considering non-occlusive conditions in order to confirm its validity. 
Evaporation studies were performed in order to figure out the changes formulations undergo 
after application. Possible water loss was studied in dependence of phase fraction, time, 
dose and experimental setup, i.e. pig ear skin mounted in Franz-type diffusion cells and 
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beaker of known surface. Studies in beaker were necessary to exclude any water uptake 
from skin surface resulting from an upward diffusion out of the receiver compartment. 
Independent of experimental setup employed, water loss was apparent within the duration of 
a transport experiment (48h), although its extent was more distinct for a dose of 0.3 g/cm2 
than for 0.7 g/cm2 and hence a reduced vehicle layer thickness. It turned out that evaporation 
profile and percentage of water loss referred to original water content were the same for all 
phase fractions studied (approximately 40%). There was no water uptake from the receiver 
compartment as different experimental setup showed the same results. These finding were 
further confirmed by miglyol oil that was mixed with 7.7% Isolan PDI and applied in a dose of 
0.1 g/cm2 onto the skin. There was no difference in water content after an incubation time of 
48h under occlusive and non-occlusive conditions and consequently no water emulsification. 
Considering compositional changes vehicles underwent in the course of evaporation, further 
transport experiments were carried out across pig ear skin using a dose of 0.3 g/cm2 under 
occlusive and non-occlusive conditions (see 5.3.2.4.2 for ibuprofen and 5.3.2.4.3 for 
caffeine). In general, continuous phase drug concentration of w/o-emulsions is affected by 
two processes:  
(i) Drug permeation into and through the skin leads to a decrease of drug content in 
the external phase. However, this decrease is balanced by concomitant 
partitioning of drug between water droplets and oil phase as long as the total 
amount of permeated drug is low. This assumption is valid for occlusive and non-
occlusive application.  
(ii) Evaporation leads to a compositional change, decreasing dispersed phase 
fraction ФWt at a specific point in time t compared to original phase fraction ФW0. 
Due to the loss of water, continuous phase drug concentration increases. 
Consequently, as long as sink conditions are considered and no significant drug depletion of 
the examined vehicle occurs during the time frame studied, evaporation leads to an increase 
in continuous phase drug concentration. If drug depletion occurs, then continuous phase 
drug concentration must be calculated with the equation XIX. The assumptions can also be 
derived if the formula for calculation of new arising continuous phase drug concentration (see 
5.3.2.4.1) is considered: 
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It holds: 
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 if non-occlusive conditions are considered. Following evaporation (ФWt < ФW0) the fragment  
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will always be above unity independent whether a hydrophilic drug with a drug partition 
coefficient KW/L > 1 or a lipophilic drug with KW/L < 1 is present and consequently lead to an 
increase in continuous phase drug concentration. Dependent on which of these terms 
outweighs, evaporation will lead to an increase of decrease of continuous phase drug 
concentration. 
For caffeine, an increase of 51.23% for E70, 67.86% for E50 and 26.85% for E30 of 
continuous phase drug concentration was observed, whereas for ibuprofen only for E70 an 
increase of 23.32% was observed.  
However, determined apparent permeability coefficient Papp for occlusive and non-occlusive 
conditions did not reveal any statistically significant difference (t-test, two-sided, p=0.95) 
although vehicles underwent considerable changes. This was true for caffeine and ibuprofen. 
Overall drug depletion within every caffeine formulation was so distinct that continuous phase 
drug concentration did not increase due to considerable depletion. The increase of 
continuous phase drug concentration calculated with equation XIX underestimated drug 
depletion because of drug remaining in the skin. The depletion was based only on calculation 
of drug amount in the receiver compartment and did not consider drug amount in the skin. 
For caffeine drug depletion was 10%, 11% and 13% for E70, E50 and E30, respectively (see 
table 44). For ibuprofen the depletion was 6% for E30 and 8% for E70. Thus, to be more 
precise and make a clear statement, drug content of the vehicle after 48h should be taken 
into consideration additionally. 
Dermatological medications are typically applied as a thin layer and will remain on the skin 
only for a few hours, which are not exactly the conditions for the studies described in this 
work. Hence, the discussed alterations of the formulations due to evaporation of volatile 
components likely take place much faster in clinical situations. Furthermore, the residue may 
be removed before steady state drug flux is reached, commonly due to mechanical agitation. 
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The applied experimental setup, however, was deemed appropriate for reaching the specific 
goals of this study and allowed observing alterations following formulation application in 
“slow-motion”. 
To conclude, evaporation was observed for all examined formulations independent of the 
phase fraction dispersed and the experimental setup employed, but dependent on dose. 
Although dosing was the same, the extent of water loss was comparably low if compared to 
o/w-emulsions studied in a previous work [3].  
Anyhow, too little attention has been paid to the issue of evaporative processes within 
dermatological formulations up to date. Concerning examined lipophilic vehicle systems, it is 
likely that applying a finite dose (1 – 3 mg/cm2) instead of an infinite dose examined here due 
to experimental demand, will result in a more intense water loss and strongly affect 
transdermal permeation. An optimized experimental setup with respect to dose, drug 
properties, drug permeability and time schedule would allow studying this process in more 
detail in order to obtain a more profound understanding. Additionally, drug content in the skin 
and residual drug content of the formulation after the transport experiment should be 
considered. Thus, confirmation of the validity of continuous phase drug concentration 
concept discussed in part II for non-occlusive conditions in w/o-emulsions requires further 
investigation. 
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6 Appendix 
6.1 Characterization of Pig Ear Skin  
Transepidermal water loss (TEWL), skin moisture, skin pH and skin temperature were 
measured 1h after equilibration of pig ear skin mounted inside a Franz-type diffusion cell with 
receiver solution and directly after a completed transport experiment (52h). The idea was to 
pursue changes skin undergoes in the course of a transport experiment. For measurements, 
specific sensors provided by Courage & Khazaka electronic GmbH (Cologne, Germany) 
were used, i.e. Tewameter TM300 for TEWL measurements, Corneometer CM 825 for skin 
surface hydration, Skin-pH-Meter PH 905 and Skin-Thermo-Meter TH 500. The values are 
depicted below (table 47): 
 
Table 47. Characterisation of pig ear skin 
 Before transport experiment (1h)1 After transport experiment (52h)1 
TEWL 15.24 ± 3.69 23.90 ± 13.94 
Skin surface hydration 22.84 ± 3.03 27.97 ± 10.82 
Skin pH 6.11 ± 0.57 5.91 ± 0.54 
Skin temperature 24.73 ± 0.13 25.15 ± 0.67 
1
 all values denote mean ± standard deviation. n = 3 
 
Skin pH and skin temperature were not changed, but skin surface hydration and 
transepidermal water loss were slightly increased. As transport experiments were performed 
under occlusive conditions, these findings are in good agreement with literature that indicates 
an increase stratum corneum hydration, a swelling of corneocytes and an increased skin 
temperature. The latter, however, was not observed as experiments were performed in-vitro 
and not in vivo [91]. 
6.2 Stability Testing of the Examined Formulations 
Prior to examining transdermal delivery rate of the selected dermatological formulations, all 
vehicles were tested for stability. No phase separation was allowed to occur within 24h after 
manufacturing at room temperature and additional 48h at 32°C (water bath heating). For that 
purpose, emulsions were filled into falcon tubes and closed to avoid any possible water loss. 
Additionally, lipophilic character was confirmed by conductivity measurements, dilution with 
water / oil, dyeing with a hydrophilic (indigocarmin) and lipophilic (sudan III) compound 
before and after stability testing. Conductivity measurements before and after the stability 
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testing were performed using a conductometer 660 and a conductivity-measuring cell 
60323110 with a cell constant of 0.8cm-1 (Metrohm AG, Herisau, Switzerland) were used. 
Figure 28. Dying of an emulsion comprising 70% dispersed water phase in miglyol 812N (E70) 
with indigocarmin (hydrophilic) and sudan III (lipophilic) 
 
 
 
 
Figure 29. Dilution of w/o-emulsion with oil (miglyol 812N) and water 
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6.3 Validation of Time for Ultracentrifugal Separation 
w/o - emulsions comprising of varying phase fractions of dispersed water phase within 
continuous oil phase were separated into their distinct phases by ultracentrifugation 
experiments. Therefore, formulations were filled into quick-seal centrifuge tubes, 5/8X3 
(Beckmann Instruments, Palo Alto, USA) and centrifuged at 222000 – 450000 g using an 
ultracentrifuge type Centricon T-1075 and a rotor TFT 7013 (Kontron Instruments, Mailand, 
Italy) until complete separation occurred. 
 
Table 48. Staged separation of w/o - emulsions comprising varying phase fractions of dispersed water 
phase by ultracentrifugation - effect of time(h) and speed (rpm) 
Time 
(h) 
Speed 
(rpm) 
Water phase (weight - %)                             
after ultracentrifugation 
EMULSION E701 
Water phase (weight - %)                           
after ultracentrifugation 
EMULSION E301 
1 5000 No separation No separation 
1 10000 No separation No separation 
1 20000 No separation 40.70 
1 40000 88.14 37.20 
1 68000 79.50 35.36 
2 68000 76.89 34.14 
4 68000 75.78 33.25 
required 70 30 
1
 w/o - emulsion comprising 70% or 30% of dispersed water phase in miglyol 812N, respectively 
 
For the emulsions E70 and E30 best phase separation was achieved if ultracentrifugation 
was performed for 2h at 220000 – 450000 g (equivalent to 68000 rpm). Even if centrifugation 
time was expanded to 4h instead of 2h, no improvement was achieved. Thus, all 
ultracentrifugation experiments in order to quantitatively determine continuous phase drug 
concentrations were performed at 220000 – 450000 g for 2h. 
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6.4 Distribution Experiment between Stratum Corneum and 
Oil 
Originally, the idea was to determine drug distribution between (continuous) oil (phase) and 
dried stratum corneum pieces (see 4.2.2.4). For that purpose, miglyol 812N oil with varying 
concentrations of ibuprofen (1, 2 and 4 weight-%, respectively) was incubated with dried 
stratum corneum pieces of known weight.  At predetermined time points (20h, 25h, 40h, 48h) 
samples were withdrawn from the oil and analyzed for their drug content. Depletion was 
solely due to partitioning into stratum corneum as confirmed by blank control samples. The 
stratum corneum drug content was quantified indirectly by calculation assuming a density of 
1000 mg/g for the skin. Additionally, stratum corneum drug content was directly determined 
after cleaning the skin sheets (dabbing dry with tissue and washing with water) and 
subsequent extraction with water solution. However, both approaches failed (no linear 
regression) as illustrated in the figures below (figure 30): It was not possible to remove 
adherent oil entirely for stratum corneum pieces without loosing drug substance or destroying 
the skin sheets. Furthermore, direct quantification of drug content in oily vehicles required 
dilution steps and therefore it was very likely to implicate experimental failures in this step. 
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Figure 30. Determination of drug partition coefficient between dried stratum corneum and ibuprofen in 
miglyol 812N - oil in dependence of incubation time 
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6.5 Freeze Fracture Scanning Electron Microscopy 
 
6.5.1 W/O-emulsion with Isopropyl myristate 
 
 
Figure 31. w/o-emulsion with isopropyl myristate (E70): 70% of dispersed water 
phase 
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6.5.2 W/O-emulsion with Miglyol 812N 
 
 
Figure 32. w/o-emulsion with miglyol 812N (E70): 70% of dispersed water phase 
 
 
 
 
Figure 33. w/o-emulsion with miglyol 812N (E50): 50% of dispersed water phase 
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Figure 34. w/o-emulsion with miglyol 812N (E30): 30% of dispersed water phase 
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6.5.3 W/O-emulsion with Paraffinum liquidum 
 
 
Figure 35. w/o-emulsion with paraffinum liquidum (E70): 70% of dispersed water 
phase 
 
 
 
 
Figure 36. w/o-emulsion with paraffinum liquidum (E50): 50% of dispersed water 
phase 
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Figure 37. w/o-emulsion with paraffinum liquidum (E30): 30% of dispersed water 
phase 
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6.6 Composition of Employed Solutions 
6.6.1 Benzyltrimethylammonium Chloride 
 
Phosphate buffer of the mobile phase for HPLC quantification (pH 3.5; buffer capacity β = 0.5) 
  
sodium dihydrogenphosphate dihydrate 14.296 g 
1-octansulfonic acid sodium salt monohydrate 0.2925 g 
bidistilled water Ad 1000.0 g 
6.6.2 Caffeine 
 
Phosphate buffer of the mobile phase for HPLC quantification (pH 7.4; buffer capacity β = 
0.01) 
  
sodium dihydrogenphosphate dihydrate 3.1195 g 
bidistilled water Ad 1000.0 g 
 
Solution for the determination of caffeine distribution coefficient between oil and water phase 
  
caffeine 10.0 g 
sodium chloride 5.0 g 
bidistilled water Ad 1000.0 g 
 
6.6.3 Ibuprofen 
 
Phosphate buffer of the mobile phase for HPLC quantification (pH 2.1; buffer capacity β = 
0.02) 
  
ortho-phosphoric acid 85% 8.4 ml 
bidistilled water Ad 1000.0 ml 
 
 
Sodium acetate buffer used for ibuprofen in emulsions and distribution coefficient 
determinations (pH 4.5; buffer capacity β = 0.01) 
  
sodium acetate 1.60376 g 
bidistilled water Ad 1000.0 g 
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6.6.4 Receiver Solution of the Transport Experiments  
 
Phosphate buffer for the transport experiments (pH 7.4; buffer capacity β = 0.05) 
  
sodium dihydrogenphosphate dihydrate 14.28 g 
sodium azide 1.0 g 
bidistilled water Ad 1000.0 g 
 
6.6.5 Preparation of Stratum Corneum by Trypsin Digestion 
 
Phosphate buffer used for trysin digestion (pH 7.4; buffer capacity β = 0.05) 
  
sodium dihydrogenphosphate dihydrate 1.56008 g 
sodium azide 16.364 g 
bidistilled water Ad 1000.0 g 
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